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Abstract
Uterine Papillary Serous Carcinoma (UPSC) is an uncommon form of endometrial
cancer comprising 10% of all endometrial carcinomas. It is a highly aggressive
tumour and because of its poor prognosis, it accounts for a disproportionately large
proportion of deaths from endometrial carcinoma. The reason for its aggressive
behaviour is uncertain. The aim of the thesis was to investigate potential mechanisms
of invasion of UPSC, using an immunohistochemical approach, using high-grade
endometrioid endometrial carcinoma (EEC) as a comparator.
An audit of all cases of UPSC diagnosed in South East of Scotland over a 10 year
period confirmed the poor prognosis of UPSC and showed that this was conferred
even in those cases where the tumour was composed of 5% UPSC regardless of the
additional tumour type. It also raised awareness of the need for accurate and
complete surgical staging. Tissue microarrays (TMAs) were created from the central
viable part of the tumour and the invasive edge of UPSC and EEC and were shown
to be valid for studying expression of the markers involved in this study. There was
intertumoural variation in expression of E- and P-cadherin, CD98, matrix
metalloproteases (MMPs) -2 and -9 and ER and PR in both UPSC and EEC. ER
status is known to affect expression of E cadherin, (3 catenin, CD98 and MMPs -2
and -9, and E cadherin levels were decreased and the other protein molecules all
showed higher expression in EEC compared to UPSC. The results are consistent with
the role that oestrogen plays in the development ofEEC.
Intratumoural variation in expression of E cadherin, P cadherin, P catenin, CD98,
Galectin-3, MMPs -2 and -9 was demonstrated, supporting the theory of a subclone
of the tumour developing properties necessary for invasion. These data contribute to
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the growing body of literature on UPSC, and address diagnostic and treatment
uncertainties for the pathology, surgical and oncological teams.
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Literature Review of Uterine Papillary Serous Carcinoma.
1. Introduction
This chapter is a literature review of Uterine Papillary Serous Carcinoma (UPSC).
Over the past few years there has been growing awareness of the importance of the
diagnosis and consequently there has been an increase in the number of studies on
UPSC, ranging from audits on presentation of UPSC through molecular studies,
methods of diagnosis and numerous different potential treatment modalities.
1.1 Incidence and Age
Endometrial carcinoma is the most common pelvic genital malignancy in the western
world {Creasman, 2003}. The majority of these cancers are of adenocarcinoma type,
arising from endometrial epithelium. The most common subtype is endometrioid
endometrial carcinoma (EEC), which accounts for about 80% of endometrial
carcinomas {Burton, 1998;Santin, 2002;Santin, 2003}. UPSC is a highly aggressive
variant of endometrial carcinoma and accounts for approximately 10% of cases
(Burton, 1998}, but a much smaller proportion of Stage 1 endometrial carcinomas
{Hendrickson, 1983;Bancher-Todesca, 1998;Dembo, 1985}. Patients present later




Endometrial carcinomas are often split into 2 groups, determined by their clinical,
histopathological and molecular features {Bokhman, 1983;Sherman, 1992}. These
groups comprise: EEC (Type I) and non-endometrioid endometrial carcinomas (Type
II). EEC usually arises from atypical hyperplasia of the endometrium of
premenopausal, perimenopausal and postmenopausal women and is associated with
nulliparity, obesity, exogenous oestrogen therapy and tamoxifen therapy. In contrast,
UPSC usually occurs in elderly, postmenopausal women and is not associated with
either atypical hyperplasia or oestrogen status. Indeed, most tumours arise from
atrophic endometrium from a precursor lesion, Endometrial Carcinoma in Situ
(ECIS), also known as Endometrial Intraepithelial Carcinoma, or Uterine Surface
Carcinoma {Moll, 1996;Zheng, 1998;Spiegel, 1995;Sherman, 1992}. Zheng et al
{Zheng, 2004} recently postulated that UPSC and ECIS might develop from
dysplastic endometrial glands rather than de novo from normal postmenopausal
endometrium. In a small series of cases they found endometrial glandular dysplasia
(EmGD) in 17/32 (53%) uteri with UPSC compared with 1/60 (1.7%) uteri removed
for EEC. EmGD was identified in 12/16 (75%) ECIS uteri. Areas of both EmGD and
ECIS were found in 15/32 (47%) of the UPSC uteri. Transitions from either EmGD
to ECIS or ECIS to UPSC were present in 8/32 (25%) of the UPSC cases. No
transitions from EmGD to UPSC were identified in any hysterectomy specimen.
EmGD was frequently found in endometrial polyps. There was no statistically
significant difference between EmGD in a polyp (48%) and EmGD in non-polypoid
endometrium (52%). In the majority of cases, EmGD was multifocal and involved
superficial endometrial glands. However, single glandular involvement and surface
17
epithelial involvement of the endometrium was also seen. Although this is a small
series, it does seem likely that there is some type of "interval'' stage from normal
endometrium to ECIS. However, further study is required in this area to elucidate the
molecular changes occurring at these different stages.
1.2.1 Association with Breast Carcinoma
UPSC rarely expresses oestrogen receptors (ER) and progesterone receptors (PR)
{Carcangiu, 1990). Whilst some studies have demonstrated association of
development of UPSC with tamoxifen therapy {Magriples, 1993}, other studies were
unable to reproduce these findings, observing a similar rate of type I and type II
endometrial carcinoma in breast cancer patients regardless of tamoxifen use
{Barakat, 1994}. Geisler et al {Geisler, 2001} found that patients with UPSC had an
increased risk of either synchronous breast cancer or subsequently developing breast
cancer. Since UPSC is not a hormonally driven tumour, this raises the question as to
why these patients are at risk of developing breast cancer compared to other patients
with endometrial cancer. In the study by Geisler et al {Geisler, 2001} there was no
significant difference in the mean age of patients with UPSC versus EEC, therefore
age alone could not account for the difference. A case report and a study of 12
women raised a possible link between carrying the BRCA1-2 mutations and the
development of UPSC {Lavie, 2000;Hornreich, 1999}. Existing studies show
conflicting results as to whether endometrial cancer in general and UPSC in
particular have an increased incidence of BRCA 1-2 mutations {Lavie, 2004;Goshen,
2000;Biron-Shental T, 2006}. Although all of these studies have been small, with
limited power to determine significance, the disparity in results suggests that the
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observed association between UPSC and breast cancer may be due to the presence of
mutations in other cancer predisposing genes, such as P53 {Goshen, 2000}.
1.2.2 Association with Lymphoma
A case report by Chang et al {Chang, 2004} described a patient undergoing
chemoradiotherapy for Stage IV non-Hodgkin's lymphoma who developed UPSC.
They postulated that the depressed host immunity might have had a role in the
development of UPSC. However, it is most likely that depression of the immune
system plays a small role in the development of UPSC, as otherwise chronically
immunosuppressed patients including renal transplant patients and those with
HIV/AIDS also should have an increased incidence of UPSC and this has not been
noted in the literature. In contrast, a recent paper demonstrated decreasing expression
of HLA-DR and increasing expression of CD4 in normal endometrium, ECIS and
UPSC respectively {Tamiolakis, 2005}. The authors suggested that low HLA-DR
caused an "immune attract" mechanism. However, they also concluded that this
probably played a minor role in the development of UPSC.
1.3 Pathogenesis
The exact pathogenesis of UPSC is unknown. However, recently many molecules
including oncogenes and tumour suppressor genes have been demonstrated in




Oncogenes are derived from proto-oncogenes: cellular genes that promote normal
growth and differentiation. They may be found on the cell membrane (as growth
factor receptors), or in the cytoplasm involved in signal transduction or in the
nucleus, where they play a role in the cell cycle.
1.3.1.1 Growth Factor Receptors
C-erbB-2 (also known as HER-2/neu) is a member of the epidermal growth factor
receptor family (EGFRF). EGFR proteins function as cell surface receptors and
comprise three separate regions; the extracellular ligand binding site, a hydrophobic
transmembrane region and a highly conserved intracellular signalling area, which
contains tyrosine kinase {Prenzel, 2001}. The tyrosine kinase constituent can be
phosphorylated to initiate complex intracellular signalling cascades, which in turn
control cell cycle, survival, proliferation and gene transcription {Prenzel, 2001}. The
C-erbB-2 gene can be amplified causing increased responsiveness of the signalling
pathways and thus increased cell division and proliferation of damaged cells.
Alternatively deletions may occur in the gene resulting in permanent activation of the
receptor and increased cell division and proliferation {Prenzel, 2001;Moscatello,
1995}. Studies have shown overexpression of C-erbB-2 and amplification of the
gene in USPC {Santin, 2002;Santin, 2003;Santin, 2005;Santin, 2005;Macwhinnie,
2004} .
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1.3.1.2 Proteins Involved in Signal Transduction
Platelet derived growth factor receptor (PDGFR) and Abl overexpression has been
identified immunohistochemically in primary and recurrent EEC and UPSC
{Slomovitz, 2004}. Both of these proteins play a part in signal transduction from the
cell membrane receptor, through the cytoplasm to the nucleus. When PDGFR is
activated, it activates ras, found on the inner surface of the cell membrane, which in
turn is transformed into its activated state and thus triggers the MAP kinase pathway,
and proliferation. Thus, in UPSC, when PDGFR is overexpressed, the ras pathway is
increasingly activated. Abl is a member of the non-receptor associated tyrosine
kinase family and has tyrosine kinase activity, which is regulated by inhibitory
domains. The main drawback of immunohistochemical studies is that they can only
determine the presence or absence of a protein. However, the study examining the
immunohistochemical expression of PDGFR and Abl also demonstrated expression
of phosphorylated PDGFR and Abl, suggesting that these proteins are present in
UPSC in the activated state {Slomovitz, 2004}.
1.3.1.3 Cell Cycle Regulators
The ultimate outcome of all growth promoting stimuli is the entry of quiescent cells
into the cell cycle. Therefore genes associated with the cell cycle and in particular
with the Gl/S interface are frequently altered in cancer. P27 belongs to the kinase
inhibitor protein (KIP) family and this protein inhibits the cyclin dependant kinases
(cdks) associated with the cyclins E and D {Lloyd, 1999}. These particular cyclin
kinase complexes regulate cell proliferation by stimulating the phosphorylation of
the retinoblastoma protein (Rb), causing the release and activation of elongation
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factor 2 (E2F), a transcriptional factor. E2F facilitates the traverse of the Gl/S
checkpoint of the cell cycle. Figure 1.1 shows a diagram of the cell cycle courtesy of
Cotran et al {Cotran RS, 2006} Copyright © Elsevier 2005.
UPSC displays a high incidence of p27 alterations, suggesting that p27 abnormalities
play an important role in the development of UPSC {Schmitz, 2000}. Cyclin D1
overexpression has also been noted in a small percentage of UPSC cases {Schmitz,
2000;Stamenkovic, 2000;Moreno-Bueno, 2004}. Cyclin E overexpression also
occurs in UPSC, and may be associated with gene amplification {Cassia, 2003}.
High levels of cyclin E, cdk2 and cdk4 correlate with weak or absent ER expression
and pi6 and p21 expression is associated with low PR expression {Milde-Langosch
K,2001}.
Recent studies have demonstrated that loss of cables, a cdk binding protein, is
associated with a high incidence of endometrial hyperplasia and endometrial
adenocarcinoma. This has been demonstrated not only in low grade EEC, but also in
high grade EEC, UPSC and clear cell carcinoma {DeBernardo, 2005;Zukerberg,
2004}. Cables plays a role in proliferation and differentiation of the cell and its
activity appears to be increased by progesterone and decreased by oestrogen
{Zukerberg, 2004}.
1.3.2 Tumour Suppressor Genes
In normal cells tumour suppressor genes inhibit cell proliferation. Therefore loss of
tumour suppressor genes causes an increase in cell proliferation. Tumour suppressor
genes may be found on the cell surface, under the plasma membrane, in the
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1.3.2.1.1 Transforming Growth Factor p
Transforming growth factor p (TGF-p) is a member of the large family of
structurally related cytokines that play an important role in controlling cell
proliferation, differentiation, migration and apoptosis {Derynck, 2001;Siegel, 2003}.
Somatic mutations in the TGF-P signalling pathway are associated with loss of
proliferative control, malignant progression, invasion and metastasis {Vogelmann,
2005}. TGF-p binds to specific transmembrane serine/threonine kinase TGF-P
receptors such as type II (TGF-PRII), which in turn transphosphorylates type I
receptor (TGF-PRI). Receptors convey signals across the plasma membrane through
intracellular effectors such as SMAD proteins, which are translocated to the nucleus
where they act as transcription factors {Massague, 2000;Itoh, 2000;Miyazono,
2000}. SMAD proteins have been divided into 3 functional classes: receptor
regulated (R-SMADS), common mediator (Co-SMAD), and inhibitory (I-SMADs)
{Miyazono, 2000}. Representatives of the first class are directly phosphorylated by
TGF-PRI and are involved in the various signalling pathways. SMAD2 and SMAD3
are effectors of TGF-p/activin signalling while SMAD1, SMAD5 and SMAD8 are
involved in bone morphogenetic protein (BMP) signalling. Co-SMAD is critical for
TGF-p/activin and BMP signalling cascades. Representatives of the third class of
SMADs (SMAD6 and SMAD7) have the ability to inhibit the TGF-P signalling
pathway {Shi, 2001;Massague, 2000}. TGF-P can play multiple roles in human
tumorigenesis, behaving as a tumour suppressor at early stages and a tumour
promoter at late stages of carcinogenesis {Reiss, 1999;Wong, 2001;Wakefield,
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2002}. Studies showed TGF-PRII protein level was higher and SMAD 2 and SMAD
4 mRNAs were lower in infiltrating endometrial carcinomas compared to Stage la
EECs {Piestrzeniewicz-Ulanska, 2004}. Liu et al {Liu FS, 2003} showed that
although LOH of chromosome 18q21 (the location of the SMAD4 gene) was
frequent in endometrial carcinomas, immunohistochemistry showed that inactivation
of the gene occurred infrequently. Both of these studies examined a mixed group of
endometrial tumours and neither attempted to separate expression of type I and type
II endometrial carcinomas. Therefore the role of TGFP specifically in UPSC is still
uncertain.
1.3.2.1.2 E Cadherin
E cadherin is the most common cadherin in epithelial cells. It is made from 4.5 kb
mRNA as a 135kDa precursor polypeptide, which is processed rapidly by proteolytic
cleavage to the mature 120kDa form {Shore, 1991}. The E cadherin gene (CDH1) is
found on chromosome 16q22.1 and it is thought to be a tumour suppressor gene,
whose loss has been shown to cause tumour invasion and metastasis in various
cancer models {Christofori, 1999}. In EEC loss of heterozygosity at 16q22 has been
related to poor prognosis and CDH1 mutations and promoter hypermethylation have
been found in a small percentage of cases {Kihana, 1996;Risinger, 1994;Moreno-
Bueno, 2003;Saito, 2003}. In addition to abnormalities in promoters of the E
cadherin gene, or the gene itself, the E cadherin-catenin complex can be disturbed by
the action of TGF-p. Vogelmann et al {Vogelmann, 2005} demonstrated that TGF-p
induced destabilisation of the E cadherin-catenin complex and thus dissociation of P
catenin from a catenin and the actin cytoskeleton. They also demonstrated that the
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mechanism involved phosphorylation of P catenin by PTEN. Signalling through the
cadherin-catenin complexes is involved in the regulation of EGFR distribution
{Deugnier, 1999}. There is decreased expression of E cadherin in atypical
hyperplasia compared to normal endometrium and even less in EEC {Shih,
2004;Moreno-Bueno, 2003}. Studies have also shown that loss of E cadherin
expression increases with increasing grade of the endometrial carcinoma, such that
the most poorly differentiated tumours have the least E cadherin expression
{Moreno-Bueno, 2003;Shih, 2004;Dvalishvili, 2005}. Studies have shown
conflicting results of E cadherin loss in type I, compared to type II endometrial
carcinomas {Demopoulos, 1999;Moreno-Bueno, 2003;Shih, 2004}.
1.3.2.2 Nucleus
Numerous studies of P53 have been performed on endometrial carcinoma. P53 is
involved in apoptosis, a complex energy dependent mechanism that eliminates
unwanted cells selectively with minimal disturbance to surrounding cells {Kerr,
1972}. No p53 alteration is found in atypical hyperplasia, the precursor of EEC,
whereas P53 alteration is common in both ECIS and UPSC {Zheng, 1998 ;Busmanis,
2005}. These data suggest that p53 inactivation may occur at an early stage in the
pathogenesis of UPSC. P21 is a downstream effector of p53 mediated G1 arrest after
DNA damage and is sometimes used as an indicator of p53 function. Kovalev et al
{Kovalev, 1998} demonstrated that although 78% of UPSC cases showed strong
nuclear staining for p53, only 53% of these tumours had detectable p53 mutations. In
addition, 70% of those tumours with mutated p53 had concomitant lack of p21
expression consistent with transcriptionally inactive p53, whereas the other tumours
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had p21 staining suggesting p53 independent p21 expression. Of the cases which did
not show any p53 mutation, more than half still showed strong positive nuclear
staining, but lacked concomitant p21 expression. These findings suggest that nuclear
expression of p53 in UPSC can be associated with both mutation dependent and
independent type of p53 inactivation. In addition, p53 expression is associated with
loss of ER and PR expression {Moll, 1996}. A recent paper demonstrated
expression of p63 in ECIS and UPSC. P63 is a p53-homologous gene which codes
for multiple protein isotypes, including full length forms with p53 like actions and
truncated forms with p53 antagonistic actions {Idrees MT, 2006}. The authors also
demonstrated that p63 expression correlated with p53 and therefore postulated that
p63 mutations also occurred early in the development ofUPSC.
1.3.3 Genes that Regulate Apoptosis
In addition to p53, genes and gene-protein products such as Bcl-2, Bax and Bcl-x are
involved in the control of apoptosis {Crescenzi, 2000;Lu, 1996}. Bcl-2 is a proto-
oncogene, first identified from the t (14-18) translocation, which occurs in follicular
lymphoma {Chen-Levy, 1989}. Bax is a 21-kDa protein that shares homology with
Bcl-2 and forms homodimers {Oltvai, 1993}. It is thought that Bcl-2 suppresses
apoptosis through heterodimerisation with Bax, but that Bax/Bax homodimerisation
triggers programmed cell death {Yin, 1994}. Through an alternate splicing
mechanism the Bcl-x gene encodes two proteins that have opposing functions
{Boise, 1993}. Bc1-xl is the long form and inhibits apoptosis. The short form, Bcl-
xs, triggers apoptosis. Studies have shown that expression of Bcl-2, Bax and Bc1-Xl
varies between normal endometrium, atypical hyperplasia, EEC, ECIS and UPSC
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{Bozdogan, 2002;Busmanis, 2005}. Bcl-2 expression in normal endometrium was
significantly less than ECIS or UPSC, but no difference was found between ECIS
and UPSC, suggesting that Bcl-2 loss occurs early in the pathogenesis of UPSC
{Busmanis, 2005}.
1.3.4 Genes that Regulate DNA Repair
UPSC less commonly shows microsatellite instability (MSI) compared to EEC
{King, 1995}. Hereditary Nonpolyposis Colorectal Carcinoma (HNPCC) is an
inherited condition, characterised by germ line mutations in the mismatch repair
genes MLH1 and MSH2. Abnormal methylation or mutations in these genes lead to
MSI. Broaddus et al {Broaddus, 2006} showed that in those patients with HNPCC
who developed EEC, hypermethylation of MLH1 had occurred leading to MSI.
However, in those patients with HNPCC, who went on to develop non-EEC,
Mutations ofMSH2 were more likely to be found.
1.3.5 Karyotypic Changes.
Loss of heterozygosity (LOH) at chromosome lp occurs in more than 63% UPSC,
rarely in EEC and not in ovarian serous papillary carcinoma (OSPC). This suggests
the presence of a tumour suppressor gene on chromosome lp, important in UPSC
tumorigenesis {Arlt, 1996;Herzog, 2001}.
1.4 Presenting Features
Most patients with UPSC present in a similar way to those with EEC. The most
common presenting symptom is abnormal vaginal bleeding. Abdominal symptoms
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such as bloating, pain or change in weight are occasionally seen and these symptoms
are more common in patients presenting at a later stage {Podratz, 2003}.
1.5 Macroscopic appearances
UPSC has similar macroscopic features to all endometrial carcinomas. It usually
forms exophytic lesions within the endometrial cavity, with varying degrees of
myometrial invasion. Occasionally UPSC may arise in a polyp or form a polyp. Hui
et al {Hui, 2005} studied 40 cases of UPSC, where macroscopically, the tumour was
confined to the endometrium. They found that UPSC involved an endometrial polyp
in 35 cases (88%) and in 18 cases (45%) extra-uterine tumour was present. In those
cases, which were surgically staged as Stage la, either confined to a polyp or the
endometrium, the overall survival after an average of 26 months follow up was 94%.
They did not find any difference in outcome within the Stage la category where
tumour was either confined to a polyp or was confined to the endometrium. There are
no macroscopic features present, which can help differentiate between USPC and
any other type of endometrial carcinoma.
1.6 Microscopic Appearances
UPSC was first recognised as a clinical variant in 1947 but it was not until 1982 that
Hendrickson et al published a full clinical and morphological description of the
lesion {Hendrickson, 1982}. Their criteria for diagnosis included complex papillary
architecture with tufted stratification of the lining epithelium, marked nuclear
polymorphism, high nuclear to cytoplasmic ratio, macronuclei and high mitotic rate.
Solid areas could also be identified {Hendrickson, 1982}. Psammoma bodies can be
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present in up to 33% of UPSC (See Figures 2.1 to 2.4 in chapter 2). UPSC is often
found along with other subtypes of endometrial carcinoma including endometrioid
and clear cell variants. Sherman et al (Sherman, 1992} suggested that the term
UPSC should be used when it comprised at least 25% of the tumour. However, to
date no study has been performed determining the exact amount of UPSC needed to
be present to give the poor prognosis associated with "pure" UPSC. Some tumours
are diffusely infiltrative, whereas others have a pushing border. The significance of
this is uncertain.
1.6.1. Immunohistochemistry
Like all endometrial carcinomas, immunohistochemistry (IHC) shows UPSC to
express CK7 and focal Cal25. UPSC is associated with overexpression of p53 and
IHC for p53 is sometimes helpful in confirming the diagnosis. However, antibodies
to p53 are not helpful in distinguishing between EEC and UPSC as both carcinomas
express p53 to a variable degree, with increasing expression seen in any type of
higher grade tumours (Macwhinnie, 2004;King, 1995}. GLUT1, a membrane bound
facilitative glucose transporter, whose expression is associated with tumour hypoxia,
has been demonstrated in ECIS and UPSC (Idrees MT, 2006}. Therefore it may
have a role in distinguishing ECIS from normal or reactive endometrial epithelium.
However, as it has also been demonstrated in atypical endometrial hyperplasia and
EEC, it would not be useful in distinguishing UPSC from EEC. Expression ofWT1,
a tumour suppressor gene, can be used to distinguish OSPC from UPSC as OSPC
uniformly expresses nuclear WT1 and UPSC shows either no expression or
cytoplasmic expression ofWT1 (Euscher, 2005}.
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1.7 Spread
1.7.1 Pattern of Spread
UPSC resembles OSPC in its microscopic appearance and pattern of spread, but has
a different molecular pathology {Hendrickson, 1982;King, 1995;Herzog, 2001 ;Zorn
KK, 2005}. UPSC has a propensity for lymphovascular space involvement, stromal
invasion and peritoneal spread {Lim, 2001}. It is upstaged at the time of surgery in
60% of cases {Gehrig, 2001;Jeffrey, 1986;Kato, 1995;Goff, 1994;Dunton, 1991}.
1.7.2 Mechanism of Spread
Invasion and metastasis involves many complex interactions and processes. Figure
1.2 shows the metastatic cascade, courtesy of Cotran et al {Cotran RS, 2006}
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1.7.2.1 Detachment from Adjacent Cells
The role of E cadherin as a tumour suppressor gene has been previously discussed.
This section focuses on its possible role in invasion of tumour cells. Cadherins are a
widely distributed family of cell-cell adhesion molecules with varying degrees of
tissue specific expression. E cadherin is found in all normal epithelia. As
transmembrane cell adhesion molecules involved in cell-cell interactions, cadherin
binding is homotypic and calcium dependent {Nose, 1988;Matsuzaki, 1990).
Intracellularly E cadherin is linked to members of the catenin family (P, y, or a-
catenin) through which it is connected to the actin cytoskeleton {Nathke,
1994;Hinck, 1994;Jou, 1995}. Cadherin-catenin complexes have roles in intercellular
communication and modulation of cell function in both normal and malignant
tissues. Failure to assemble the E cadherin-catenin complex or properly connect to
the actin cytoskeleton results in loss of cell adhesion.
Decreased E cadherin expression levels have been observed in some "non EECs"
{Moreno-Bueno, 2003}, and also has been associated with an increased risk of
development of distant metastases {Pijnenborg, 2004}. However, nuclear
localization of P catenin (associated with mutations in the P catenin gene) and
mutations in the adenomatous polyposis coli (APC) gene were not predictive for
recurrent disease. The exact role of E cadherin has not been fully elucidated and
more work is needed in this area.
1.7.2.2 Attachment to Matrix Components
To penetrate the surrounding extracellular matrix (ECM), the tumour cells must first
adhere to the ECM components. There is considerable evidence that receptor
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mediated attachment of tumour cells to laminin and fibronectin is important for
invasion and metastasis {Price JT, 1997;Ziober BL, 1996}. Normal epithelial cells
express high affinity receptors for basement membrane (BM) laminin that are
polarised to their basal surface. In contrast some carcinoma cells have many more
receptors and they are distributed all round the cell membrane and there appears to
be correlation between the density of receptors and invasion in colon and breast
carcinoma {Ziober BL, 1996}. In addition to laminin receptors tumour cells also
express integrins that can serve as receptors for many components of the ECM
including fibronectin, laminin collagen and vitronectin {Vizirianakis, 2001 ;Yao,
1996}. Studies examining in vivo integrin expression in normal endometrium
showed that (31 integrin expression was mostly seen in endometrial stromal cells
{Castelbaum, 1997}. In addition, in vitro studies showed that progesterone treatment
of oestradiol-primed cells resulted in increased expression of the a 1(31 collagen-
laminin receptor and suppression of the av|33 vitronectin receptor {Castelbaum,
1997}. Lessey et al {Lessey, 1995} found alteration of integrin expression between
benign and malignant endometrial epithelium, with the a5(31 integrin, most
commonly seen on benign endometrial stromal cells, being found in almost 20% of
cases of endometrial carcinoma. They also showed that integrin expression correlated
with steroid receptor status, as well as with grade, stage and depth of invasion
{Lessey, 1995;Ziober BL, 1996}.
1.7.2.3 Invasion of Extracellular Matrix
Degradation of the ECM is an essential element of angiogenesis, cellular invasion
and tumour metastasis. Matrix metalloproteinases (MMP), a family of zinc-
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dependent endoproteinases, are widely accepted to play a role in these processes
{Chang, 2001;Vihinen, 2002}. MMPs are normally expressed at a very low level in
adult tissues, except in tissues that undergo remodelling such as cycling
endometrium and wound healing. However, loss of control of MMP expression has
been implicated in a number of diseases such as rheumatoid arthritis, osteoarthritis,
chronic wounds and cancer {Chang, 2001;Vihinen, 2002;Stamenkovic, 2000;Parks,
1999;John, 2001;Jiang, 2002}. Based on their structure and substrate specificity
MMPs are divided into several groups that include collagenases (MMP-1, MMP-3
and MMP-8), gelatinases (MMP-2 and MMP-9), stromeolysins (MMP-3, MMP-10,
MMP-11), matrilysins (MMP-7, MMP-26), metalloelastase (MMP-12) and
membrane type matrix metalloproteinases (MT-MMPs) {Chang, 2001
;Vihinen, 2002;Stamenkovic, 2000;Parks, 1999;John, 2001;Jiang, 2002 }.
The expression of MMPs is highly regulated at transcription, translation and
secretion of latent enzyme, proenzyme activation and inactivation levels. The
catalytic activity of MMPs is specifically controlled at least in part by their
physiological inhibitors, the tissue inhibitors ofMMPs (TIMPs), composed of TIMP-
1, -2, -3 and -4 {Chang, 2001;Kugler, 1999;Jiang, 2002}. TIMP-1, -2 and -4 are
secreted in soluble forms whereas TIMP-3 is insoluble due to binding to ECM
proteins {Chang, 2001;Vihinen, 2002;Stamenkovic, 2000;Parks, 1999;John,
2001;Kugler, 1999;Jiang, 2002}. Although TIMP -4 appears to have restricted tissue
expression and function, TIMP expression is found in many tissues and is regulated
in coordination with MMPs. In addition to regulating MMPs, TIMPs have been
demonstrated to have angiogenic and growth factor-like activity {Parks, 1999;John,
2001;Kugler, 1999;Jiang, 2002;Stetler-Stevenson, 1999}.
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In the female reproductive tract tissues the expression of several MMPs and TIMPs
is associated with menstruation, abnormal uterine bleeding, ovulation, embryo
implantation, cervical ripening and parturition {Martelli, 1993;Rodgers,
1994;Matrisian, 1992}. Altered expression ofMMPs (MMP-1, -2, -3, -7, -8, -9, -13)
and TIMPs (TIMP-1, -2 and -3) have been shown to occur in endometrial
adenocarcinoma and the results indicate increased expression ofMMP-9 and MMP-7
is associated with myometrial invasion and lymph node metastasis respectively
{Yabushita, 2000;Ueno, 1999;Moser, 1999}. In contrast MMP-2 expression is used
to help differentiate high grade from low-grade endometrial carcinoma and MMP-9
in differentiating normal from sarcomatous endometrial stroma {Iurlaro,
1999;Liokumovich, 1999;Inoue, 1997}. Park et al {Park, 2001} demonstrated that
cells from an endometrial adenocarcinoma cell line invaded by recruiting MMP-2
secreted by endometrial stromal cells and this was enhanced by the presence of beta
oestradiol.
MMP-26 and TIMP-4 expression is elevated in endometrial carcinomas with the
highest expression correlating with deeper myometrial invasion and grade 3 (high
grade) tumours. There is no difference in expression between grade 3 EEC and
USPC {Tunuguntla, 2003}.
1.8 Treatment
The most effective treatment for UPSC is surgery, and then depending on the stage
of the disease, adjuvant chemotherapy, radiotherapy or both may be given. However,
due to the relative rarity of the disease no chemotherapeutic regimes have been fully
ratified in patients with UPSC.
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1.8.1 Surgery
In 1988 the International Federation of Gynaecology and Obstetrics (FIGO) changed
the staging criteria for endometrial carcinoma from a clinical to surgical system. To
appropriately stage endometrial carcinoma by the FIGO system, the surgeon must
perform a total extrafascial hysterectomy and bilateral salpingo-oophorectomy,
obtain peritoneal washings, and sample any suspicious pelvic or para-aortic lymph
nodes. Several authors have shown that 40% to 60% of clinical Stage I UPSC are
upstaged at the time of surgical staging and lesions clinically confined to the
endometrium are upstaged in approximately 60% of cases {Gehrig, 2001;Jeffrey,
1986;Kato, 1995;Goff, 1994}. Several studies have shown the presence of lymph
node metastases in up to 50% of cases at the time of surgery {Huh, 2003;Slomovitz,
2003;Goff, 1994}. Therefore the use of prognostic factors appropriate for EEC
including depth ofmyometrial invasion and lymph vascular space invasion may not
apply to UPSC {Carcangiu, 1997;Carcangiu, 1992;Goff, 1994;Cirisano,
1999;Geisler, 1999;Gallion, 1989;Lee, 1991}.
The 1988 FIGO system does not include omental evaluation as part of the surgical
staging criteria for endometrial carcinoma. However, this is frequently performed in
cases where UPSC has been diagnosed preoperatively as UPSC and OSPC have a
similar pattern of intra abdominal spread with a propensity to spread to the upper
abdomen. Gehrig et al {Gehrig, 2003} performed a study on 52 women with UPSC
who had had omentectomy as part of their surgical staging. Thirty-four of the omenta
were macroscopically and microscopically benign, 2 contained microscopic
metastases and 16 were macroscopically and microscopically involved with tumour.
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The sensitivity of a visually negative omentum was 89%. The authors concluded
that, with a microscopic metastasis rate of 4%, surgical sampling does not need to be
included in the routine surgical staging ofUPSC. However this would mean that 1 in
25 patients with UPSC would be under staged. Full surgical staging does appear to
decrease local recurrences but using surgery as the sole therapy in UPSC is not
useful due to the high recurrence rates, which mostly occur in the upper abdomen
{Hendrickson, 1982;Jeffrey, 1986;Goff, 1994;Sutton, 1987}.
1.8.2 Radiation Therapy
The current rationale of treatment of endometrial carcinoma is to consider adjuvant
pelvic radiotherapy in those patients with high-risk disease endometrial carcinoma
(positive retroperitoneal lymph nodes, high histological grade or deep myometrial
invasion). This is thought to reduce the risk of local recurrence, but has demonstrated
less effect on overall survival as these patients usually die of distant disease {Gehrig,
2004;Elit, 2002;Bristow, 1999}. Huh et al {Huh, 2003} showed a similar overall
survival in those patients with Stage I and II UPSC who were managed
conservatively and those who received adjuvant radiotherapy suggesting that
adjuvant radiotherapy may not have a role in those patients where the tumour is
confined to the uterus. Whole abdominal pelvic irradiation (WART) has not been
extensively studied, and consensus has not been reached regarding the benefits of
this approach, but it is recommended, following resection due to the risk of upper
abdominal dissemination {Lim, 2001}. However studies examining the survival of
patients treated with post operative WART have shown conflicting results
{Mallipeddi, 1993;Gibbons, 1991;Frank, 1991;Mehta, 2003}.
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1.8.3 Hormonal Therapy
Progesterone therapy may be used empirically to treat metastatic EEC, as this is
often a PR and ER positive tumour. However this has not been extensively used for
patients with UPSC, as UPSC is usually an ER, and PR negative tumour {Umpierre,
1994;Carcangiu, 1990}.
1.8.4 Systemic Chemotherapy
Despite the microscopic similarity ofUPSC to OSPC, UPSC does not show the same
degree of chemosensitivity. However, the similarity of pattern of spread and
recurrence to OSPC has led researchers evaluate similar treatments {Bristow, 1999}.
1.8.4.1 Platinum Based Chemotherapy
The most extensively evaluated treatment option in patients with UPSC is platinum-
based chemotherapy, most commonly using cisplatin. Platinum-based agents act by
cross-linking DNA, making it impossible for proliferating cells to replicate their
chromosomes for mitosis. The cross-linked DNA activates DNA repair mechanisms,
which ultimately induce apoptosis. Response rates associated with cisplatin-based
chemotherapy range from 10% to 33% {Price, 1993;Chambers, 1996;Levenback,
1992}. However the combination of cisplatin, doxorubicin and cyclophosphamide
chemotherapy is less effective in UPSC than in ovarian carcinoma {Price,
1993;Chambers, 1996}. Doxorubicin is a cytotoxic antibiotic and cyclophosphamide
acts by alkylating DNA, thus damaging it and interfering with cell replication. To




Paclitaxel (Taxol), a member of the taxane group of drugs, is another treatment of
ovarian cancer, which has also had some success in the treatment of UPSC. Single
agent paclitaxel showed a tumour response in 77% of patients {Ramondetta, 2001},
and used in a neo-adjuvant fashion with cisplatin produced objective responses in 8
out of 9 patients {Zanotti, 1999}.
1.8.4.3 Topotecan
Topotecan is an established treatment in recurrent ovarian cancer, with response rates
of 13% to 33% {McGuire, 2000;Swisher, 1997;Bookman, 1998}. Topotecan acts by
blocking the action of topoisomerase I, an enzyme critical for cellular replication and
repair. A pilot study assessing a 5-day regimen of topotecan as first line therapy in 15
women with UPSC found that 12 patients received topotecan as first-line therapy and
3 patients received it as second line treatment after failure of platinum therapy {Gore,
2002}. At median follow up of 13 months, 11 of the 12 patients who received first
line topotecan (93%) remained in remission. Of the 3 patients receiving second line
topotecan, 2 died and the other patient remained disease free at the end of the trial.
1.8.4.4 Herceptin
Several studies have showed amplification of the HER-2/neu (c-erbB2) oncogene in
UPSC {Macwhinnie, 2004;Santin, 2003;Santin, 2002;Santin, 2005}. In addition,
Santin et al {Santin, 2005} demonstrated that those UPSC patients with c-erbB2
amplification had a poorer prognosis than those without c-erbB2 amplification. On
the basis of these findings as well as those of previous reports showing a positive in
vivo correlation between the efficacy of Herceptin R therapy and the level of HER-
2/neu overexpression by tumour cells, Herceptin R therapy may be a novel strategy in
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a significant number of patients with chemotherapy resistant recurrent or metastatic
UPSC {Santin, 2002}.
1.8.4.5 imatinib Mesylate
Imatinib mesylate is a tyrosine kinase inhibitor that specifically targets c-kit, Abl and
PDGFR. It has been shown to be effective in the treatment of patients with chronic
myeloid leukaemia and gastrointestinal stromal tumours. These cancers are
characterized by activating mutations of Abl and c-kit tyrosine kinases respectively.
As both Abl and PDGFR are expressed in primary and recurrent UPSC, imatinib
mesylate may be a useful treatment for these patients {Slomovitz, 2004}.
1.8.4.6 Summary
The benefit to patients from such multimodality therapy remains uncertain because
no significant improvement after adjuvant therapy has been noted in the last decade
{Bancher-Todesca, 1998;Tay, 1999}. However, there is clearly a need to continue
investigating possible treatments due to the dismal prognosis ofUPSC.
1.9 Prognosis
The outcome of endometrial carcinoma is influenced by the initial stage, and grade
of the tumour. While early stage endometrial carcinoma is associated with relatively
good cure rates, advanced stage disease is characterized by a poorer prognosis.
Overall survival for women with surgically staged endometrial carcinoma ranges
from 70% to 90% for those with Stages I and II disease and 5% to 60% for those
with III and IV disease. However, when grouped by histological type, overall
survival for women with EEC is 76% while survival for women with UPSC is much
worse, ranging from 0 to 45% {Zanotti, 1999;Price, 1993;Gitsch, 1995;Creasman,
39
2003;Chambers, 1987;Carcangiu, 1992;Abeler, 1990}. Approximately 75% of
women with EEC present with disease clinically confined to the uterus (Stage I),
whereas 37-66% of women with UPSC tend to present with more advanced stage
disease {Creasman, 2003;Gitsch, 1995}. Most series report survival rates of 35%-
50% for Stages I and II and 0-15% for Stages III and IV UPSC {Jeffrey,
1986;Dunton, 1991;Gallion, 1989;Sutton, 1987;Abeler, 1990;Piura, 1998;Bristow,
2001}. Despite the best treatment attempts, relapse rates are reported to be as high as
50% to 80% {Christman, 1987;Chambers, 1987;Ramondetta, 2001;Hendrickson,
1982}.
Many studies have been performed in the attempt to identify factors that might be
useful in predicting outcome of these patients. Population based data from the
American National Cancer institute found that although the incidence of endometrial
cancer was higher in white patients, black patients actually had a worse outcome
{Hicks, 1998}. Santin et al {Santin, 2005}, found that earlier deaths were seen in
those UPSC patients that overexpressed c-erbB2, black patients and those over 65
years of age at presentation. However, multivariate Cox regression showed that
although short survival was significantly associated with c-erbB2 expression it was
not associated with either race or age, suggesting that the c-erbB2 amplification
caused much of the race disparity in survival in the patient population.
High serum levels of interleukin-6 (IL-6) are associated with, and expressed by,
UPSC {Bellone, 2005;Santin, 2005}. IL-6 is a pleiotropic cytokine which is involved
in the immune system, acute phase responses and has various effects on
haematopoiesis {Hirano, 1998}. IL-6 regulates cell growth of a variety of human
cancers and inhibits the antitumour effects of the immune system. High serum levels
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of IL-6 correlate with shorter survival in patients with renal cell, prostatic and
ovarian carcinoma {Blay, 1992;Nakashima, 2000;Scambia, 1995;Bachelot, 2003}.
The kallikrein family is large and its members are all proteases, which encode for
trypsin-like or chymotrypsin-like serine proteases. Kallikrein -6 and -10 have been
detected both in vivo and in vitro in UPSC {Santin, 2006;Santin, 2005}. Kallikrein
10 is implicated in the growth and invasion of breast, ovarian and prostate cancer
{Diamandis, 2002;Goyal J, 1998}. Kallikrein-6, -10 and IL-6 may be useful in
monitoring early disease recurrence and response to therapy.
Busmanis et al {Busmanis, 2005} did not find that p53 was a useful predictor for
either survival time or disease stage. However, there is evidence that p73 expression
profiles and p53 status are useful in differentiating between patients with good and
poor prognosis. Despite P73 having significant homology to p53, it is not thought to
be a tumour suppressor gene. The TP73 gene has 5 N-terminal isoforms including
TAp73, DeltaNp73 and DeltaN'p73. Delta Np73 derives from an alternative
promoter in intron 3 and lacks the transactivation domain of full length Tap73. It
counteracts transactivation function, apoptosis and growth suppression mediated by
wild-type p53 and TAp73 and confers drug resistance to wild type p53 harbouring
tumour cells. Conversely down regulation of endogenous DeltaNp73 levels inhibits
its suppressive action and enhances p53- and Tap73-mediated apoptosis {Zaika AI,
2002}. Using a support vector machine algorithm Becker et al {Becker K, 2006}
demonstrated that TAp73, DeltaNp73 and DeltaN'p73 were significantly upregulated
in all gynaecological tumours.
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1.10 Summary
Uterine papillary serous carcinoma is a highly aggressive variant of endometrial
carcinoma and accounts for approximately 10% of cases, but a much smaller
proportion of Stage I endometrial carcinomas. It has a grim prognosis. This chapter
has described what is currently known about UPSC and has focussed on the
aetiology, pathogenesis and treatment of this aggressive cancer. Recently there have
been several reviews of series of UPSC patients, predominantly focussing on the
molecular pathology of UPSC or current treatment strategies, and all suggesting the
value of a larger scale clinical trial {Slomovitz, 2003;Ramondetta, 2001;Zanotti,
1999;McGuire, 2000;Swisher, 1997}. To date there is no clinically proven treatment
strategy for UPSC, and patients with this tumour receive ad hoc therapy, which has
no proof of efficacy. A large scale clinical trial is important because all previous
studies have been limited by the relative rarity of the disease; therefore the small
numbers of patients seen in all centres and also the small numbers involved in these
reviews have limited the power of the studies.
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Chapter 2
Materials and Methods for Chapters 5, 6 and 7.
2.1 Tissues
2.1.1 Identification of Cases
Suitable cases were identified in three ways. Firstly, a search of the APEX computer
system was made from 1992 to 2004. The codes used to identify suitable cases were
T-84000 (endometrium), T-82920 (Total hysterectomy), T-82000 (Uterus), T-82900
(Uterus and cervix) and M-80103 (carcinoma), M-83803 (endometrioid carcinoma)
and M-82603 (papillary carcinoma). The data that was recovered also included the
patient's name, date of birth and the numbers accorded to the specimens by the
Department of Pathology. Secondly a separate search was performed on the
Department of Oncology Gynaecology database from 1994 to 2003, where the search
parameter was any patients in whom a diagnosis of uterine papillary serous
carcinoma (UPSC) had been made. This data was predominantly used for the audit
into the diagnosis and management of UPSC. Lastly the paper records of the weekly
regional Gynae-oncology multidisciplinary meeting were examined and those cases
that on review were described as either UPSC or Grade 3 endometrioid endometrial
carcinoma (EEC) were selected. The results from all three searches were combined.
For the purposes of the audit on the diagnosis and management of UPSC, all of the
cases from 1994 to 2003, selected by the oncology database were used. For the
creation of the tissue microarrays (TMAs), all cases where blocks and remaining




2.1.2.1 Uterine Papillary Serous Carcinoma
The demographic details for those patients selected for the audit on the diagnosis and
management of UPSC are described in Chapter 4. Seventy-eight patients were
identified for the TMAs. Their demographics are described here. The median age of
the patients was 68 years (range 49-89). Nine patients (12%) had a past medical
history of breast cancer. No patients developed breast cancer after the time of
diagnosis of UPSC. The FIGO staging system (Creasman, 1990} was used in
describing the stage of disease. Table 2.1 shows the FIGO staging system. The
numbers and percentages of each patient with each stage of disease are presented in
Table 2.2. Hui et al {Hui, 2005} showed that UPSC confined to either an
endometrial polyp or the endometrium had good prognosis. However, as only 4 of
our UPSC cases were Stage la, these were not treated as a separate group.
2.1.2.2 Endometrioid Endometrial Carcinoma
Twenty patients with FIGO grade 3 EEC were identified. The median age of the
patients was 66 years (range 46-85 years). No patients had either a past history of
breast carcinoma, or developed it subsequently. The numbers and percentages of
each patient with each stage of disease are presented in Table 2.2.
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Table 2.1 FIGO Staging for Carcinoma of the Endometrium
Stage I Tumour confined to uterine corpus
IA Limited to endometrium
IB Invasion less than half ofmyometrium
IC Invasion more than half of
myometrium
Stage II Tumour involves cervix
IIA Endocervical glandular (mucosal)
involvement only
IIB Invasion into cervical stroma
Stage III
IIIA Tumour invades serosal of corpus uteri
and/or adnexae and/or positive
cytological findings
IIIB Vaginal metastases
IIIC Metastases to pelvic and/or paraaortic
lymph nodes
Stage IV
IV A Tumour invades bladder mucosa
and/or bowel mucosa
IV B Distant metastases, including intra¬
abdominal metastasis and/or inguinal
lymph nodes
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Table 2.2 Demographic Details of Patients Used to Create Tissue
Microarrays.
UPSC EEC
Median Age 68 years 66 years
(Range) (49-89) years (45-85) years
History of Breast 9 0
Carcinoma
(Patients)




Stage II 21 (27%) 1 (5%)
IIA 10 0
IIB 11 1




Stage IV 11 (14%) 1 (5%)
Total Patients 78 20
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2.1.3 Tissue Samples
Archival tissue samples were selected from the Royal Infirmary of Edinburgh
Department of Pathology, the slides were reviewed by HM and ARWW (a
subspecialist gynaecological pathologist), the diagnosis of UPSC or EEC was
confirmed and the appropriate paraffin blocks were selected. All tissue had been
routinely fixed in 4% buffered formaldehyde and processed into paraffin blocks. The
diagnostic features used to classify cases as UPSC and EEC are well described and
are as follows {Robboy}:
2.1.3.1 Uterine Papillary Serous Carcinoma
At low power UPSC shows either papillary architecture or solid areas where the
papillae are composed of broad fibrovascular cores with secondary or tertiary
papillary processes and with prominent dropping off of cells into the lumen. The
cells are generally rounded and the nuclei are pleomorphic with occasional
multinucleation. In addition the nuclei tend to be centrally placed rather than lying
adjacent to the basement membrane. Mitoses and foci of necrosis are common.
Psammoma bodies are found in some cases (Figures 2.1 to 2.4).
4-k A
Figure 2.1
Figure 2.1. Papillary Architecture ofUPSC (H&E xlO).
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Figure 2.3. Pleomorphic Nuclei forming a papillary pattern in UPSC
(H&Ex40).
Figure 2.4 Psammoma Bodies Lying within Tumour Adjacent to Myometrial
Arteries (H&Ex20).
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2.1.3.2 Endometrioid Endometrial Carcinoma
EEC can range from low to high grade. The well-differentiated (Grade 1) carcinomas
can be difficult to distinguish from atypical complex hyperplasia. EEC typically has
at least a focus of glandular differentiation lined by stratified columnar cells, with
oval nuclei arranged at right angles to the basement membrane. As the carcinoma
becomes more poorly differentiated (Grade 3), the prominent gland formation
decreases and solid areas and sheets of cells are more apparent {Tavassoli, 2006}
(Figures 2.5 to 2.8). EEC is typically divided into three grades, namely; Grade 1,
Grade 2 and Grade 3, which are also referred to as well-, moderately- and poorly-
differentiated respectively. The classification of grading developed by the World
Health Organisation {Scully} is used and Table 2.3 shows the grading of EEC with
architecture being the most important determinant. Significant nuclear atypia,
described as round nuclei, variation in shape and size, variation in staining,
hyperchromasia, coarsely clumped chromatin, prominent nucleoli, frequent mitoses
and abnormal mitoses, will increase the grade by one, irrespective of the architectural
features. Only cases of Grade 3 (high grade) EEC were selected for comparison with
UPSC for this study.
At least one area from the viable central part and invasive edge of the tumour were
then marked by a circle (Figure 2.9).
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Figure 2.5. Classical Gland Formation ofEEC (H&E x20).
Figure 2.6. Solid Architecture ofEEC (H&E xlO).
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Figure 2.7
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Figure 2.7. Stratification of cells in glands in Grade 1 EEC (H&E x20).
Figure 2.8. Pleomorphic nuclei in Grade 3 EEC (H&E xlO).
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Figure 2.9
Figure 2.9. Circles showing area to be sampled by Beecher Instrument. At least
three cores can be taken from within each circle (Magnificationx4).

















Nuclear atypia Increase grade by 1.
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2.2 Tissue Microarray
A tissue microarray (TMA) instrument by Beecher Instruments was selected (Figure
2.10). In order to construct the microarray, empty paraffin blocks of a depth 5-10mm
were produced. Cores ofwax, 0.8mm diameter were extracted from the empty blocks
and replaced with cores of 0.6mm diameter taken from the tissue blocks at sites
corresponding to the previously selected areas on the H&E slides (Figure 2.11). Two
cores were taken from each area marked on the slide, so that at least two cores were
taken from each case. The cores were punched at 1mm intervals, at least 2 cores per
case, and the numbers of cores taken from each case ranged from 2 to 10. A grid
system with each core having a coordinate reference (X axis, Y axis) was used to
allow cross-reference between core location and parent case.




Figure 2.10. Beecher instrument used to create Tissue Microarrays courtesy of
Skacel et al.
Figure 2.11. Tissue Microarray Block used for EEC cases.
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2.3 Immunohistochemistry
From the TMA blocks, sections were cut at 3pm thickness and mounted on
positively charged capillary action slides (Dako, Copenhagen, Denmark) and
incubated at 60 °C overnight. The slides were dewaxed and rehydrated prior to
antigen retrieval. Table 2.4 shows a summary of the details of the antibodies used.
2.3.1 P53
Antigen retrieval was performed by immersing the test slides and a case of breast
carcinoma (as the positive control) in 0.01 M ethylenediamine tetraacetic acid
(EDTA), PH8.0 and microwaving at high power for 15 minutes. The primary
antibody was the D-07 clone (Dako, Denmark) and was used at dilution 1:50.
Negative controls were obtained by omitting the primary antibody. All slides were
stained on the Dako TechMate™ 500 plus, using the Dako ChemMate™ EnVisionIM
Detection kit and the standard operating procedure for routine
immunohistochemistry.
2.3.2 ER
Antigen retrieval was performed by immersing the test slides along with a slide of
breast carcinoma (as the positive control) in 0.01M EDTA, PH8.0 and microwaving
at high power for 15 minutes. The primary monoclonal antibody was the 6F11/2
clone (Novocastra, UK) and was used at dilution 1:200. Negative controls were
obtained by omitting the primary antibody. All slides were stained on the on the
Dako TechMate™ 500 plus, using the menapath supersensitive detection kit polymer
HRP and the standard operating procedure for routine immunohistochemistry.
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Table 2.4. Primary Antibodies and Antigen Retrieval Conditions used in
IHC.
Antigen Manufacturer Clone Dilution Antigen
Retrieval
Control



















































Antigen retrieval was performed by immersing the test slides along with a section of
normal appendix (as the positive control) in 0.01 M EDTA, PH8.0 and microwaving
at high power for 15 minutes. The primary monoclonal antibody was the 17B11
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clone (Novocastra Laboratories, UK) and was used at dilution 1:40. Negative
controls were obtained by omitting the primary antibody.
All slides were stained on the Dako TechMateIM 500 plus, using the Dako
ChemMate™ EnVisionIM Detection kit and the standard operating procedure for
routine immunohistochemistry.
2.3.4 MMP-7
No antigen retrieval was performed. A slide of breast carcinoma was used as the
positive control. The primary monoclonal antibody was the clone 1D2 (Chemicon
International, UK) and was used at dilution 1:25. Negative controls were obtained by
omitting the primary antibody. All slides were stained on the Dako TechMate™ 500
TK A TKA
plus, using the Dako ChemMate EnVision Detection kit and the standard
operating procedure for routine immunohistochemistry.
2.3.5 MMP-9
Antigen retrieval was performed by immersing the test slides along with a slide of
kidney (as the positive control) in 0.01 M EDTA, PH8.0 and pressure-cooking for 7
minutes. The primary monoclonal antibody was the clone 15W2 (Novocastra
Laboratories, UK) and was used at dilution 1:80. Negative controls were obtained by
omitting the primary antibody. All slides were stained on the Dako TechMate™ 500
plus, using the Dako ChemMate™ EnVision™ Detection kit and the standard
operating procedure for routine immunohistochemistry.
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2.3.6 PR
Antigen retrieval was performed by immersing the test slides along with a slide of
breast carcinoma (as the positive control) in 0.01M EDTA, PH8.0 and microwaving
at high power for 15 minutes. The primary monoclonal antibody was the PgR 636
clone (Dako, Denmark) and was used at dilution 1:100. Negative controls were
obtained by omitting the primary antibody. All slides were stained on the Dako
TechMate1M 500 plus, using the Dako ChemMate™ EnVision1 M Detection kit and
the standard operating procedure for routine immunohistochemistry.
2.3.7 Galectin-3
Antigen retrieval was performed by immersing the test slides along with a slide of
papillary carcinoma of the thyroid (as the positive control) in 0.01M EDTA, PH8.0
and microwaving at high power for 15 minutes. The primary monoclonal antibody
was the 9C4 clone (Novocastra, UK) and was used at dilution 1:150. Negative
controls were obtained by omitting the primary antibody. All slides were stained on
the Dako TechMate™ 500 plus, using the Dako ChemMate™ EnVision™ Detection
kit and the standard operating procedure for routine immunohistochemistry.
2.3.8 CD98
Antigen retrieval was performed by immersing the test slides along with a slide of
tonsil (as the positive control) in PC citrate and microwaving at high power for 2.5
minutes. The primary polyclonal IgG antibody was the clone C-20 (Santa Cruz) and
was used at dilution 1:200. A rabbit antigoat secondary antibody was used. Negative
controls were obtained by omitting the primary antibody. All slides were stained on
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the Dako TechMate™ 500 plus, using the ABC-vector kit and the standard operating
procedure for routine immunohistochemistry.
2.3.9 E Cadherin
Antigen retrieval was performed by immersing the test slides along with a slide of
tonsil (as the positive control) in 0.01M EDTA, PH8.0 and microwaving at high
power for 2.5 minutes. The primary monoclonal antibody was the NCH-38 clone
(Dako, Denmark) and was used at dilution 1:25. Negative controls were obtained by
omitting the primary antibody. All slides were stained on the Dako TechMate™ 500
plus, using the Dako ChemMate™ EnVision™ Detection kit and the standard
operating procedure for routine immunohistochemistry.
2.3.10 P Cadherin
Antigen retrieval was performed by immersing the test slides along with a slide of
placenta (as the positive control) in 0.01M EDTA, PH8.0 and microwaving at high
power for 15 minutes. The primary monoclonal antibody was the 56C1 clone
(Novocastra, UK) and was used at dilution 1:100. Negative controls were obtained
by omitting the primary antibody. All slides were stained on the Dako TechMate™
500 plus, using the Dako ChemMate™ EnVision™ Detection kit and the standard
operating procedure for routine immunohistochemistry.
2.3.11 p Catenin
Antigen retrieval was performed by immersing the test slides along with a slide of
tonsil (as the positive control) in 0.01M EDTA, PH8.0 and microwaving at high
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power for 15 minutes. The primary monoclonal antibody was the (3 catenin-1 clone
(Dako, Denmark) and was used at dilution 1:50. Negative controls were obtained by
omitting the primary antibody. All slides were stained on the Dako TechMate1M 500
plus, using the Dako ChemMate™ EnVision™ Detection kit and the standard
operating procedure for routine immunohistochemistry.
2.4 Scoring
To score P53, a similar scoring system to that used by Leversha et al was used
{Leversha, 2003}. As all cores showed homogenous staining, the intensity was
scored. The intensity was classified into 0 = no staining, 1 = weak staining, 2 =
moderate staining and 3 = strong staining. The positive control was used as a
comparator for strong staining. As the staining pattern is known to be homogenous,
the maximum score of P53 was used in calculations.
ER and PR were scored using a histoscore used in assessing expression in breast
carcinoma cases. This was created by adding the intensity of staining (where 0 = no
staining, 1 = weak staining, 2 = moderate staining and 3 = strong staining) to the
percentage of cells stained (where 0 = no cells staining, 1 = 1-9% of cells staining, 2
= 10-33% cells staining, 3 = 33% - 66% cells staining, 4 = 67-99% cells staining and
5 = 100% cells staining). This gave a range of scores from 0 to 8. As both ER and PR
show heterogeneous staining and both had a wide range of possible scores, the
average score of the informative punch biopsies was used.
The scores for MMP-2, MMP-7, MMP-9, Galectin-3, CD98, E cadherin, P cadherin
and |3 catenin were assessed using a histoscore. This was calculated by multiplying
the intensity of staining (l=weak, 2=moderate and 3=strong) by the percentage of
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cells showing positive staining (1=<20%, 2= 20-80% and 3=>80%), thus giving a
score between 1 and 9. To minimise erroneous results, the average score between the
sample cores' score was used in calculations.
As there is some evidence that the site of staining of Galectin-3 changes according to
action of Galectin-3, the site of staining, either cytoplasmic, nuclear or cytoplasmic
and nuclear was noted.
As we were expecting a decrease in E cadherin expression compared to normal
endometrium, the fragments of normal endometrium within the TMAs were used as a
positive control, as well as the section of tonsil. All the fragments of endometrium
and epithelium in the section of tonsil showed strong, universal expression, with an
overall score of 9.
To ensure the scoring was consistent, the TMAs stained for E cadherin, P cadherin, |3
catenin and ER were rescored 6 months after the initial scoring. Kappa statistics were
applied to the repeat scores and showed good correlation with the results with a score
of 0.63.
2.5 Statistical Analysis
All statistical analysis was performed using SPSS 13.0 software (SPSS Inc,
Chicago).
2.5.1 Tissue Microarray
The mean scores of the representative cores of tumour assessed for each case of
USPC and EEC were calculated. The results from the main part of the tumour were
used in calculations to determine if there were any differences in expression of
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antibodies between tumour types. A paired T-test was performed for the parametric
results and a Mann Whitney U test was performed for the non-parametric results. As
multiple comparisons were being made, there is a risk that this could be interpreted
as "a fishing expedition" and erroneous significant differences may be detected.
Therefore a Bonferroni correction was made. This is a statistical adjustment of the p
value for multiple comparisons, decreasing the liklehood of erroneous false positive
findings. Therefore, for Chapters 5 and7, a p value of less than 0.017 was considered
significant and for Chapter 6, a p value of less than 0.025 considered significant.
The Wilcoxon matched-pairs signed-ranks test was used to estimate relationship
between staining patterns of the different antibodies used between the main part of
the tumour and at the invasive edge. A p value of less than 0.05 was considered
significant. The Pearson pairwise correlation coefficient was used to determine any
relationship between the antibody expressions.
2.5.2 Audit of the Pathology and Management of Uterine Papillary
Serous Carcinoma (UPSC) and Correlation with Outcome (Chapter 4)
The Spearman's Rank test was used to assess the correlation of the initial diagnostic
biopsy with the definitive hysterectomy histology percentage histological subtype.
Overall survival and progression free survival were estimated on the basis of Kaplan-
Meier curves and the log-rank test used as a univariate analysis of prognostic factors.
A p value of less than 0.05 was considered statistically significant, and variables that
had a p value of less than 0.05 were entered into a Cox regression model.
Chapter 3
Validation of Tissue Microarray of Endometrial Carcinoma
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3.1. Introduction
Battifora et al {Battifora, 1986} introduced the multitumour tissue block in 1986 and
Kononen et al {Kononen, 1998} refined this technique to develop the tissue
microarray (TMA) in 1998. Since then the TMA has been widely used in
retrospective analysis of large numbers of formalin fixed paraffin embedded
tumours. The use of TMAs allows screening of up to several hundred tumours for
immunohistochemistry (IHC) or fluorescent in situ hybridisation (FISH) on a single
block, with a minimum outlay of reagents. As all the cores are of the same size and
because all the cores are present on limited numbers of slides they can be treated
identically with regards to antigen retrieval and staining thus reducing the
experimental errors and discrepancies produced during analysis.
A potential shortcoming of TMA is sampling bias, whereby lack of tumour
representation in the cores selected may give erroneous results, due to heterogeneity
of tumours. To address this issue, the sampling of multiple cores is recommended
from each case. However, there is uncertainty as to the optimal number of cores that
need to be taken to give a result that is representative of the tumour as a whole. As
this is likely to vary with different tumour types, it is advisable to perform a
validation study from tumours arising in specific organs. Validation studies have
been performed and published on a range of tumours including those from the breast,
prostate, gastrointestinal tract and ovary (Gillett, 2000;Mousses, 2002;Gulmann,
2003;Rosen, 2004},and have recommended between 2 and 6 cores be taken from
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each case. No tissue validation study on endometrial carcinoma has yet beeti
published in the literature, therefore a validation study was performed to determine
whether TMAs could be used in place of whole sections for IHC and, in addition, to
calculate the number of cores needed from each case to ensure adequate
representation of the tumour.
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3.2 Materials and Methods
3.2.1 Tissues
Archival tissue samples of 78 cases of Uterine Papillary Serous Carcinoma (UPSC)
were selected from the Royal Infirmary of Edinburgh Department of Pathology, the
slides were reviewed by myself and Dr A Williams (a subspecialist gynaecological
pathologist), the diagnosis of UPSC was confirmed, using the criteria described in
"Materials and Methods", and the appropriate blocks were selected. The H&E
sections then had at least one area from the centre of the tumour marked on the slide
by the pathologist. All tissue had been routinely fixed in 4% buffered formaldehyde
and processed into paraffin blocks. Forty-three of the 78 tissue blocks used in the
TMA also had immunohistochemistry (IHC) performed on whole-tissue sections for
comparison of the immunohistochemical staining patterns.
3.2.3. Tissue Microarray
The TMA was created using the technique as described in " Material and Methods".
Once the TMA was made and sealed, sections were cut, with the most superficial
section being stained with Haematoxylin and Eosin (H&E) and the deepest being
used for IHC for Oestrogen Receptor (ER) and P53.
3.2.4. Immunohistochemistry
Both ER status and P53 expression has been well documented in UPSC
{Demopoulos, 1999;Vasil'eva, 2005;Wu, 2003}. ER expression is known to be lower
in UPSC than in endometrioid endometrial carcinoma (EEC) and P53 expression is
increased in UPSC compared with EEC {Demopoulos, 1999}. In addition ER
expression tends to be heterogeneous whereas P53 expression tends to be
homogenous. Therefore antibodies to ER and P53 were used to validate the TMA,
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using the techniques described in "Materials and Methods". Expression of both
antibodies was assessed using the systems described in "Materials and Methods".
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3.3 Results
3.3.1 Technical Efficiency of Tissue Microarray Construction
Technical issues, including poor sealing may result in poor section quality and
misalignment of cores. Misalignment of cores can result in higher cores being cut
through and disappearing before other cores placed lower in the block emerge.
The H&E, P53 and ER sections were screened and the presence of tumour was
checked at each level. Table 3.1 shows a summary of the efficiency of the sections
taken from the TMA. Fourteen percent of cores on the H&E section did not show
tumour and were not informative. Of these, 8 cores showed blood only, 19 showed
myometrium only and 19 cores were missing. This resulted in 2 tumours not being
represented by the TMA. A similar result was seen with the P53 slide with 8 cores
showing blood only, 19 showed myometrium only and 23 cores were missing. This
resulted in 4 cases not being represented by the TMA. Six of the ER cores showed
blood only, 17 showed myometrium only and 22 cores were missing. This resulted in
8 cases not being represented.
3.3.2 Technical Aspects of TMA Immunohistochemistry
The percentage of informative cores was 86%, 85% and 86% for H&E, P53 and ER
respectively. Although there was no significant increase in core loss as the sections
were taken through the TMA block, the number of cases not represented increased
through the TMA. This appeared to be due to different cores cutting out the tumour
at deeper levels resulting in tumour loss. Appendices 2 and 3 show the individual
results of each core compared to the whole sections.
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All P53 staining was nuclear and appeared homogeneous (Figure 3.1). Table 3.2
shows the results of the sections stained with P53. Of the 74 cases with informative
cores stained for P53, 54 showed complete agreement of scores between cores. In 14
cases there was a difference in score of 1, 3 cases had a difference in score of 2 and
one case showed a difference of 3 in the scoring (where 1 punch was negative, 3
showed a score of 2 and 4 showed a score of 3). Counting the score +/- 1 as
concordance, this gave an overall concordance of 92% between cores. When the
scores were compressed into positive and negative the overall concordance between
cores was 93%.
All ER staining was nuclear and in some cases appeared heterogeneous (Figure 3.2).
Table 3.2 shows the results of the ER IHC. Of the 70 cases stained with ER with
informative punches, 41 either had the same score or a difference of 1 between all
punches in the same case, 15 cases had a difference of 2, 6 cases had a difference of
6 and 9 cases had a difference in scores of more than 4. This gave an absolute
concordance of 59%. When the ER scores were compressed into positive (greater
than 4) or negative (less than 4), 58 cases had the same score and in 13 cases, the
variation in scores between punches ranged from positive to negative. This gave an
overall concordance of 82%.
Figure 3.1
Figure 3.1. P53 Immunohistochemistry in UPSC Tissue Microarray
(Magnificationx20).
Figure 3.2. ER Immunohistochemistry in UPSC Tissue Microarray
(Magnificationx20).
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Table 3.1 Technical Results of TMA stained with H&E, P53 and ER
Section Tumour Tumour Total Informative Non Informative Cores Total
present not number cores number
present of Core of
cases Blood Myometrium Missing cores
H&E 76 2 78 283 8 19 19 329
P53 74 4 78 279 8 19 23 329
ER 70 8 78 284 6 17 22 329
3.3.3 Comparison of Data from Whole Sections and Microarray
Samples
3.3.3.1 P53
Expression of P53 in the whole sections was similar to that seen in the TMA (Figure
3.3). Table 3.2 shows the results of the whole sections stained with P53. When the
consensus result for the replicate punches was compared with the IHC result from the
whole sections, the data were concordant for 35 of 39 tumours (90%) for P53. In the
four discordant cases the whole sections results were higher compared with the TMA
results. When the data were compressed into positive and negative, 34 of the 39
tumours gave the same result, with an 87% concordance. In the 5 discordant results,
in all cases, the whole sections were positive and the TMA results were negative.
Simple regression was used to determine whether the compressed or non-compressed
TMA P53 score could predict the P53 score on whole sections. In both cases this
showed a correlation (R) of 0.814 and the coefficient of determination (r ) of 0.663.
This is a large effect size and indicated that the TMA P53 score was a good predictor
of the P53 score on whole sections.
3.3.3.2 ER
On examining the whole sections, most tumours revealed heterogeneous nuclear
staining for the ER antibody (Figure 3.4). This was more apparent than on
examination of the TMA sections. Table 3.2 shows the results of the whole sections
scored with ER. The assessment of concordance was more difficult between the
TMA and whole section for ER as scores ranged from 0 to 8. However in comparing
the whole section result with the TMA score, a result that was +/- 1 was deemed to
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be concordant. Therefore when the consensus result for the replicate punches was
compared with the IHC result from the whole sections, the data were concordant for
22 of 36 tumours (61%) for ER. However, when the consensus data was distributed
into positive and negative we showed that 31 of 36 cases (86%) had absolute
concordance with the whole sections and in the 5 discordant cases the whole sections
were positive and the TMA sections were negative (false negative results). There
were no false positive results.
Simple regression was used to determine whether the TMA ER score could predict
the ER score on whole sections. This showed a correlation (R) of 0.727 and the
coefficient of determination (r2) of 0.515. This was a large effect size and indicated
that the TMA ER score was a good predictor of the ER score on whole sections.
When the ER results were compressed into positive and negative the correlation (R)
was 0.756 and the coefficient of determination was 0.559. This again, was a large
effect size and indicated that the TMA ER score was a good predictor of the ER




Figure 3.3. Whole section showing P53 Immunohistochemistry with hole at the
Site of Core Biopsies (Magnificationx20).
Figure 3.4. Whole section showing ER Immunohistochemistry with hole at the
Site of Core Biopsies (Magnificationx20).
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Table 3.2 P53 and ER Expression in TMA and Whole Sections
P53 ER









40 (95%) 2 (5%) 23 (54%) 19(46%)
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3.4 Discussion
The objective of this chapter was to determine whether TMAs of UPSC could be
used for IHC in place of whole sections. P53 and ER expression in TMAs was
concordant with that of whole sections and the levels of expression in both TMAs
and whole sections were generally in agreement with that in the literature
{Demopoulos, 1999;Wu, 2003;Vasil'eva, 2005}. Agreement was higher with P53
where expression appeared more homogenous compared with ER where expression
tended to be heterogeneous. It is possible that the different scoring criteria applied,
with 4 categories for P53 and 8 categories for ER, also affected the level of
concordance.
Leversha et al {Leversha, 2003} suggested that the most robust method of assessing
antibody expression was to use 2 categories, either "positive" or " negative",
whereas Gomaa et al {Gomaa, 2005} recommended splitting results into 4 groups for
analysis. However, simplifying the scoring can produce erroneous results when the
antibody staining pattern is heterogeneous. Compressing the ER results into positive
and negative improved concordance, but there was no improvement in concordance
when the P53 results were compressed. This may be due to the wider possible range
of scores available for ER, whereas P53 only had 4 categories. Therefore, I feel that,
where the antibody staining pattern is uncertain it is wiser to adopt a Histoscore-type
scoring system, which gives a wider range of categories and thus may minimise
erroneous results.
Reviewing previous validation studies, the statistical techniques used in evaluating
validation have varied and have included kappa analysis, regression analysis,
Pearson correlation coefficient, and re-sampling methods {Hoos, 2001 ;Gillett,
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2000;Rosen, 2004;Rubin, 2002}. I used simple regression analysis as I felt this most
directly answered the research question "can TMAs be used to predict the pattern of
expression of an antibody from whole sections". For both P53 and ER we
demonstrated a large effect size supporting the conclusion that TMAs can be used in
place ofwhole sections.
The second objective was to determine the optimal number of cores that needed to be
taken from each case to give the most accurate results. Our informative yield was
approximately 86% in sections taken from both the top and bottom of the TMA
block. Punch loss occurred in 6%, 7% and 7% of sections stained with H&E, P53
and ER respectively and this is similar to that in the established literature {Leversha,
2003;Wu, 2003;Demopoulos, 1999}. In all sections taken the majority of
uninformative punches were due to sampling error where all that was present was
either myometrium or blood. The punches showing myometrium only may reflect
that some of the samples were taken from Stage la UPSC (Figure 3.5) and therefore
the tumour was focal and was cut through in deeper sections or may have been taken
from cases where the tumour spread in an infiltrative pattern rather than as a solid
mass (Figure 3.6), thus making sampling more difficult. The punches showing blood
only were cases where the tissue sampled were endometrial pipelle specimens, where
often scanty fragments of tumour lie in blood and therefore these punches were prone
to being cut through and the tumour was more susceptible to being missed during
sampling. Overall our percentage of uninformative samples was at the higher end of
the range reported in the literature (5-17%) {Leversha, 2003;Rosen, 2004;Fernebro,
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Figure 3.5. Whole Section Showing P53 Staining and Site ofTMA cores in
Stage laUPSC (Magnificationx4).
Figure 3.6. Whole Section Showing P53 Staining and Site ofTMA cores in
infiltrating UPSC (Magnificationx4).
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with 5% {Leversha, 2003}. The difference in informative punches in part reflects the
diversity of specimens being sampled, rather than solid fragments of tumour, which
are most commonly used in creating TMAs.
We found that taking more than one punch from each case increased the level of
informative data from the TMA, which otherwise would have been lost. In addition,
in the case of ER where expression was heterogeneous this lessened discrepancies. It
is difficult to determine the exact number of punches, which should be taken from
each case to ensure adequate and accurate representation, but in the case of the
pipelle specimens more specimens were advisable. Torhorst et al {Torhorst, 2001}
suggested that 4 cores was optimal for measuring Progesterone Receptor expression,
but that only one core was necessary in assessing prognostic significance when the
data covered more than 390 patients. However, most validation studies have shown
that analysis of three 0.6mm cores produces higher concordance rates than use of one
core and that the use of three cores also reduces the problems associated with case
loss where only 2 cores are taken {Camp, 2000;Kallioniemi, 2001 ;Fernebro, 2002}.
Studies have shown difficulties assessing the significance of protein expressed at a
low level in TMA and whole sections {Leversha, 2003}. However I did not find this
to be the case where ER expression was not only low but also heterogeneous.
Whilst the UPSC TMA was validated for P53 and ER the obvious question is
whether or not this validation can be extended to include all high grade endometrial
carcinomas and also to the assessment of antibodies where the normal or abnormal
staining patterns are uncertain. As we have demonstrated good levels of concordance
with ER and P53 which not only are known to be present in low and high amounts
respectively but also show heterogeneous and homogenous patterns of staining
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respectively {Koshiyama, 1995}, the conclusion I have drawn is that the validation
results can be extended to the wider group of endometrial carcinomas and unknown
antibodies.
3.4.1 Summary
The protein expression of P53 and ER in our TMA matched that seen in the whole
sections. On balance the minimum number of cores sampled should be two and the
optimal number of cores sampled should be three as this decreases variation seen in
heterogeneous tumours and also increases the likelihood of an informative section in
those tumours which were either focal, infiltrative or present in a pipelle specimen.
In addition TMA use can be extended to include other high grade endometrial
carcinomas and antibodies with uncertain patterns of expression.
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Chapter 4
A Review of the Pathology and Management of Uterine Papillary Serous
Carcinoma and Correlation with Outcome
4.1 Introduction
While papillary morphology has been recognised in endometrial carcinoma since the
turn of the last century, uterine papillary serous carcinoma (UPSC) was first
described as a distinct clinical entity in 1982 by Lauchlan {Lauchlan, 1981} and
Hendrickson et al {Hendrickson, 1982;Hendrickson, 1982} UPSC usually occurs in
elderly, postmenopausal women and in contrast to endometrioid endometrial
carcinoma (EEC), is not associated with excess oestrogen. There is conflicting data
regarding the association of breast cancer with high-risk endometrial carcinomas
{Barakat, 1994;Magriples, 1993}. It is thought that patients with breast cancer have a
similar rate of low- and high-risk endometrial subtypes irrespective of tamoxifen use.
However, patients with UPSC may have an increased risk of synchronous, or
subsequent development of breast cancer {Geisler, 2001;Goshen, 2000}. This raises
the possibility that UPSC and breast cancer may, in some patients, be due to the
presence ofmutations in cancer predisposing genes such as BRCA 1, BRCA2 or p53
{Lavie, 2004}.
Although accounting for only 10% of endometrial carcinomas, UPSC is an important
diagnosis to make on initial biopsy since it behaves particularly aggressively, with a
propensity for early metastasis which results in upstaging at the time of operation in
50-75% of clinical Stage I cancers {Goff, 1994;Christman, 1987;Walker, 1982}.
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This underscores the need for accurate pre-operative diagnosis, so that the surgeon
can plan definitive treatment and perform accurate and thorough surgical staging by
the FIGO system, including a total extrafascial hysterectomy and bilateral salpingo-
oophorectomy, peritoneal washings, and removal of any suspicious pelvic or para¬
aortic lymph nodes. Although omentectomy is not in the 1988 FIGO system for
staging, it is also frequently performed. This is because UPSC behaves aggressively,
and has a pattern of spread similar to that of ovarian serous carcinoma. There is no
evidence to date that this radical surgery affects outcome, but accurate staging may
help influence current advice regarding adjuvant therapy. UPSC may exist in both
"pure' and 'mixed' forms with other endometrial cancer subtypes, in particular EEC
and clear cell endometrial carcinoma (CCEC). Sherman et al {Sherman, 1992} states
that the diagnosis of UPSC should be reserved for cancers with more than 25%
UPSC pattern in the final resection specimen, although this figure appears arbitrary.
Data as to the optimum management of UPSC are limited due to its relative rarity.
This audit was performed to look at the patient characteristics, histopathological
characteristics and outcomes of various treatment regimens of UPSC. In particular,
this study focussed on the accuracy of diagnosing UPSC on endometrial pipelle
biopsies or curettings, whether the histological subtypes seen in the diagnostic biopsy
correlated with those seen in the final resection specimen, and also what percentage
of UPSC pattern was required to confer the poor prognostic phenotype. To date there
have been several studies looking at either the oncological or surgieal pianagement
of UPSC, ranging from 9 to 129 cases {Abeler, 1990;Carcangiu, 1992;Chambers,
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1987;Christopherson, 1982;Geisler, 2001;Goff, 1994;Hendrickson, 1982;Slomovitz,
2003;Sykiotis, 2001}.
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4.2 Materials and Methods.
4.2.1 Identification of Cases.
Cases were identified as described in "Materials and Methods".
The patient demographics, histopathology, and treatment were recorded as described
in "Materials and Methods".
4.2.2 Patient Characteristics.
Surgical and oncological medical records were reviewed by Dr A Stillie (an
Oncology Specialist Registrar) to obtain patients' age at presentation, any previous
history of breast cancer, the treatment and follow-up data, in particular the site of any
relapse. The primary endpoints were progression-free survival (PFS) and overall
survival (OS), defined as the period from the date of diagnosis to the date of
recurrence or the last clinic visit (if alive) or the date of death. Data were censored if
information on survival was not available or the patient had ceased to be followed up
for any reason but had not died of cancer.
4.2.3 Histopathological Characteristics.
HM and Dr D Faratian (a Specialist Registrar in Pathology) reviewed all diagnostic
biopsies and hysterectomy sections from the 67 patients. The diagnosis of UPSC,
clear cell carcinoma (CCEC) and EEC were made using the criteria as described in
"Material and Methods". The pipelle or endometrial curettings were reviewed to
determine if definitive diagnosis of UPSC was possible on the original biopsy. Then
the hysterectomy specimens were reviewed to determine if it was a pure UPSC or
mixed tumour. If it was a mixed tumour, the percentage ofUPSC, EEC and CCEC of
the total tumour present was estimated in the tissue processed for histological
analysis. Estimates were made by counting low power (x20-x40) fields of each
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pattern and dividing this by the total number of fields. Data were compared and the
three discrepancies resolved by discussion. The number and nature of specimens
additional to the hysterectomy specimen received (i.e. omentum, pelvic lymph nodes
or peritoneal washings) were noted, along with the pathological stage at the time of
resection using the FIGO staging criteria as described in "Materials and Methods".
4.2.4 Oncological Characteristics
The adjuvant therapy was recorded and the chemotherapy and radiotherapy regimens
(external beam +/- vaginal caesium) were documented. Where the data was available,
details of the treatment of recurrence were also noted.
4.2.5 Statistical Analysis




Sixty-seven patients were identified. The median age of the patients was 68 years
(range 49-89). Nine patients (13%) had a past medical history of breast cancer. No
patients developed breast cancer after the time of diagnosis of UPSC. The median
follow-up for all patients was 14.5 months (range 1-114). The numbers and
percentages of each patient with each stage of disease are presented in Table 4.1,
along with 1 year and 3 year OS and PFS by stage. Overall survival and PFS
correlated significantly with the stage of disease (p<0.01, Figure 4.1), the median OS
was 67 months, 43 months, 14 months and 9 months for Stage I, II, III and IV
disease, respectively. The median PFS for Stage I disease was not reached in this
study, due to censoring, but the median PFS for Stage II, III and IV disease was 43
months, 9 months and 8 months respectively.
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Table 4.1. Progression Free Survival and Overall Survival by Stage
Stage Number of
patients (%)
Progression Free Survival Overall Survival
1 year 3 years 1 year 3 years




Stage II 14 (20) 81.8 "60.1 81.8 "50.9
IIA 7(10)
IIB 7(10)




Stage IV 9(13) 0 ND 41.6 ND
All Patients 67 61.5 46.2 67.0 39.4
*PFS, p<0,01 (Kaplan-Meier); *OS, p<0.01 (Kaplan-Meipr); ND = No data
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Fifty-nine patients underwent surgery. All these patients had a total abdominal
hysterectomy, bilateral salpingo-oophorectomy (TAH BSO). Twenty-four patients
(40.1%) had, in addition, omental sampling, of these, 21 patients (87.5%) an omental
biopsy, where only a few centimetres of omentum was removed and 3 patients
(12.5%) had full omentectomy, where all the visible omentum was removed. Seven
patients (11.9%) had a pelvic node clearance; in 30 patients (50.9%) peritoneal
washings were taken. Seven patients had TAH BSO, omentectomy, pelvic node
sampling and peritoneal washings taken. No patients had para-aortic node sampling.
Seven (29%) omental samples were positive for metastatic disease, 2 (28.5%) pelvic
lymph node clearances were positive, while 6 of 30 (20%) of peritoneal washings
contained malignant cells. Patients who had a negative omental biopsy at the time of
operation had a significantly better PFS and OS (p<0.01) than those patients who had
a positive biopsy (Figure 4.2). Of the three omentectomies performed, one was
positive and two were negative. Positive peritoneal cytology was weakly associated
with poor prognosis (log-rank test, p=0.15), while the effect of pelvic
lymphadenectomy on prognosis could not be analysed due to small numbers of
patients.
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100 120 100 120
Strvival, (months) Survival (months)
(A) Omental sampling p<0.01 (log-rank test), (B) Radiotherapy p<0.01 (log-rank
test), (C) Intra-cavitary radiotherapy p<0.01 (log-rank test), (D) Chemotherapy
p=0.64 (log-rank test).
Abbreviations: RT = radiotherapy, Cis = cisplatinum, C&T = carboplatin and
paclitaxel (Taxol), C - carboplatin.
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4.3.3 Histopathological Analysis
On reviewing the pathology reports, 63 of the cases were diagnosed by pipelle
biopsy, curettage, or hysteroscopic biopsy; 1 case was diagnosed on cervical
cytology, and 3 cases from hysterectomy histology. Of the 63 patients who had a pre¬
operative diagnostic biopsy, 23 biopsies (36.5%) showed pure UPSC histology and
39 (62%) showed mixed histological subtypes including a UPSC component. Thirty-
nine of the diagnostic biopsies (63%) were described as serous, papillary, mixed
serous or other histological subtype in the original pathological reports, and on
review 62 of the biopsies (98.5%) contained a UPSC component. The one biopsy
(1.5%) that did not contain a UPSC component was reviewed as 100% CCEC, and
on hysterectomy the tumour was reviewed as 100% UPSC. The correlation between
the initial biopsy and hysterectomy histology subtypes is illustrated in Figure 4.3.
While there was a weak positive correlation between the diagnostic biopsies and
hysterectomy diagnoses for UPSC and CCEC (Spearman's Rank Correlation
Coefficient 0.47 and 0.30 respectively, p<0.01), the correlation is much stronger for
EEC (Spearman's Rank Correlation Coefficient 0.70, p<0.01). In addition, those
biopsies, which overestimated the amount of UPSC in the resection, were usually the
same cases in which the percentage of CCEC was underestimated. In Kaplan-Meier
analyses of survival, the OS and PFS were not significantly different in patients with
pure and mixed histological patterns or percentage of UPSC (including less than 25%
UPSC compared to more than 25% UPSC) in the diagnostic biopsies or the
resections (Figure 4.4). In addition, whether UPSC was mixed with EEC or CCEC
made no difference to survival. Serous endometrial intraepithelial carcinoma was
identified in 2 of the hysterectomy specimens.
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Figure 4.3. Percentages of Histological Subtypes in Diagnostic Biopsies
Vs Resection Specimens.
Figure 4.3. Scatterplots to
represent percentages of
histological subtypes in
diagnostic biopsies vs resection
specimens. Each spoke on a
data point represents one case.
Best fit lines (red) show a
positive correlation between the
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Fifty-seven patients received adjuvant therapy. Thirty patients (52.6%) received
radical radiotherapy, and 3 patients (5.2%) palliative therapy. Of the 2 patients who
did not receive radiotherapy, one was deemed to have had curative surgery (Stage I
disease) and the other was deemed unfit for therapy. In addition to radiotherapy 28
patients (49.1%) received adjuvant chemotherapy with different regimens including
carboplatin alone, carboplatin and paclitaxel, or cisplatin (Table 4.2). Patients treated
with radical radiotherapy postoperatively had a significantly better prognosis by
univariate analysis (p<0.01, Figure 4.2). The median overall survival was 29 months
in patients receiving radical radiotherapy compared with 12 months without, and the
median overall survival was 67 months with palliative radiotherapy compared with
12 months without. There were no significant differences in survival in patients
treated with or without chemotherapy (Figure 4.2), or between the different
chemotherapy regimens.
Table 4.2. Chemotherapy Regimens by Stage.
Stage C C&T Cis Nil
I 7 2 1 13
II 4 0 1 6
III 5 3 0 5
IV 5 0 0 4
C = carboplatin, Cis = cisplatinum, C&T = carboplatin and paclitaxel.
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4.3.5 Recurrence Analysis
Fifteen (22.4%) patients had recorded recurrences. Of these, 5 (33%) were distant
metastases (lung, liver, omentum and neck lymph nodes) and 10 (67%) were loco-
regional recurrences. Median time to recurrence was 9 months (range 4-17 months).
Two omental recurrences were in patients who had had positive omental biopsies.
Neither had had complete omentectomy. The recurrence rate in Stage I to IV patients
was 12%, 14%, 36% and 33%, respectively. Further survival analysis was not




This study of UPSC is the third largest retrospective series of its kind with focus on
the effect of histopathology on outcome. The high median age of the patients, and
postmenopausal status, is similar to that previously documented for UPSC {Dunton,
1991;Slomovitz, 2003}. Thirteen percent of patients had a personal history of breast
cancer, identical to that observed by Slomovitz et al {Slomovitz, 2003} and similar
to Barakat et al {Barakat, 1994} who observed a similar rate of low- and high-risk
endometrial subtypes in breast cancer patients regardless of tamoxifen use.
Following case reports and studies on Ashkenazi Jews, it was initially thought that
mutations in the BRCA gene might account for this finding {Geisler, 2001;Lavie,
2000}. However, a larger study by Goshen et al {Goshen, 2000} of 56 patients with
both UPSC and breast carcinoma (not limited to Ashkenazi Jews) showed that
although women with mutations in the BRCA1 gene have an increased incidence in
ovarian serous papillary carcinoma and endometrial cancer, there was no specific
increased risk in the development of UPSC. In addition, they failed to demonstrate
mutations in either BRCA1 or BRCA2 genes in these patients. They postulated that
either the BRCA mutations occurring in these patients were out with the scope of the
screening techniques, or that the association between UPSC and breast cancer may
be due to the presence of mutations in a variety of other cancer predisposing genes
such as P53 and cerbB2.
Only 63% of the biopsies were diagnosed as pure or mixed UPSC histological
patterns, in line with previous reports {Bristow, 2001;Carcangiu, 1992;Goff,
1994;Sherman, 1992;Slomovitz, 2003;Tay, 1999;Kelly, 2005}, which have reported
the accuracy of pre-operative biopsy from 65-93%. Most biopsies not explicitly
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stated as UPSC were given Grade 3 endometrial carcinoma diagnoses or classified
according to the other major histological subtype, usually CCEC. However, on
retrospective review of the biopsies, only one (1.5%) of the pre-operative biopsies
did not contain any UPSC, according to traditional diagnostic criteria, and the major
pattern in this case was CCEC. This may be explained by the heterogeneity of the
disease.
We sought to evaluate whether 25% UPSC pattern, the value above which the
tumour is classified as UPSC, is prognostically valid (Walker, 1982}. We found that
the survival of patients with less than 25% or more than 25% UPSC in the biopsy or
the resection was the same, suggesting that tumours should be classified, and
managed, as UPSC regardless of the percentage of UPSC in the pathological
specimen. Our lowest percentage of UPSC used was 5%. In addition, in keeping with
previous reports, pure or mixed histological patterns did not show any survival
difference, and survival was the same regardless of whether UPSC was mixed with a
high-risk subtype, such as CCEC, or a low-risk subtype, such as EEC (Slomovitz,
2003;Goff, 1994}, suggesting that UPSC is biologically dominant in heterogeneous
tumours.
We found a low number of patients had complete surgical staging (40% omental
staging, 11.9% pelvic node clearance, 50% cytology), which may in part be
explained by the changing surgical practice over the period analysed, and difficulties
with the interpretation of the diagnostic biopsies. Whilst this raises the possibility
that the patients might not be accurately surgically staged, our survival rates are
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consistent with the generally accepted long-term survival rates of 35-50% for Stage I
and II UPSC and 0-15% for patients with Stage III and IV disease {Nicklin, 1996}.
Gehrig et al {Gehrig, 2003} showed that the sensitivity of a visually negative
omentum was 89%, concluding that, with a microscopic metastasis rate of 4%,
surgical sampling does not need to be included in the routine surgical staging of
UPSC. The clinical consequences of under-staging is underscored by the fact that in
our data two recurrences (13%) occurred in biopsy positive omenta which were not
removed by omentectomy, and these two patients had Stage III disease which, while
still a poor prognosis group, may have benefited from additional abdominal surgical
clearance. Omentectomy may result in better local control of disease and more
directed and appropriate adjuvant therapy. Unfortunately our data were too small to
establish a link between omentectomy and survival.
The rate of pelvic lymphadenectomy was low, but it is difficult to draw any
conclusions from this. There has been ongoing discussion about the value of pelvic
lymphadenectomy. Slomovitz et al {Slomovitz, 2003}, reported 19% lymph node
involvement in patients without myometrial invasion and Huh et al {Huh, 2003}
demonstrated no pelvic side wall failures following observation in a population at
risk for recurrence, and found in two of the patients who had not had formal pelvic
lymphadenectomy, pelvic recurrence. However, the first results of the MRC-ASTEC
trial, the first (and currently, the only) randomised trial investigating the role of
lymphadenectomy in clinical Stage 1 endometrial carcinoma have shown that there
was no benefit of lymphadenectomy, with 3-year overall survival rates of 89% (TAH
BSO alone) and 88% (TAH, BSO and lymphadenectomy). In addition the 3-year
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recurrence free survival was also better in the TAH BSO alone arm and relapse rates
were similar (H Kitchener, oral presentation at the European Society for Gynecologic
Oncology, Istanbul, September 2005).
We did not show any significant impact of adjuvant radiotherapy or chemotherapy
on PFS or OS. Ramondetta et al {Ramondetta, 2001} showed that single agent
paclitaxel showed a tumour response in 77% of patients, and used in a neo-adjuvant
fashion with cisplatin, Zanotti et al {Zanotti, 1999} saw responses in 8 out of 9
patients. In addition Kelly et al {Kelly, 2005} recently showed that platinum based
chemotherapy improved disease free and overall survival of patients with Stage I
UPSC and vaginal cuff radiation provided local control of disease. However, our
study failed to show that treatment with these agents converted into an objective
improvement in PFS or OS. This is probably due to the short average follow up time
(14 months) and possibly the inadequate surgical staging, resulting in patients being
understaged.
Twenty-two percent of patients in this study had further disease. This is far fewer
than the percentage observed by other groups, who have documented recurrence
rates of between 50-75%, using various adjuvant therapies, radiotherapy alone or
with the addition of chemotherapy using platinum and/or paclitaxel alone, as used in
our study {Sood, 2003;Zanotti, 1999;Mallipeddi, 1993;Frank, 1991}. Our results
therefore compare favourably with similarly staged tumours at equivalent median
follow-up, although similar to these studies Stage III and IV tumours remain a
particular management problem due to higher rates of recurrence (36% and 33% for
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Stage III and IV carcinomas compared with 12% and 14% for Stage I and II
carcinomas, respectively). Establishing the exact reasons for favourable recurrence
rates is hampered by limited patient numbers and inconsistent and non-randomised
adjuvant therapies, but it appears that surgery produces good regional control in this
group, with 67% locoregional control compared to the 87% observed by Sood et al
{Sood, 2003}.
4.4.1 Summary
Despite having been described as a distinct clinical entity for over twenty years,
UPSC remains a management challenge for the multidisciplinary team due to the
paucity of understanding on the epidemiology, pathogenesis, natural history and
optimal treatment strategies for this important and aggressive variant of endometrial
adenocarcinoma. These data contribute to the growing body of literature on UPSC,
and addresses diagnostic and treatment uncertainties for the pathology, surgical and
oncological teams. This study raised awareness for the need of accurate and complete
surgical staging at a local level. However, we have not altered our approach to the
use of adjuvant chemoradiotherapy for patients with UPSC as our patient numbers
were small with a limited follow up time. This study contributes to the increasing
local, national and international awareness of the need to invest in randomised
clinical research trials on UPSC, at a time where alternative treatment modalities
may become increasingly effective.
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Chapter 5
The Role of E Cadherin, P Cadherin and p Catenin in Uterine Papillary
Serous Carcinoma and Endometrioid Endometrial Carcinoma.
5.1 Introduction
This chapter focuses on the first step on invasion; namely detachment of tumour cells
from each other. Normal cell-cell adhesion determines the morphology of a tissue
type and regulates major cellular processes including motility, growth differentiation
and survival. Cadherins are a widely distributed family of cell-cell adhesion
molecules which are composed of 3 parts, a single domain transmembrane portion,
which, using calcium, binds to another transmembrane domain of a cadherin
molecule and a cytoplasmic portion composed of 2 domains {Nose, 1988;Matsuzaki,
1990}. The cytoplasmic domain is connected to P- and y-catenins which in turn bind
to the actin cytoskeleton through a catenin {Nathke, 1994;Hinck, 1994;Jou, 1995}.
The family of cadherins currently has more than 80 members including the classical
cadherins, desmogleins, desmocollins and protocadherins. The most completely
described cadherins are the classical types, Epithelial (E)-, Placental (P)- and
Neuronal (N)- cadherin and all vertebrate cells seem to express at least one cadherin
{Niessen, 2002;Takeichi, 1991}. Cadherin-catenin complexes also have roles in




E cadherin is the most common cadherin in epithelial cells. It is made from 4.5 kb
mRNA as a 135kDa precursor polypeptide, which is processed rapidly by proteolytic
cleavage to the mature 120kDa form {Shore, 1991}. The E cadherin-catenin complex
is necessary for cell-cell adhesion of epithelial cells. Failure to assemble the E
cadherin-catenin complex or to properly connect to the actin cytoskeleton results in
loss of cell adhesion, which may be involved in tumour spread {Van Roy,
1992;Birchmeier, 1993;Guilford, 1998;Perl, 1998}. The E cadherin gene (CDH1) is
found on chromosome 16q22.1. CDH1 is thought to be a tumour suppressor gene,
whose loss has been shown to cause tumour invasion and metastasis in various
cancer models {Christofori, 1999}. In endometrial endometrioid carcinoma (EEC)
loss of heterozygosity at 16q22 has been related to poor prognosis and CDH1
mutations and promoter hypermethylation have been found in a small percentage of
cases {Kihana, 1996;Risinger, 1994;Moreno-Bueno, 2003;Saito, 2003}. In addition
to abnormalities in promoters of the E cadherin gene, or the gene itself, the E
cadherin-catenin complex can be disturbed by the action of TGF-p. Vogelmann et al
{Vogelmann, 2005} demonstrated that TGF-P induced destabilisation of the E
cadherin-catenin complex and thus dissociation of P catenin from a catenin and the
actin cytoskeleton. Somatic mutations in the TGF-P signalling pathway are
associated with loss of proliferative control, malignant progression, invasion and
metastasis {Vogelmann, 2005}. They also demonstrated that the mechanism
involved ppq^ppptrylftfion of p catenin by PTEN {Vogelmann, 200$},
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E cadherin is present in endometrial epithelium in proliferative phase and decreases
in secretory phase {Shih, 2004}. It is possible that the cadherin-catenin complex
may have a role in the maintenance of the normal endometrial architecture.
There is decreased expression of E cadherin in atypical hyperplasia compared to
normal endometrium and even less in endometrial carcinoma {Shih, 2004;Moreno-
Bueno, 2003}. Studies have also shown that loss of E cadherin expression increases
with increasing grade of the endometrial carcinoma, such that the most poorly
differentiated tumours have the least E cadherin expression {Moreno-Bueno,
2003;Shih, 2004;Dvalishvili, 2005}. Some studies have shown that E cadherin loss is
more frequent in UPSC and clear cell carcinoma, compared to EEC {Elolcomb,
2002;Moreno-Bueno, 2003}. In contrast, Demopoulos et al {Demopoulos, 1999} did
not find any differential expression of E cadherin between EEC and UPSC.
However, this study examined a relatively small number of tumours (14 cases of
EEC and 10 cases ofUPSC).
E cadherin negative endometrial tumours are more likely to be poorly differentiated,
with local and distant dissemination of disease {Pijnenborg, 2004;Leblanc,
2001;Sakuragi, 1994;Holcomb, 2002}. Shih et al {Shih, 2004} found that nuclear P
catenin expression was inversely correlated with E cadherin expression. However,
Moreno-Bueno et al {Moreno-Bueno, 2003} did not find any link between reduced E
cadherin expression and nuclear accumulation of P catenin.
As E cadherin has roles in cell-cell adhpsiop it is possible that the differential
expression in E cadherin between EEC and UPSC may be, in part responsible for the
poor prognosis ofUPSC and increased propensity for myometrial and distant spread.
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5.1.2 P Cadherin
P cadherin is expressed in trophoblast and shows restricted expression in epithelia,
being expressed predominantly in basal cells of bronchial and mammary epithelium
{Smythe, 1999;Deugnier, 1999}. This basal expression suggests that P cadherin may
not only have a role in cell-cell adhesion, but also may have a role in differentiation
and cell growth. Studies on pancreatic cell lines demonstrated that over expression of
P cadherin caused increased motility of cells and accumulation of cytoplasmic
pl20ctn, a protein involved in cell-cell adhesion which acts by stabilising cadherin
and regulating cadherin turnover {Taniuchi, 2005;Kowalczyk, 2004}.
Although P cadherin is similar to E cadherin the pattern of expression in malignancy
and in particular in both normal and malignant endometrium is less well defined. An
immunohistochemical study by Van Der Linden et al {Van der Linden, 1994}
showed similar staining characteristics of P cadherin to E cadherin in normal
endometrium and they suggested that P cadherin might play a role in maintenance of
proliferative endometrial glands. P cadherin up regulation has been demonstrated in
inflammatory bowel diseases and some neoplasias such as breast and cervical
adenocarcinomas {Sanders, 2000;Palacios, 1995;Han, 2000}. In addition up
regulation of P cadherin has been found, in increasing frequency, in atypical
endometrial hyperplasia, EEC and in a group of "non EEC", which included UPSC
and clear cell carcinoma {Moreno-Bueno, 2003}. Interestingly in breast and cervical
adenocarcinoma and "non EEC" increased P cadherin expression is related to cell
proliferation, dedifferentiation, and negative oestrogen and progesterone receptors,
and in addition, increased P cadherin has been shown to confer poor prognosis in
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breast cancer {Han, 2000;Gamallo, 2001}. In contrast decreased expression of P
cadherin has been described in both oral squamous cell carcinoma and melanoma. In
addition P cadherin loss is associated with poor prognosis in oral squamous cell
carcinoma {Lo, 2005}. Recent studies have shown that a truncated form of the N
terminal part of P cadherin is expressed by human melanoma cell lines and tissue
from melanomas, but not by normal melanocytes or keratinocytes {Bauer,
2005;Hoek, 2004}. In addition, analysis showed that melanoma cells, rather than
binding this short form of P cadherin to the cell membrane, which classically occurs
in melanocytes, secreted it. The secreted form of P cadherin was shown to regulate
the homophilic interaction between cadherin molecules by antagonising their
homophilic binding, acting as a dominant negative form to interrupt cell-cell
attachment. In addition to the shift from the membranous form to the secreted form
expression of P cadherin is down regulated in malignant melanoma {Hoek, 2004}.
5.1.3 p Catenin
P catenin has roles in both cell-cell adhesion and intracellular signalling. It controls E
cadherin mediated cell adhesion at the plasma membrane and mediates the interplay
of adherens junction molecules with the actin cytoskeleton. In addition, P catenin
acts in the Wnt signalling pathway, activating the transcription of target genes
responsible for cellular proliferation and differentiation, along with LEF/TCF
(lymphoid enhancer factor/T-cell factor) DNA binding proteins {Morin,
1997;Rubinfeld, 1997}. The signalling function of P catenin is mainly regulated by
altering its stability and Wnt signalling induces the stabilisation of the free
cytoplasmic pool of p catenin {Polakis, 2000}. In the absence ofWnt signalling, p
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catenin is rapidly degraded by a destruction complex consisting of adenomatous
polyposis coli (APC), axin, glycogen synthase kinase beta, conductin and casein
kinase {Behrens, 1998;Kishida, 1998;Liu, 2002}.
Both functions of (3 catenin are deregulated in malignancy leading to the loss of both
cell-cell adhesion and to the increased transcription of Wnt target genes. Mutations
that activate the Wnt-P catenin pathway promote stabilisation of P catenin and
induce its nuclear accumulation {Munemitsu, 1995}. This results in activated gene
transcription, altered cell migration and cell polarity. Inactivating mutations in the
APC gene product, a protein that promotes degradation of cytoplasmic P catenin,
leads to an accumulation of cytoplasmic P catenin {Munemitsu, 1995;Morin,
1997;Rubinfeld, 1997}. However, neither LOH nor promoter hypermethylation of
APC is associated with nuclear expression of P catenin {Koppert, 2004}. Other
mutations that decrease the degradation of p catenin include those that affect the
function of conductin or axin {Liu, 2000;Satoh, 2000;Jin, 2003}.
P catenin co-localizes with E cadherin and y catenin at the cell membrane in all
phases of the menstrual cycle {Nei, 1999;Miyamoto, 2000}. In addition, nuclear P
catenin expression has been observed in the proliferative phase, suggesting a role for
the Wnt signalling pathway in the normal endometrium {Miyamoto, 2000}. Chen et
al {Chen, 1998} demonstrated that progesterone, but not P oestradiol increased P
catenin mRNA levels in cultured human endometrial stromal cells and this finding is
supported by Fujimoto et al {Fujimoto, 1998} who demonstrated that P catenin and E
cadherin levels were less in the proliferative phase, where progesterone levels are
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comparatively higher compared to the secretory phase, where oestrogen levels are
comparatively higher.
The activation of the Wnt signalling pathway due to P catenin mutations has been
implicated in the development of some endometrial carcinomas {Kariola, 2005}.
Moreno-Bueno et al {Moreno-Bueno, 2004} showed that nuclear (3 catenin
expression was found in 31% of EECs and 3% of "non EECs". However, up to 25%
of endometrial carcinomas have (3 catenin nuclear accumulation without evidence of
(3 catenin mutations, suggesting alterations in other molecules that can modulate the
Wnt pathway such as APC, y catenin, and axin {Moreno-Bueno, 2004}. Pijnenborg
et al {Pijnenborg, 2004} found that nuclear localization of (3 catenin, associated with
mutations in the (3 catenin gene and mutations in the APC gene are not predictive for
recurrent disease.
In vitro studies on breast cell lines have shown that decreased E cadherin can
augment P catenin oncogenic signalling {Yang, 2001} and Shih et al {Shih, 2004}
demonstrated an inverse correlation between nuclear P catenin and E cadherin
expression in normal and malignant endometrium. However, Moreno-Bueno et al
{Moreno-Bueno, 2003} did not find any link between reduced E cadherin expression
and nuclear accumulation of P catenin.
Abnormal expression of E cadherin and a-, P-, and y-catenins has been shown to be
associated with poor prognosis in many malignancies, including endometrial and
ovarian cancer {Bremnes, 2002;Lim, 2002;Umbas, 1994;Zhao, 2003;Bringuier,
1993;Ropponen, 1999;Aaltomaa, 1999;Bohm, 2000;Zhou, 2002;Lee, 2002;Pantel,
1998;Shimazui, 1997;Endo, 2000;Voutilainen, 2006}.
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5.1.4 Summary
Previous studies examining the expression of E cadherin, P cadherin and (3 catenin
have concentrated on EEC and its precursors and in those papers which have also
looked at UPSC, the numbers of cases have been small, or they have been
incorporated into a "non EEC" group alongside other carcinomas such as clear cell
carcinoma. Whilst Holcomb and Moreno-Bueno et al {Moreno-Bueno,
2003;Holcomb, 2002} showed that E cadherin expression was lower in "non EEC"
compared to EEC, Demopoulos et al {Demopoulos, 1999} failed to make this
distinction. Therefore this chapter aims to clarify whether or not E cadherin
expression is lower in UPSC compared with EEC and also to determine if there is
any differential expression of E cadherin between the central viable part of the
tumour and at the invasive edge.
The expression and role of P cadherin in endometrial carcinomas is unclear,
although some studies have proposed that increased expression of P cadherin may be
related to increased cell proliferation, dedifferentiation and negative ER and PR, and
in the case of breast cancer may be associated with poor prognosis. This chapter
aims to determine whether or not P cadherin is upregulated in UPSC compared with
EEC and also if there is differential expression of P cadherin between the central
viable part of the tumour and at the invasive edge. As P catenin forms complexes
with both E cadherin and P cadherin as part of its role in cell-cell adhesion, its
expression was also studied in order to determine if there was differential expression
between UPSC and EEC, whether or not there was an inverse correlation between E
cadherin expression and p catenin expression and also to determine if there was any
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difference in expression of (3 catenin between the viable central part of the tumour
and at the invasive edge.
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5.2 Materials and Methods
5.2.1 Tissues
Tissues were obtained as described in "Materials and Methods", Section 2.1.
5.2.2 Tissue Microarray
The tissue microarray was constructed as described in "Materials and Methods",
Section 2.2.
5.2.3 Immunohistochemistry
Immunohistochemistry was performed for E cadherin, P cadherin and (3 catenin using
the technique described in "Materials and Methods", Sections 2.3.9, 2.3.10 and
2.3.11 respectively.
5.2.4 Scoring
Scoring of antibody expression was assessed using the technique as described in
"Materials and Methods", Section 2.4.
5.2.5 Statistical Analysis





E cadherin expression in both EEC and UPSC was significantly lower than that in
the normal endometrial epithelium where the score for expression was uniformly 9 (p
values <0.00 for both tumour types, Independent T Test, Figure 5.4). Significantly
greater E Cadherin expression was present in EEC compared to UPSC (p = 0.03
Independent T Test, Table 5.1) and significantly less expression of P cadherin was
noted in EEC compared to UPSC (p = 0.013 Independent T Test, Table 5.1). There
was no significant difference in P catenin expression between UPSC and EEC.
Scatterplots and Pearson pairwise correlation coefficient showed a direct correlation
between p catenin immunohistochemical staining and E- and P cadherin expression
for both EEC and UPSC. Of the UPSC cases, correlation between P catenin and P
cadherin showed a correlation coefficient of 0.685 and a p value of <0.000, and
between P catenin and E cadherin showed a correlation coefficient of 0.389 and a p
value of 0.001 (Pearson Pairwise Correlation Coefficient).
Of the EEC cases, correlation between P catenin and P cadherin showed a correlation
coefficient of 0.705 and a p value of 0.001, p catenin and E cadherin
immunohistochemistry showed a correlation coefficient of 0.767 and a p value of
<0.000 (Pearson Pairwise Correlation Coefficient).
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Table 5.1. Expression of E Cadherin, P Cadherin and p Catenin in the




SD 1.69 SD 2.91
"7.53 "7.24
P Cadherin
SD 1.9 SD 3.1
7.04 7.78
P Catenin
SD 2.0 SD 1.7
Standard Deviation
0.03 (Independent T Test)






5.3.2.1 Uterine Papillary Serous Carcinoma
Although there was decreased E cadherin and P cadherin expression at the invasive
edge compared to the viable central part of the tumour, Wilcoxon Signed Ranks Test
failed to reach significance (Table 5.2). All E cadherin and P cadherin expression
was membranous (Figures 5.1 and 5.2 respectively).
There was significantly greater expression of (3 catenin at the invasive edge
compared to the viable central part of the tumour (P = 0.03, Wilcoxon Signed Ranks
Test, Table 5.2). However, all (3 catenin expression was membranous (Figure 5.3).
5.3.2.2 Endometrioid Endometrial Carcinoma
Although there was decreased E cadherin and P cadherin expression at the invasive
edge compared to the viable central part of the tumour, Wilcoxon Signed Ranks Test
failed to reach significance (Table 5.2). All E cadherin and P cadherin expression
was membranous (Figures 5.5 and 5.6 respectively). There was no difference in
expression of P catenin between the viable part of the central tumour or the invasive
edge. Two of the twenty EEC cases showed nuclear p catenin expression (Figure









Figure 5.1. Membranous E Cadherin Expression in UPSC (Magnificationx40).





















Figure 5.3. Membranous (3 catenin expression in UPSC (Magnificationx40).
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Table 5.2. Expression of E Cadherin, P Cadherin and p Catenin in the





































0.08 (Wilcoxon Signed Ranks Test)






Figure 5.4. E Cadherin Expression in Normal Endometrial Epithelium
(Magnificationxl 0).




Figure 5.6. Membranous P Cadherin Expression in EEC (Magnificationx40).
Figure 5.7. Nuclear p catenin Expression in EEC (Magnificationx40).
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5.4 Discussion
UPSC is an aggressive endometrial tumour with a notable propensity for
lymphovascular space invasion and a poor prognosis. The cadherin-catenin complex
is well described and disturbances in this are associated with a variety of cancers
{Van Roy, 1992;Birchmeier, 1993;Guilford, 1998;Perl, 1998}. In addition, alteration
in expression of both E- and P cadherin are associated with poor prognosis in many
tumours {Pijnenborg, 2004;Leblanc, 2001;Sakuragi, 1994;Holcomb, 2002}. Along
with its role in cell-cell adhesion, P catenin also affects cell proliferation via its role
in the Wnt pathway. Although the expression of E-, P- cadherin and P catenin has
been previously described in endometrial carcinoma, this chapter aimed to further
investigate the differential expression between the tumour types and also within
tumours, focussing on differences in expression between the viable central part of the
tumour and the invasive edge.
We confirmed the findings of Shih et al, Holcomb et al and Moreno-Bueno et al
{Shih, 2004;Holcomb, 2002;Moreno-Bueno, 2003} and demonstrated that although
there was decreased E cadherin expression in both tumour types compared to the
normal endometrium, the decrease in E cadherin expression was greater in UPSC
than in EEC.
The finding of significantly lower E cadherin expression in UPSC compared to EEC
may partly reflect the different biological properties of these tumours. EEC is a
tumour which usually arises on a background of oestrogen excess, and it commonly
expresses ER and PR and can produce intratumoural oestrogen using aromatase
{Segawa, 2005}. On the other hand, UPSC usually arises from atrophic
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endometrium, is generally ER negative and does not produce intratumoural
oestrogen. We found significantly higher ER and PR expression in our EEC cases
compared to UPSC (results shown in chapter 7).
To support the theory that the variation in E cadherin expression between EEC and
UPSC is due to the difference hormone environments of these tumours, Fujimoto et
al {Fujimoto, 1998} demonstrated that the mRNA levels of E cadherin, a- and (3
catenin in the endometrium in the proliferative phase were significantly less than
those in the secretory phase. In addition, treatment with oestradiol dipropionate
significantly reduced their levels in the secretory phase. They suggested that sex
steroids could affect the adherens junction in endometrial epithelium. However a
separate study showed that this effect could be reversed by treatment with progestins
{Fujimoto, 1996} Therefore whilst oestrogen might play a part in lowering E
cadherin in EEC, it is likely that the decrease in UPSC is due to a separate pathway.
In addition PTEN is involved in the tyrosine phosphorylation of P catenin and thus
destabilisation of the cadherin catenin complex {Vogelmann, 2005}. It is well
recognised that PTEN mutations occur in EEC but not in UPSC {Lax, 2004}.
Two of the EEC cases showed no E cadherin staining at all. This is an interesting
finding as Pijnenborg et al {Pijnenborg, 2004} found that absence of E cadherin
expression was predictive for distant metastases, but not local recurrence. However
the ethics submission for this study limited the investigations to
immunohistochemistry. Therefore follow up data for the patients could not be
obtained.
In addition to confirming these established observations, the present study looked for
differences in expression of these proteins between the viable central part of the
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tumour and at the invasive edge. In both tumour types we found a decrease in E
cadherin at the invasive edge of the tumour compared with the viable central part of
the tumour, although the difference did not reach significance for either UPSC or
EEC. The loss of E cadherin at the invasive edge of these tumours might reflect
decreased cell-cell adhesion at the invasive edge and thus play a part in the
mechanism of invasion for both tumours.
We demonstrated P cadherin expression in both EEC and UPSC. This is in keeping
with previous studies on inflammatory bowel disease and in some cancers including
breast and cervical adenocarcinoma where up regulation has been demonstrated
{Sanders, 2000;Palacios, 1995;Han, 2000}. P cadherin expression was also
significantly higher in UPSC compared to EEC and this is supported by previous
studies, which have shown an association with negative ER and PR status. We also
noted a significant decrease in P cadherin expression at the invasive edge of the EEC
compared with the viable central part of the tumour. Although there was a decrease
in expression between the viable central part of the tumour and at the invasive edge
of the UPSC cases, this did not reach significance. The decrease in P cadherin at the
invasive edge of both tumours raises the possibility that its main role in the viable
central part of the tumours is related to cell proliferation and dedifferentiation.
However, as studies on melanoma cells have shown secretion of a truncated form of
P cadherin, which disrupts cell-cell adhesion {Bauer, 2005;Hoek, 2004}, it is
possible that the decreased expression of P cadherin at the invasive edge of the
tumours is due to a similar process, which cannot be detected in this study as the
antibody used in this study binds with the C terminal rather than at the N terminal. It
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would be interesting to further investigate this finding and to see if secretion of the
truncated form also occurs in endometrial carcinoma. However, this is beyond the
scope of this chapter.
(3 catenin was present in both UPSC and EEC. This is in keeping with the published
literature {Shih, 2004;Moreno-Bueno, 2003;Moreno-Bueno, 2002;Palacios, 2001}.
All UPSC cases and the majority of EEC cases demonstrated membranous
expression of P catenin and only 2 EEC cases (10%) demonstrated nuclear
expression. Our finding that 10% of EEC cases showed nuclear expression is less
than that in the literature where nuclear (3 catenin expression has been demonstrated
in 31% of EECs and 3% of non-endometrioid endometrial carcinomas {Nei,
1999;Moreno-Bueno, 2004;Moreno-Bueno, 2002;Palacios, 2001;Moreno-Bueno,
2003}. It is possible that this discrepancy is due to our case selection of only high
grade EEC, and P catenin mutations may be more important in the development of
Grade 1 and Grade 2 EEC. In addition, those cases, which showed nuclear P catenin
expression, maintained this pattern of expression in both the viable central part of the
tumour and at the invasive edge. There were no cases where the pattern of expression
changed between the central part of the tumour and at the invasive edge, suggesting
that P catenin mutation is an early event in the development of endometrial
carcinoma and does not influence the capacity for invasion. Nei et al {Nei, 1999}
showed that P catenin expression was highest in those cases with nuclear p catenin
rather than the samples with membranous staining using western blotting. They
postulated that the P catenin /Wnt-1 signal transduction was highly activated in
carcinogenesis of the endometrium.
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Although there was a lower level of expression of P catenin in UPSC compared to
EEC, this did not reach significance. This difference may be due to the fact that EEC
is associated with ER and PR excess, whereas UPSC classically is an ER and PR
negative tumour. Progesterone, but not P oestradiol has been shown to increase P
catenin mRNA levels in cultured human endometrial stromal cells {Chen, 1998},
and P catenin levels are known to be higher in the proliferative phase of the
menstrual cycle rather than the secretory phase {Fujimoto, 1998}. Therefore it is
possible that the differential secretion may be due to increased expression of PR and
thus increased sensitivity to any circulating progesterone in EEC compared to UPSC.
As well as roles associated with cadherin function, P catenin is also involved in
intracellular signalling, as it is a member of the Wnt pathway, which controls cell
proliferation. The activation of the Wnt signalling pathway due to P catenin
mutations has been implicated in the development of some endometrial carcinomas
{Kariola, 2005}. However, up to 25% of endometrial carcinomas have P catenin
nuclear accumulation without evidence of P catenin mutations, suggesting alterations
in other molecules that can modulate the Wnt pathway such as APC, y catenin and
Axin {Koppert, 2004;Liu, 2000;Satoh, 2000;Jin, 2003}.
Some studies have shown an inverse correlation between nuclear P catenin
expression and E cadherin expression in normal endometrium and endometrial
cancers {Shih, 2004}. However, other studies have not demonstrated this {Moreno-
Bueno, 2003}. As only 10% of our EEC cases and none of the UPSC cases showed
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nuclear P catenin expression, statistical associations could not be determined. As
UPSC shows a greater loss of E cadherin than EEC, but not a correspondingly higher
incidence of nuclear P catenin expression, then it is possible that the correlation
demonstrated by Shih et al {Shih, 2004} may only be relevant to EEC. To support
this, some in vitro studies have demonstrated that cell lines with inactive E cadherin
as a result of CDH1 mutations do not display constitutive Wnt signalling {van de,
2001}.
The membranous P catenin expression at the invasive edge of UPSC was
significantly higher than that seen in the central viable part of the tumour. This was
in contrast to the pattern of expression of E cadherin and P cadherin in UPSC where
both showed a non-significant decrease in expression in at the invasive edge. This
pattern of expression was similar to that seen in EEC where there was no difference
in P catenin expression between the viable central part of the tumour and at the
invasive edge, whereas both E cadherin and P cadherin expression was significantly
lower at the invasive edge of the tumour. The decrease in E cadherin and P cadherin
expression relative to P catenin raises the possibility that the relative increase in P
catenin expression at the invasive edge of the tumours is due to activation of
intracellular signalling along a separate pathway such as the Wnt signalling pathway.
5.4.1 Summary
This chapter has confirmed that E cadherin, P cadherin and p catenin are expressed in
high grade endometrial carcinoma and that there is differential E cadherin and P
cadherin expression between UPSC and EEC. This is in part may be due to the
important role of oestrogen and progesterone in the development and progression of
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EEC compared to UPSC. In addition we have shown alteration of expression of E
cadherin, P cadherin and P catenin between the viable central part of the tumour and
the invasive edge, supporting the theory of the invasive subclone acquiring mutations
in order to invade and metastasise.
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Chapter 6
The Expression of CD98 and Galectin-3 in Uterine Papillary Serous
Carcinoma and Endometrioid Endometrial Carcinoma
6.1 Introduction
Endometrioid endometrial carcinoma (EEC) is the most commonly diagnosed type of
endometrial carcinoma, comprising 80% of all cases. Uterine papillary serous
carcinoma (UPSC) accounts for only 10% of cases {Burton, 1998}, but it accounts
for a much smaller proportion of Stage I endometrial carcinomas {Hendrickson,
1983;Bancher-Todesca, 1998;Dembo, 1985}. UPSC is an aggressive tumour, with a
propensity for lymphovascular space invasion and peritoneal metastases.
Invasion and metastasis of tumour cells requires a variety of complex interactions
including cell-cell interactions, cell-matrix interactions and degradation of the extra
cellular matrix (ECM). For metastasis to occur, cancer cells must detach from each
other, attach to matrix components, degrade the ECM and then migrate into the blood
stream which involves binding to the endothelium in target organ microvessels {A1
Mehdi, 2000;Chambers, 2002}. This chapter focuses on the attachment of tumour
cells to matrix components. Tumour cells adhere not only to themselves but also to
the ECM and endothelial cells as part of the process of invasion and metastasis and
tumour cell adhesion is mediated by specific interactions between cell surface lectins
and their carbohydrate ligands presented on glycoproteins and glycolipids {Glinsky,
2003;0rr, 2000;Inohara, 1996;Kannagi, 1997;Inohara, 1995}.
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6.1.2 CD98.
CD98 is a disulphide-linked 125 kDa heterodimeric membrane glycoprotein
composed of a glycosylated 85 kDa heavy chain and one of at least six alternative
non-glycosylated 40 kDa light chains. CD98 is encoded on chromosome 11 ql3
{Haynes, 1981;Hemler, 1982} and it is found on the cell surface ofmost normal cells
and some tumour cells and has been shown to be involved in various cellular
activities including cellular proliferation, cell transformation, cell fusion and cell
adhesion {Yagita, 1986;Haynes, 1981;Hemler, 1982;Hara, 1999;Fenczik, 1997}.
CD98 was originally identified as a cell surface antigen associated with lymphocyte
activation {Haynes, 1981;Hemler, 1982}. Further experiments have shown that
CD98 is quickly induced from low levels in quiescent cells to higher levels,
following cellular activation. It is upregulated early in transition from GO to G1
phase of the cell cycle and remains at elevated levels until the cell cycle is complete.
CD98 has been identified as a unique and highly specific regulator of integrin
affinity {Fenczik, 2001}. It has been shown to stimulate adhesion of breast cancer
cells to laminin via a3|31 integrin {Chandrasekaran, 1999} and recent studies have
shown CD98 to co-localise with p 1 integrin on the cell membrane of keratinocytes
and to promote integrin-like signalling {Lemaitre, 2005;Rintoul, 2002}. It is
possible that by cross-linking CD98, CD98 acts as a facilitator in the plasma
membrane, clustering pi integrins to form high density complexes, thus
subsequently leading to integrin activation and adhesion, integrin signalling and
anchorage independent growth. In addition, it has been shown that pi integrin-
mediated adhesion of the small cell lung cancer cell line H345 to fibronectin and
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laminin can be markedly upregulated by cross-linking CD98 {Fenczik, 1997}.
Kakugawa et al {Kakugawa, 2003} also demonstrated that CD98 stimulation could
activate CEA-CAM-1 mediated cell adhesion independently of integrins.
The heavy chain of CD98 is an integral membrane protein with a single membrane
spanning domain, classified as a type II membrane glycoprotein {Teixeira,
1987;Quackenbush, 1987;Lumadue, 1987}. Hara et al {Hara, 2000} demonstrated
that truncation of the extracellular domain of the CD98 heavy chain enhanced
tumorigenicity in cell lines. Both the extracellular domain and the cytoplasmic tail of
CD98 appear to be crucial for its action and CD98 that lacks either a cytoplasmic
domain or the unpaired cysteine in the extracellular domain disrupts virus-induced
cell fusion and does not inhibit Tac-(31 suppression of integrin affinity.
Six CD98 light chains have been identified, all of which are associated with L-type
amino acid transport (LAT) activity {Mannion, 1998;Kanai, 1998;Torrents,
1998;Estevez, 1998;Mastroberardino, 1998;Pfeiffer, 1998;Pfeiffer, 1999;Tsurudome,
1999}. LAT-1 protein is widely distributed on normal cells and is involved with
cellular amino acid uptake. The LAT-2 protein is predominantly expressed in renal
proximal tubules and the CD98 heavy chain has been shown to control delivery of
the LAT-2 protein to the membrane in a Xenopus oocyte model system {Kanai,
1998;Mastroberardino, 1998;Mannion, 1998;Nakamura, 1999;Pineda, 1999;Segawa,
1999;Torrents, 1998;Pfeiffer, 1999;Kanai, 2000;Sato, 1999;Fukasawa, 2000;Pineda,
1999;Rossier, 1999}. In transformed cells it is thought that L-type amino acid
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transporters are upregulated to support the high level protein synthesis for continuous
growth and proliferation {Christensen, 1990}.
The pattern of expression of CD98 varies between tumours. Studies have shown that
the CD98 heavy chain is overexpressed in oral squamous cell carcinoma and in
bladder carcinomas {Kim, 2002;Kim, 2004}. Esteban et al {Esteban, 1990} found
that CD98 was present on all squamous cell carcinomas of the larynx and that a
diffuse pattern of expression was associated with more extensive disease and poorer
differentiation. In contrast, other studies have shown down-regulation of CD98 gene
expression in cell lines made from metastatic adenoid cystic carcinoma when
compared to cell lines created from adenoid cystic carcinomas that had not
metastasised {Huang, 2003}. To date, no studies have been published on the pattern
of expression of CD98 in endometrial carcinomas. However, previous studies
examining in vivo integrin expression in normal endometrium showed that pi
integrin expression was mostly seen in endometrial stromal cells {Castelbaum,
1997}. In addition, in vitro studies showed that progesterone treatment of oestradiol-
primed cells resulted in increased expression of the al (31 collagen-laminin receptor
and suppression of the avP3 vitronectin receptor {Castelbaum, 1997}. Lessey et al
{Lessey, 1995} found alteration of integrin expression between benign and
malignant endometrial epithelium, with the a5pi integrin, most commonly seen on
benign endometrial stromal cells, being found in almost 20% of cases of endometrial
carcinoma. They also showed that integrin expression correlated with steroid
receptor status, as well as with grade, stage and depth of invasion {Lessey, 1995}.
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Thus, mounting evidence suggests that CD98 may be important in cancer and
inflammation through its effects on cellular activation and integrin-mediated
adhesion.
6.1.3. Galectin
The galectin family of carbohydrate binding proteins currently comprises 14
members identified by their conserved sequence elements. They all have a
carbohydrate binding domain, a repetitive collagen-like sequence and a functionally
distinct amino-terminal domain {Hughes, 1994;Barondes, 1994}. They appear to
show some tissue and developmental specificity where galectin-1 (Gal-1) is
predominantly found in tissues derived from mesoderm, galectin-3 (Gal-3) is
commonly found in epithelium and macrophages, as well as cartilage, galectin-4
(Gal-4) is identified in the gastrointestinal epithelium and galectin-7 (Gal-7) is found
in stratified epithelium such as the epidermis. Galectins exist as monomers but can
undergo homophilic binding to form polymers through interactions of either the N
terminal domain or the C terminal domain {Yang, 1998;Birdsall, 2001}. They are
synthesized on cytoplasmic ribosomes and following synthesis there is selective
intracellular targeting of specific galectins to subcompartments of the cytosol, to
distinct subcellular organelles, and to the cell membrane and membrane bound
vesicles.
6.1.4. Galectin-3
Gal-3 exists in a non-phosphorylated and a phosphorylated form. The former is
found exclusively in the nucleus, while the latter is found in both the nucleus and in
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the cytoplasm suggesting that phosphorylation may be important for nuclear export
of the protein {Openo, 2000;Cherayil, 1989}.
Possible ligands for intracellular Gal-3 include, Bcl-2, ALIX/AIP-1, Gemin4 and
CBP70. Nuclear Gal-3 is thought to play a role in pre-mRNA splicing, which in turn
may be related to regulation of cell growth and proliferation {Dagher, 1995}. Gal-3
may also act to increase metastatic potential of tumour cells by promoting tumour
cell adhesion {Raz, 1987;Inohara, 1995}, invasiveness {Le Marer, 1996} and
inducing endothelial cell proliferation and angiogenesis {Nangia-Makker, 2000}.
A further possible role for Gal-3 is in antagonising tumour cell apoptosis via Fas
ligand binding and this is thought to only occur when Gal-3 is in the phosphorylated
state. The exact mechanism underlying the anti-apoptotic activity ofGal-3 is unclear,
but it does share a NWGR quartet in the C terminal part with Bcl-2 and this has been
shown to be critical for the anti apoptotic function Bcl-2. However it is not known
whether these proteins interact in vivo, as Gal-3 expression does not alter the
expression levels of Bcl-2 family members including Bcl-xL and Bax {Akahani,
1997;Matarrese, 2000;Yu, 2002}.
Gal-3 expression varies between tumour types. It is highly expressed in head and
neck squamous cell carcinoma, melanoma, angiosarcoma and thyroid carcinoma
{Gillenwater, 1996;Raz, 1981} In vivo expression correlates with tumour cell
transformation and metastatic phenotype and it has been shown to significantly
enhance tumour cell adhesion to common ECM proteins {Raz, 1990;Ochieng,
1999}, increase the incidence of lung metastases {Raz, 1990} and protect cancer
cells from apoptosis {Akahani, 1997;Matarrese, 2000;Yu, 2002}. In addition, pre-
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treatment of tumour cells with anti-Gal-3 antibodies reduce the incidence of
metastatic lung colonies by 90% {Meromsky, 1986}.
In contrast down regulation of Gal-3 has been demonstrated in small cell lung
cancer, endometrial carcinoma and breast carcinoma {Buttery, 2004;van den Brule,
1996;Castronovo, 1996} and varying results have been found in colonic carcinomas
{Lotz, 1993;Bresalier, 1998}. Squamous cell carcinoma and melanoma are not
chemosensitive tumours whereas small cell lung cancer and breast carcinoma are
characteristically chemosensitive at presentation, but develop resistance to
chemotherapy following treatment. This suggests that up-regulation of Gal-3 confers
a relative resistance to chemotherapy whereas down-regulation of Gal-3 may be
associated with chemosensitivity.
Gal-3 has been identified in the nucleus, cytoplasm and at the cell membrane
{Openo, 2000;Cherayil, 1989}.
In addition to its intracellular roles, Gal-3 is actively secreted into the extracellular
tissues where potential binding proteins include CD98, laminin and fibronectin
{Dong, 1997;Sato, 1994}.
Loss of nuclear staining of Gal-3 has been demonstrated with progression of disease
in colonic carcinoma and squamous cell carcinoma of the tongue {Lotz, 1993;Honjo,
2000}. However, these studies had conflicting results in that the former demonstrated
an overall down-regulation of Gal-3 expression whereas the latter found an
associated up-regulation of Gal-3 expression.
Van Den Brule {van den Brule, 1996} found up-regulation of Gal-1 and down-
regulation of Gal-3 in EEC in comparison to normal endometrium. In addition they
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found those cases with only cytoplasmic expression (i.e. no nuclear staining) of Gal-
3 had increased myometrial invasion compared to those cases with both cytoplasmic
and nuclear expression of Gal-3. To date, no studies on the expression of Gal-3 in
any other types of endometrial carcinoma have been performed.
6.1.5. Summary
This chapter attempted to determine if differences in interaction between tumour
cells and the extracellular matrix were responsible for the recognised differences in
clinical behaviour between UPSC and EEC. As no studies of CD98 expression in
endometrial carcinomas have been published and CD98 expression varies according
to tumour type in other carcinomas, this chapter aimed to determine the pattern of
expression of CD98 in EEC and UPSC. As down regulation of CD98 has been found
in metastatic adenoid cystic carcinoma, this chapter also focussed on differential
expression of CD98 between the central viable part of the tumour and the invasive
edge. Gal-3 is a recognised ligand of CD98, so it was also included in this chapter.
The expression of Gal-3 has been studied in EEC, but not in UPSC. Therefore this
chapter was undertaken to determine whether there is differential expression of
CD98 and Gal-3 between EEC and UPSC, which might explain the increased
aggressiveness ofUPSC compared to EEC.
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6.2 Materials and Methods
6.2.1 Tissues
Tissues were obtained as described in "Materials and Methods", Section 2.1.
6.2.2 Tissue Microarray
The tissue microarray was constructed as described in "Materials and Methods",
Section 2.2.
6.2.3 Immunohistochemistry
Immunohistochemistry was performed for CD98 and Gal-3 using the technique
described in "Materials and Methods", Sections 2.3.7 and 2.3.8 respectively.
6.2.4 Scoring
Scoring of antibody expression was assessed using the technique as described in
"Materials and Methods", Section 2.4.
6.2.5 Statistical Analysis





There was significantly greater CD98 expression in EEC compared to UPSC (P =
0.009, Mann Whitney U Test, Table 6.1). All CD98 expression was membranous.
Figures 6.1 and 6.2 show the pattern of expression of CD98 in EEC and UPSC
respectively.
Although Gal-3 expression was higher in UPSC compared to EEC, this did not reach
significance. All Gal- 3 expression was either cytoplasmic and nuclear, or
cytoplasmic only. There was no difference in the pattern of expression between
UPSC and EEC; Figures 6.3 and 6.4 show the pattern of expression of Gal-3 in EEC
and UPSC respectively. Stromal Gal-3 staining was identified in very few cases of
both UPSC and EEC. The number of cases involved was too small for statistical
analysis.
Table 6.1. Expression of Galectin-3 and CD98 in the Viable Central Part
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*P =0.009 (Mann Whitney U Test)
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Figure 6.1. Membranous Expression ofCD98 in EEC (Magnificationx40).
Figure 6.2. Membranous Expression ofCD98 in UPSC (Magnificationx40).
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Figure 6.3
Figure 6.3. Cytoplasmic Expression of Galectin-3 in EEC (Magnificationx40).




6.3.2.1 Uterine Papillary Serous Carcinoma
There was significantly greater expression ofCD98 at the invasive edge compared to
the viable central part of the tumour (p = 0.005 Wilcoxon Signed Ranks Test, Table
6.2). There was significantly less Gal-3 expression in the tumour at the invasive edge
compared to the viable central part of the tumour (p = 0.031, Wilcoxon Signed Ranks
Test). Although there was a decrease in the percentage of cells showing nuclear
expression of Gal-3 from the viable central part of the tumour to the invasive edge,
this did not reach significance (Table 6.2).
6.3.2.2 Endometrioid Endometrial Carcinoma
No significant differences in expression of Gal-3 and CD98 were noted between the
invasive edge of the tumour and the viable central part of the tumour (Table 6.2).
Although there was a decrease in the percentage of cells showing nuclear expression
ofGal-3 from the viable central part of the tumour to the invasive edge, from 52 % to
14%, this did not reach significance (Table 6.2).
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Table 6.2. Expression of Galectin-3 and CD98 in the Central Part of the





























C 51 67 48 86
C&N 49 33 52 14
C= cytoplasmic staining, C&N = cytoplasmic and nuclear staining.
+P = 0.005 (Wilcoxon Signed Ranks)
*P = 0.031 (Wilcoxon Signed Ranks)
6.4. Discussion
This chapter examined the immunohistochemical pattern of expression of CD98 and
Gal-3 in EEC and UPSC. with the aim of determining if differential expression may,
in part, contribute to the differing clinical behaviour of these tumours.
CD98 was demonstrated in all tumours examined. The finding of CD98 in both EEC
and UPSC was unsurprising as CD98 plays a role at the Gl/S interphase of the cell
cycle in all proliferating cells.
In addition, there was significantly higher expression of CD98 in EEC compared to
UPSC. The variation in expression of CD98 may be related to its association with (31
integrin. Studies have shown integrin expression to vary between benign and
malignant endometrial epithelium. (31 integrin is most commonly seen on benign
endometrial stromal cells, but has been found in almost 20% of cases of endometrial
carcinoma {Lessey, 1995}. In addition, (31 integrin expression may be modulated by
oestrogen and progesterone and Lessey et al {Lessey, 1995} found that integrin
expression correlated with steroid receptor status, as well as with grade, stage and
depth of invasion. Therefore if high oestrogen levels affect (31 integrin, it is possible
that CD98 expression may also be upregulated by high intratumoural oestrogen.
EEC usually arises on a background of oestrogen excess, commonly expresses
oestrogen receptors (ER), and can produce intratumoural oestrogen using aromatase.
In contrast, UPSC usually arises from atrophic endometrium, is generally ER
negative and does not produce intratumoural oestrogen. We found significantly
higher ER and progesterone receptors (PR) positivity in our EEC cases compared to
UPSC (results shown in chapter 7).
126
Alternatively CD98 expression may be due to activity of the LAT amino acid
transporter system, making amino acids available for protein synthesis by
proliferating tumour cells.
Significantly lower levels of CD98 were seen in the viable central part of UPSC
when compared to the invasive edge, suggesting a different role of CD98 in UPSC
compared to EEC. The increased expression of CD98 at the invasive edge of UPSC
compared to the viable central part may reflect activation of the (31 integrin signalling
pathway, increased anchorage independent growth and thus invasion. It is well
known that integrin is a key factor for cell invasion and migration, allowing the
cancer cell to penetrate adjacent tissues and attach itself to the target tissue's basal
matrix by binding to components of the extracellular matrix {Hood, 2002}.
In contrast, our finding of increased expression of CD98 in the viable central part of
EEC and a non significant decrease at the invasive edge has similarities to the
findings of Huang et al {Huang, 2003} who compared expression of CD98 in both
primary and metastatic adenoid cystic carcinoma. It is possible that the decrease in
CD98 at the invasive edge of EEC compared to the central viable part and the
metastatic adenoid cystic carcinoma compared to the primary tumour reflects a
similar mechanism. The loss of CD98 might cause or enable loss of tumour cell-cell
adhesion in a mechanism different to that where increased expression stimulates (31
integrin signalling and thus anchorage independent growth. The high CD98 in the
viable central part of EEC may be due in part to the relative increase in PR and ER,
affecting (31 integrin status and activity and therefore CD98 indirectly, but it is also
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possible that CD98 plays a role in increasing nutrient uptake in proliferating cells via
the LAT system.
Similarly to CD98, we identified Gal-3 expression in all cases examined. Although
there was higher Gal-3 expression in UPSC compared to EEC, this difference did not
reach significance. Gal-3 expression was significantly less at the invasive edge of
UPSC and there was also a non-significant decrease in Gal-3 expression at the
invasive edge of EEC when compared to viable central part of the tumour. This
decrease in Gal-3 expression was also mirrored by the loss of nuclear expression of
Gal-3 in a high proportion of both tumours at the invasive edge. Gal-3 expression
was both nuclear and cytoplasmic and cytoplasmic alone. In the central part of both
tumours the site of Gal-3 expression was equally split between nuclear and
cytoplasmic and cytoplasmic alone, raising the possibility that Gal-3 was acting in a
variety of roles including cell growth, proliferation and cell adhesion. At the invasive
edge of both tumours a higher proportion of cases showed cytoplasmic expression
only. However, this did not achieve significance. This non-significant loss of nuclear
staining at the invasive edge is in keeping with previous studies showing an
association with loss of nuclear expression and progression of disease {Lotz,
1993;Castronovo, 1996;Bresalier, 1998}. The authors of these studies suggested that
nuclear expression of Gal-3 conferred specific antiapoptotic properties to the cell,
whereas cytoplasmic expression conferred invasive properties to the cell.
In addition we found a significant decrease of Gal-3 expression at the invasive edge
of UPSC and a non-significant decrease in Gal-3 expression at the invasive edge of
EEC. This is similar to the findings of Lotz et al {Lotz, 1993} who showed an
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overall down regulation of Gal-3 in colonic carcinoma along with loss of nuclear
expression. Lotz et al {Lotz, 1993} suggested that nuclear localisation of Gal-3 was
associated with cessation of cell division and differentiation and therefore loss of
nuclear expression may be associated with increasing cell division and
dedifferentiation. It would be interesting; in a further study to determine if the down
regulation and loss of nuclear expression of Gal-3 in colonic adenoma-carcinoma
sequence is mirrored in either the progression of endometrial carcinoma in situ
(ECIS) to UPSC or in the atypical hyperplasia-carcinoma sequence of EEC.
Stromal Gal-3 was identified in very few cases of EEC and UPSC. Therefore it was
not possible to determine any association between Gal-3 expression and CD98
expression and in particular to determine if Gal-3 was acting as a ligand for CD98 in
these tumours.
6.4.1 Summary
This immunohistochemical study has confirmed that CD98 and Gal-3 are present in
both EEC and UPSC. We found significantly higher expression of CD98 in EEC
compared to UPSC. This may be due to the known relationship of CD98 with pi
integrin and indirectly of pi integrin with ER status. Despite the lower expression of
CD98 in UPSC compared to EEC we did show increased expression of CD98 at the
invasive edge of UPSC. This is may be due to increased requirement of invading
UPSC cells for nutrients, alternately this may reflect cross linking of (31 integrin and
thus activation of pi integrin signalling and thus anchorage independent growth.
There was no significant difference in Gal-3 expression between the tumour types,
but Gal-3 expression did significantly decrease at the invasive edge of UPSC
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compared to the central viable part of the tumour. This decrease in Gal-3 expression
also occurred to a non-significant level in EEC and was mirrored by a similar loss of
nuclear expression of Gal-3. These findings raise the possibility that loss of nuclear




The Role of Matrix Metalloproteases -2, -7 and -9 in Uterine Papillary
Serous Carcinoma and Endometrioid Endometrial Carcinoma
7.1 Introduction
Endometrial carcinoma is the most common female genital malignancy in the
western world {Creasman, 2003}. There are 2 main types of endometrial
carcinomas: endometrioid endometrial carcinoma (EEC) (Type I) and non-
endometrioid endometrial carcinomas (Type II) which mainly consist of uterine
papillary serous carcinoma (UPSC), clear cell carcinoma and malignant mixed
mesodermal tumour (carcinosarcoma). EEC accounts for approximately 80% of all
endometrial carcinomas and usually arises from atypical hyperplasia of the
endometrium {Burton, 1998;Santin, 2002;Santin, 2003}. It is associated with
oestrogen excess. UPSC accounts for approximately 10% of cases of endometrial
carcinoma {Burton, 1998} and makes up the majority of the Type II carcinomas. It is
an aggressive tumour, usually occurring in elderly women and is thought to arise
from endometrial intraepithelial carcinoma {Wheeler, 2000;Ambros, 1995;Spiegel,
1995}. It is not associated with either atypical hyperplasia or oestrogen status.
Although UPSC comprises 10% of cases of endometrial carcinoma {Burton, 1998} it
accounts for a much smaller proportion of Stage I endometrial carcinomas
{Hendrickson, 1983;Bancher-Todesca, 1998;Dembo, 1985}. It is upstaged at the
time of surgery in 60% of cases {Gehrig, 2001;Jeffrey, 1986;Kato, 1995;Goff,
1994;Dunton, 1991}. Hui et al {Hui, 2005} examined a series of 40 cases of early
uterine serous carcinoma. Nine of these were endometrial intraepithelial carcinoma
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and 31 were cases of Stage la UPSC. They demonstrated that only when the
carcinoma was confined to an endometrial polyp, did the patients have good
prognosis. It is possible that this aggressive behaviour could be explained by UPSC
interacting with the extracellular matrix (ECM) in a different way to EEC.
Liotta et al {Liotta, 1986} suggested a hypothetical model in which tumour invasion
and metastasis resulted from repetition of three steps; adhesion of cancer cells to BM
glycoproteins; degradation of BMs by specific proteolytic enzymes; and migration of
cancer cells. This chapter focuses on degradation of the ECM.
The theory of tumour progression and heterogeneity is well established. Tumours are
known to lose clonality early in development and generate subclones with varying
characteristics from mutations. In theory only the selected subclone will possess the
correct genetic characteristics in order to invade and metastasise.
7.1.2 Matrix Metalloproteases
Matrix metalloproteinases (MMPs), a family of zinc-dependent endoproteinases, are
widely accepted to play a role in the invasion and metastasis of tumours {Chang,
2001;Vihinen, 2002}. Under normal physiological conditions MMPs are expressed at
a very low level in adult tissues, except in tissues that undergo remodelling such as
cycling endometrium, normal breast tissue at the time of involution and the skin
during wound healing {Parks, 1999;Chang, 2001 ;Rodgers, 1993;Rodgers, 1994}.
Alteration of MMP expression has been implicated in a number of diseases such as
rheumatoid arthritis, osteoarthritis, chronic wounds and cancer {Chang,
2001;Vihinen, 2002;Stamenkovic, 2000;Parks, 1999;John, 2001;Jiang, 2002}.
Increased MMP expression and proteolytic degradation of ECM have been detected
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in a wide range of cancers, including those arising from the breast, colon, ovary and
lung and MMP expression has been correlated with primary tumour growth and
angiogenesis and also tumour invasion and metastasis {Chang, 2001;Vihinen,
2002;Stamenkovic, 2000;John, 2001;Jiang, 2002;Kugler, 1999;Stetler-Stevenson,
1999}.
Based on their structure and substrate specificity MMPs are divided into several
groups that include collagenases (MMP-1, MMP-3 and MMP-8), gelatinases (MMP-
2 and MMP-9), stromeolysins (MMP-3, MMP-10, MMP-11), matrilysins (MMP-7,
MMP-26), metalloelastase (MMP-12) and membrane type matrix metalloproteinases
(MT-MMPs) {Chang, 2001;Vihinen, 2002;Stamenkovic, 2000;Parks, 1999;John,
2001;Jiang, 2002}.
In the past it was generally accepted that cancer cells were responsible for producing
MMPs in human tumours. However, this concept underwent revision in 1990 when
Basset et al {Basset, 1990} reported that the stromal fibroblasts within tumours,
rather than the tumour cells themselves, were responsible for the production of
MMP-11 in human breast cancer. Since then MMPs-1, -2, -3, -9, and MT1-MMP
mRNA has been shown by in situ hybridization to be primarily in fibroblasts
especially in proximity to invading cancer cells in a variety of tumours including
breast, colon, and ovary {Polette, 1996;Nelson, 2000}. In contrast, MMP-2 mRNA
has been shown in prostatic cells rather than in fibroblasts {Still, 2000}. In addition,
immunohistochemistry (IHC) on a variety of human cancers has consistently
demonstrated the localization ofMMP protein in cancer cells. These data suggested
that MMPs produced and secreted by stromal fibroblasts and inflammatory cells may
bind to the cell membrane of cancer cells, thus giving them the proteases required for
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invasion. To support this, Yu et al {Yu, 2000} demonstrated that MMP-2 binds to
the TIMP-2:MT-MMP complex on the cell surface and that MMP-9 binds to CD44.
Olson et al {Olson, 1998} also showed that MMP-9 binds to type IV collagen on the
cell surface, and Barmina et al {Barmina, 1999} demonstrated that MMP-13 binds to
a receptor on the cell surface prior to endocytosis and lysosomal degradation. A
complicating factor is that MMP expression appears to vary among host organ
microenvironments and stromal MMPs may promote metastasis to one organ in
preference to another. Therefore anti-metastatic effects based on MMP inhibition
may be dependent on MMPs derived from specific organ microenvironments as well
as tumour cells {Shiraga, 2002}.
Although some MMPs are synthesised and secreted by cancer cells others are
synthesised and secreted by stromal cells and then bind to the cell membrane of
tumour cells {Basset, 1990;Polette, 1996;Nelson, 2000;Still, 2000;Yu, 2000;01son,
1998;Barmina, 1999}. MMP expression appears to vary among host organ
microenvironments and stromal MMPs may promote metastasis to one organ in
preference to another. Therefore anti-metastatic effects based on MMP inhibition
may be dependent on MMPs derived from specific organ microenvironments as well
as tumour cells {Shiraga, 2002}.
In female reproductive tract tissues, several MMPs and tissue inhibitory
metalloproteases (TIMPs) are expressed, and there is an association with events such
as menstruation, abnormal uterine bleeding, ovulation, embryo implantation, cervical
ripening and parturition {Martelli, 1993;Rodgefs, 1994;Matrisian, 1992}.
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7.1.3 Matrix Metalloprotease 2 (MMP-2)
ProMMP-2, the precursor to active MMP-2, is widely expressed in normal tissue and
the MMP-2 gene has been described as a 'house-keeping' gene for its role in normal
cellular processes {Matrisian, 1994}. In contrast, active MMP-2 is increased
significantly in some neoplastic tissues and absent in most normal tissues. MMP-2
contributes to cell migration by a mechanism involving interaction with collagen
{Xu, 2005}. MMP-2 has been demonstrated in endometrial carcinoma cells {Misugi,
2005}.
Park et al {Park, 2001} demonstrated that synthesis and secretion of stromal MMP-2
was up regulated by P oestradiol. In addition they showed that cells from an
endometrial adenocarcinoma cell line invaded by recruiting MMP-2 secreted by
endometrial stromal cells to their cell membrane and again, this was enhanced by the
presence of P oestradiol.
MMP-2 expression is used to help differentiate high grade from low-grade
endometrial carcinoma {lurlaro, 1999;Liokumovich, 1999;Inoue, 1997}.
7.1.4 Matrix Metalloprotease 7 (MMP-7)
Altered expression of MMP-7 has been demonstrated in EEC and increased
expression of MMP-7 is associated with lymph node metastasis {Yabushita,
2000;Ueno, 1999;Moser, 1999;Misugi, 2005}. In colonic adenocarcinoma MMP-7
expression is known to be increased in tumour cells but not stromal cells {Matrisian,
1994} and is associated with the risk of distant metastases and lymph node
metastases {Adachi, 1999;Newell, 1994}. Matrisian et al {Matrisian, 1994} showed
that induction of MMP-7 expression in tumour cells increased tumorigenicity and
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metastases, while inhibition of MMP-7 led to decreased metastasis {Witty,
1994;Hasegawa, 1998}. In addition, they found that MMP-7 expression appeared to
be associated with a less aggressive phenotype, despite being involved in invasion.
In contrast, Misugi et al {Misugi, 2005} demonstrated that increased expression of
MMP-7 was found in high grade endometrial carcinomas and this expression was
also associated with tumour invasion and metastasis. Mylona et al {Mylona, 2005}
detected MMP-7 expression in both tumour and stromal cells of breast carcinoma
and showed a direct correlation of expression of MMP-7 with MMP-2 in the same
tumour types.
Crawford et al {Crawford, 1999} described a positive correlation between nuclear P
catenin protein levels and MMP-7 transcripts in colonic carcinoma. They did not find
any MMP-7 expression in cells that lacked P catenin protein accumulation. In
contrast, Mylona et al {Mylona, 2005} demonstrated an inverse correlation with
nuclear P catenin expression in breast carcinoma.
7.1.5 Matrix Metalloprotease 9 (MMP-9)
MMP-9 expression has been shown to be altered in EEC and increased expression is
associated with myometrial invasion {Yabushita, 2000;Ueno, 1999;Moser,
1999;Misugi, 2005}. In addition, Park et al {Park, 2001} showed that synthesis and
secretion ofMMP-9 was down regulated by P oestradiol. Cioppi et al {Cioppi, 2004}
found that MMP-9 expression was higher in oestrogen receptor (ER) positive
endometrial carcinomas, In addition MMP-9 has been shown to be useful in
differentiating normal from sarcomatous endometrial stroma {Iurlaro,
1999;Liokumovich, 1999;Inoue, 1997}.
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7.1.6 Matrix Metalloprotease 26 (MMP-26)
MMP-26 and TIMP-4 expression is elevated in endometrial carcinomas with the
highest expression correlating with deeper myometrial invasion and high grade
tumours. There is no difference in expression between high-grade EEC and USPC
{Tunuguntla, 2003}.
7.1.7 Summary.
Although UPSC comprises only 10% of endometrial carcinomas it accounts for a
greater proportion of deaths. This chapter investigated the expression ofMMPs-2, -7
and -9 in UPSC and EEC, and in particular to see if there was any difference in
expression between the two tumour types which might explain the observed
difference in aggressive behaviour. Previous studies have shown that the expression
of MMPs -2 and -7 may be upregulated by (3 oestradiol; therefore, we also examined
the expression of ER and progesterone receptors (PR) in these tumours. P catenin
expression was studied in more detail in Chapter 5, but as studies on colon and breast
carcinoma have shown both positive and negative correlations between the
expression of P catenin and MMP-7, any correlation between P catenin expression
and any of the MMPs was noted. It is well recognised that tumours are
heterogeneous and examining the central part of the tumour alone may give
misleading results as regards the invasiveness of the tumour as a whole. We used
tissue microarrays (TMAs), to examine a relatively large number of cases, in order to
be able to demonstrate differences in expression of these proteins between the viable
central part of the tumour and the invasive edge in UPSC and EEC.
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7.2 Materials and Methods
7.2.1 Tissues
Tissues were obtained as described in "Materials and Methods", Section 2.1.
7.2.2 Tissue Microarray
The tissue microarray was constructed as described in "Materials and Methods",
Section 2.2.
7.2.3 Immunohistochemistry
Immunohistochemistry was performed for MMPs -2, -7 and -9 and for ER and PR
using the technique described in "Materials and Methods", Sections 2.3.3, 2.3.4,
2.3.5, 2.3.2 and 2.3.6 respectively.
7.2.4 Scoring
Scoring of antibody expression was assessed using the technique as described in
"Materials and Methods", Section 2.4.
7.2.5 Statistical Analysis





Significantly greater MMP-2 expression was present in EEC carcinoma cells
compared to UPSC carcinoma cells (p<0.05 Mann Whitney U Test, Table 7.1).
There was no significant difference in MMP-2 expression between UPSC and EEC
stromal cells. In addition, there was no significant difference in either carcinoma cell
or stromal cell expression ofMMP-7 between UPSC and EEC. Although there was
no significant difference in MMP-9 expression between UPSC and EEC carcinoma
cells, there was significantly greater MMP-9 expression seen in EEC stromal cells (P
= 0.001, Mann Whitney U Test, Table 7.1). There was significantly greater
expression of ER and PR in EEC compared to UPSC (P = 0.033 and P = 0.02
respectively Mann Whitney U Test, Table 7.1). Scatterplots and Pearson paifwise
correlation coefficient did not show any direct or inverse correlation between (3
catenin expression and MMPs-2, -7 or -9, in either UPSC or EEC.
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Table 7.1. Expression of MMPs -2, -7 and -9 in the Viable Central Part of












































*P < 0.05 (Mann Whitney U Test)
+P - 0.001 (Mann Whitney U Test)
"p = 0,033 (Manp Whitney U Test)
"*P = 0.02 (Mann Whitney U Test)
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7.3.2 Intratumoural Variability
7.3.2.1 Uterine Papillary Serous Carcinoma
There was significantly greater MMP-2 expression in carcinoma cells at the invasive
edge compared to those in the viable central part of the tumour (p = 0.045, Wilcoxon
Signed Ranks Test). However, there was no significant difference in expression of
MMP-2 in stromal cells between the invasive edge and the viable central part of the
tumour (Table 7.2). MMP-2 staining was present in both the cytoplasm and at the
cell membrane (Figure 7.1).
There was no significant difference in either MMP-7 or MMP-9 expression between
the viable central part of the tumour or the invasive edge in either carcinoma or
stromal cells (Table 7.2). Staining of both MMP-7 and MMP-9 in both carcinoma
and stromal cells was cytoplasmic and membranous (Figures 7.2 and 7.3
respectively).
There was significantly greater expression of MMP-2 in stromal cells compared to
carcinoma cells in both the viable central part of the tumour and at the invasive edge
(p<0.05 and p = 0.001 respectively, Wilcoxon Signed Ranks Test, Table 7.3). In
contrast there was significantly less expression of MMP-7 in the stromal cells
compared to the carcinoma cells in both the viable central part of the tumour and at
the invasive edge (p<0.05 and p = 0.001 respectively, Wilcoxon Signed Ranks Test,
Table 7.3). There was significantly less MMP-9 expression in carcinoma cells
compared to stromal cells in the viable central part of the tumour (p = 0.02,
Wilcoxon Signed Ranks Test, Table 7.3), but there was no significant difference in
MMP-9 expression between these cells at the invasive edge.
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Table 7.2. Expression of MMPs -2, -7 and -9 in the Viable Central Part of



































































* P = 0.045 (Wilcoxon Signed Ranks Test)
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Table 7.3. Variation in Matrix Metalloproteinase Expression between
Tumour and Stromal cells in UPSC.
Antibody

































*P <0.05 (Wilcoxon Signed Ranks Test)
**P <0.05 (Wilcoxon Signed Ranks Test)
***p = o.02 (Wilcoxon Signed Ranks Test)
P = 0.001 (Wilcoxon Signed Ranks Test)







Figure 7.1. Expression ofMMP-2 predominantly in UPSC stromal cells
(Magnificationx20).




Figure 7.3. Expression ofMMP-9 predominantly in UPSC carcinoma cells
(Magnificationx20).
7.3.2.2 Endometrioid Endometrial Carcinoma
No significant differences in expression of any of the proteins (MMPs-2, -7 or-9)
were noted in either carcinoma cells or stromal cells at the invasive edge compared
to those in the viable central part of the tumour (Table 7.2). Expression of all the
MMPs was both cytoplasmic and membranous (Figures 7.4, 7.5 and 7.6
respectively).
There was no significant difference in expression ofMMP-2 between carcinoma and
stromal cells in both the viable central part of the tumour and at the invasive edge
(Table 7.4). There was significantly greater expression ofMMP-7 in carcinoma cells
compared with stromal cells in the viable central part of the tumour (p = 0.018,
Wilcoxon Signed Ranks Test, Table 7.4), but there was no significant difference in
expression between the cell types at the invasive edge. Significantly greater
expression ofMMP-9 was noted in stromal cells compared to carcinoma cells in both
the viable central part of the tumour and at the invasive edge (p = 0.011 and p =
0.012 respectively, Wilcoxon Signed Ranks Test, Table 7.4).
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Table 7.4. Variation in Matrix Metalloproteinase Expression between
Tumour and Stromal cells in Endometrioid Endometrial Carcinoma.
Antibody Main Tumour Invasive Edge
Tumour cells Stromal
cells


























*P = 0.018 (Wilcoxon Signed Ranks Test)
**P = 0.011 (Wilcoxon Signed Ranks Test)








Figure 7.4. Expression ofMMP-2 predominantly in EEC stromal cells
(Magnificationx40).








UPSC is an aggressive endometrial tumour with a notable propensity for
lymphovascular space invasion and a poor prognosis. This chapter aimed to
determine ifMMPs had a role in the increased invasiveness of UPSC in comparison
to EEC. We confirmed the findings of Misugi et al {Misugi, 2005} and Moreno-
Bueno et al {Moreno-Bueno, 2003} and demonstrated MMPs -2, -7 and -9 to be
present in both UPSC and EEC.
In addition, this chapter looked for differences in expression of these proteins
between the different histological tumour types and within the tumours (the viable
central part of the tumour and at the invasive edge). We demonstrated MMP-2
expression in both EEC and UPSC carcinoma cells, confirming the findings of Park
et al {Park, 2001}. Park et al {Park, 2001} demonstrated that synthesis and secretion
of stromal MMP-2 was up regulated by (3 oestradiol. In addition they showed that the
invasiveness of cells from an endometrial adenocarcinoma cell line was enhanced by
recruitment ofMMP-2 secreted by endometrial stromal cells to their cell membrane,
which was further enhanced by the presence of P oestradiol.
The finding of significantly higher MMP-2 expression in EEC carcinoma cells
compared to those in UPSC may partly reflect the different biological properties of
these tumours. EEC is a tumour which usually arises on a background of oestrogen
excess, which commonly expresses ER and can produce intratumoural oestrogen
using aromatase {Segawa, 2005}. On the other hand, UPSC usually arises from
atrophic endometrium, is generally ER negative and does not produce intratumoural
oestrogen. Park et al {Park, 2001} demonstrated that P oestradiol stimulated MMP-2
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secretion in adenocarcinoma cell lines, therefore it is possible that the differential
secretion may be due to increased intratumoural oestrogen in EEC compared to
UPSC. We found significantly higher ER and PR positivity in our EEC cases
compared to UPSC.
We found similar levels ofMMP-2 in EEC carcinoma and stromal cells and although
there was increased expression ofMMP-2 in carcinoma cells at the invasive edge of
the tumour, this was not statistically significant. However, we did find a significantly
higher level ofMMP-2 in UPSC stromal cells compared with carcinoma cells both in
the viable central part of the tumour and at the invasive edge. In addition, the UPSC
carcinoma cells showed a significant increase in MMP-2 expression at the invasive
edge compared to the viable central part tumour. MMP-2 is synthesised and secreted
by stromal cells and then binds to the TIMP-2:MT-MMP complex on the carcinoma
cell surface {Yu, 2000}; this difference in expression raises the possibility that the
invasive subclone of UPSC uses increased carcinoma cell binding of MMP-2 to
equip the cells with the proteases required for invasion
We did not demonstrate any intertumoural or intratumoural differences in expression
of MMP-7. There was significantly more expression of MMP-7 in carcinoma cells
compared to stromal cells in both UPSC and EEC. Our findings are in keeping with
the published literature that MMP-7 is generally expressed in tumours {Yabushita,
2000;Ueno, 1999;Moser, 1999;Misugi, 2005}. As this study examined high grade
endometrial cancers only we could not confirm or refute the findings of Misugi et al
147
{Misugi, 2005}, who showed differential expression of MMP-7 between the
different grades ofEEC.
Crawford et al {Crawford, 1999} described a positive correlation between nuclear (3
catenin protein levels and MMP-7 transcripts in colonic carcinoma. They did not find
any MMP-7 expression in cells that lacked (3 catenin protein accumulation. Mylona
et al {Mylona, 2005} demonstrated an inverse correlation with nuclear [3 catenin
expression in breast carcinoma. We did not demonstrate any inverse or direct
correlation with P catenin expression and any of the MMPs. This may be due to the
relatively small numbers of cases involved. Alternately this may be because the
studies that demonstrated either inverse or direct correlations were focussed on
colonic carcinoma where P catenin expression is nuclear, reflecting mutation in the p
catenin gene and the studies by Mylona et al {Mylona, 2005} in breast carcinoma
also focussed on P catenin mutation.
We found a significantly higher expression of MMP-9 in EEC compared to UPSC
and also a significantly higher expression ofMMP-9 in the stromal cells compared to
the carcinoma cells in the viable central part of the tumour in both EEC and UPSC.
In addition there was significantly higher expression of MMP-9 in stromal cells
compared to carcinoma cells at the invasive edge of the EEC cases. However, there
was no significant difference in MMP-9 expression between the invasive edge
stromal cells and carcinoma cells in UPSC. MMP-9 is normally synthesised and
secreted by stromal cells and binds to CD44 on carcinoma cells {Yu, 2000}. The loss
of this differential expression between carcinoma cells and stromal cells at the
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invasive edge of UPSC cases may indicate that MMP-9 synthesis and secretion by
stromal cells is unchanged at the invasive edge of the tumour, but binding ofMMP-9
by the invading carcinoma cells is increased, perhaps enhancing their invasive
potential.
Hui et al {Hui, 2005} demonstrated differences in outcome between patients with
Stage la UPSC arising in a polyp and in the normal endometrium. In view of our
results showing differences in expression of MMPs -2 and -9 between the main part
of the tumour and the invasive edge, it would be interesting to more closely examine
cases of endometrial intraepithelial carcinoma and Stage la UPSC.
7.4.1 Summary.
In summary this immunohistochemical study has confirmed that MMPs-2, -7 and -9
are present in endometrial carcinomas and specifically in both EEC and UPSC. We
also confirmed that our UPSC group had significantly lower ER and PR expression.
We found significantly higher expression of MMPs -2 and -9 in EEC compared to
UPSC. This may be due to the known relationship of these MMPs with oestrogen
status. Despite the lower expression of MMP-2 and MMP-9 in UPSC compared to
EEC we did show increased expression ofMMP-2 and MMP-9 by carcinoma cells at
the invasive edge of UPSC. This is probably due to increased binding of MMPs
secreted by the stromal cells to carcinoma cells. This difference in staining pattern
between the viable central part of the tumour and the invasive edge supports the




Despite having been described as a distinct clinical entity for over twenty years,
uterine papillary serous carcinoma (UPSC) remains a management challenge for the
multidisciplinary team due to the paucity of understanding on the epidemiology,
pathogenesis, natural history and optimal treatment strategies for this important and
aggressive variant of endometrial adenocarcinoma. The aim of this thesis is to
specifically focus on molecular changes in UPSC, which might account for its
aggressive behaviour and pattern of spread and to add to the growing volume of
literature on UPSC. This thesis briefly describes the current literature on UPSC and
demonstrates that although in the past the microscopic and clinical similarities of
UPSC to ovarian serous papillary carcinoma (OSPC) led to some clinicians and
pathologists to think that these tumours were biologically similar, they are actually
quite distinct. There are a wide number of adjuvant treatment options open to
patients with UPSC; the majority ofwhich have only been formally tested on patients
with OSPC.
The tissue microarray (TMA) validation study (Chapter 3) shows that the results of
immunohistochemical staining of TMAs made from endometrial carcinoma are
equivalent to those from whole sections of the same tumour. The ideal number of
cores sampled should be 2 to 3 in order to decrease the variation seen in
heterogeneous tumours, and also to increase the likelihood of an informative section
in those tumours, which may be focal, infiltrative or scanty when present in a pipelle
specimen. In addition, this chapter demonstrates that TMA use can be extended to
include other high-grade endometrial carcinomas and antibodies with uncertain
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patterns of expression. Chapter 4 describes an audit of the pathological diagnosis and
management of UPSC in South East Scotland. This confirms the poor prognosis of
patients with UPSC and shows that in even those cases where the tumour only
comprises 5% UPSC, the poor prognosis is conferred, regardless of the additional
tumour type. This audit raises awareness for the need of accurate and complete
surgical staging at a local level. Despite the poor response to chemoradiotherapy
identified by this audit, local treatments for patients with UPSC have not altered, as
patient numbers are small with a limited follow up time. This audit contributed to the
increasing local, national and international awareness of the need to invest in
randomised controlled trials on UPSC.
The remaining chapters focus on molecules involved in three steps associated with
invasion. Chapter 5 examines the initial step in invasion where tumour cells decrease
their homotypic binding in order to detach from one another and to invade. Therefore
the expression of the cell adhesion molecules E cadherin, P cadherin and P catenin in
UPSC is determined and this expression is compared with high-grade endometrioid
endometrial carcinoma (EEC). This chapter confirms that E cadherin, P cadherin and
P catenin are expressed in high-grade endometrial carcinoma and that there is
differential E cadherin and P cadherin expression between UPSC and EEC. This may
in part be due to the important role of oestrogen in the development and progression
of EEC compared to UPSC. In addition, decreased expression of E cadherin and P
cadherin between the viable central part of the tumour and the invasive edge is
demonstrated.
The second step in invasion, after cells have dissociated from each other, is the
attachment of tumour cells to molecules in the extracellular matrix (ECM). CD98
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and Galectin-3 (Gal-3) were selected for this chapter (Chapter 6). CD98 was chosen
due to the relatively recent discovery of its association with pi integrin and Gal-3
was chosen as it has been identified as a possible ligand of CD98. This chapter
confirms that CD98 and Gal-3 are present in both EEC and UPSC. There was
significantly higher expression of CD98 in EEC compared to UPSC. This may be
due to the known relationship of CD98 with pi integrin and indirectly pi integrin
with ER status. Despite the lower expression of CD98 in UPSC compared to EEC
there was increased expression of CD98 at the invasive edge of UPSC. This is may
be due to increased requirement of invading UPSC cells for nutrients, or it may
reflect cross linking of P1 integrin and thus activation of P1 integrin signalling and
anchorage independent growth. There was no significant difference in Gal-3
expression between the tumour types, but Gal-3 expression did significantly decrease
at the invasive edge ofUPSC compared to the central viable part of the tumour. This
decrease in Gal-3 expression also occurred to a non-significant level in EEC and was
mirrored by a similar loss of nuclear expression of Gal-3. These findings raise the
possibility that loss of nuclear expression of Gal-3 is associated with the
development of invasive properties of these tumours.
The final step in invasion examined in this thesis is degradation of the ECM. Chapter
7 confirms that MMPs-2, -7 and -9 are present in high grade endometrial carcinoma.
It also confirms that the UPSC group had significantly lower oestrogen receptor (ER)
and progesterone receptor (PR) expression. Expression of MMPs-2 and -9 was
significantly higher in EEC compared to UPSC. This may be due to the known
relationship of these MMPs with oestrogen status. Despite the lower expression of
MMP-2 and MMP-9 in UPSC compared to EEC, expression ofMMP-2 and MMP-9
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by carcinoma cells at the invasive edge of UPSC was increased. This is probably due
to increased binding to carcinoma cells of MMPs secreted by the stromal cells. The
difference in staining pattern of E cadherin, P cadherin, P catenin, CD98 and MMPs-
2 and -9, between the viable central part of the tumour and the invasive edge
supports the theory of a subclone of UPSC acquiring the properties necessary to
invade.
In conclusion, this thesis has examined the role of molecules involved in some of the
important steps involved in invasion; namely loss of cell-cell adhesion (E-cadherin, P
cadherin and P catenin), attachment to the ECM (CD98 and Gal-3) and degradation
of the ECM (MMPs -2, -7 and -9). This demonstrated differences in expression of
these molecules, not only between the central viable part of the tumour and the
invasive edge but also between UPSC and EEC. The presence of intratumoural
variation supports the theory that tumours become increasingly heterogenous with
subclones developing different properties necessary for invasion and metastasis. The
intertumoural variation emphasises the influence of oestrogen and therefore the
oestrogen receptor status of the tumours as E cadherin, P catenin, CD98 and MMPs -
2 and -9, are either directly or indirectly altered by oestrogen and, apart from E
cadherin which was decreased, the other molecules all showed higher expression in
EEC compared to UPSC. The results are consistent with the important role that
oestrogen status plays in the development of EEC and it is possible that the lack of
responsiveness ofUPSC to oestrogen plays a role in its aggressive behaviour.
These data contribute to the growing body of literature on UPSC, and addresses
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Abstract. Faratian D, Stillie A, Busby-Earle RMC, Cowie VJ, Monaghan H. A review of the pathology and
management of uterine papillary serous carcinoma and correlation with outcome, hit J Gynecol Cancer
2006;16:972-978.
Uterine papillary serous carcinoma (UPSC) accounts for 107c of endometrial carcinomas but a higher pro¬
portion of deaths due to its aggressive nature and poor response to chemotherapy and radiotherapy. In
order to add to the knowledge of UPSC in the literature and to review our local practices, we examined the
pathology, medical records, and management of all cases of UPSC (67 patients) treated in South East
Scotland over a 10-year period and also evaluated the prognostic significance of the percentage of UPSC in
endometrial pipelle and hysterectomy specimens. Although only 637c of initial diagnostic biopsies were re¬
ported to contain UPSC, rereview of the cases revealed UPSC in 98.57o of the preoperative biopsies. The
percentage of UPSC in the tumors did not affect the outcome. Stage, positive omentum, and treatment with
external-beam +/— intracavitary radiotherapy were significantly correlated with overall survival and
progression-free survival by univariate analysis, but only stage (P < 0.01) was correlated with outcome on
multivariate analysis. Chemotherapy did not affect outcome. UPSC may be difficult to diagnose in pre¬
operative biopsies, particularly when present as part of a mixed tumor. Even a small percentage of UPSC
in a diagnostic biopsy or hysterectomy specimen is correlated with a poor prognosis. This study empha¬
sizes the need of a cooperative, prospective study on this distinct uterine carcinoma.
keywords: chemotherapy, papillary, radiotherapy, serous, uterus.
While papillary morphology has been recognized in
endometrial carcinoma since the turn of the past cen¬
tury, uterine papillary serous carcinoma (UPSC) was
first described as a distinct clinical entity in 1982 by
Lauchlan(1) and Hendrickson et al.'"2'3> UPSC usually
occurs in elderly, postmenopausal women and, in con¬
trast to endometrioid endometrial carcinoma (EEC), is
not associated with excess estrogen. There is conflict¬
ing data regarding the association of breast cancer
with high-risk endometrial carcinomas'4,5'. It is thought
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Royal Infinnary of Edinburgh, 51 Little France Crescent, Edinburgh
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that patients with breast cancer have a similar rate
of low- and high-risk endometrial subtypes irrespec¬
tive of tamoxifen use. However, patients with UPSC
may have an increased risk of synchronous or sub¬
sequent development of breast cancer'6,71. This raises
the possibility that UPSC and breast cancer may, in
some patients, be due to the presence of mutations in
cancer predisposing genes such as BRCA l'8'.
Although accounting for only 107o of endometrial
carcinomas, UPSC is an important diagnosis to make
on initial biopsy since it behaves particularly aggres¬
sively, with a propensity for early metastasis that re¬
sults in upstaging at the time of operation in 50-75%
of clinical stage I cancers'9"11'. This underscores the
need for accurate preoperative diagnosis, so that the
surgeon can plan definitive treatment and perform
accurate and thorough surgical staging by the FIGO
€> 2006, Copyright the Authors
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system, including a total extrafascial hysterectomy
and bilateral salpingo-oophorectomy, peritoneal wash¬
ings, and removal of any suspicious pelvic or para¬
aortic lymph nodes. Although omentectomy is not in
the 1988 FICO system for staging, it is also frequently
performed. This is because UPSC behaves aggros
sively and has a pattern of spread similar to that of
ovarian serous carcinoma. There is no evidence to date
that this radical surgery affects outcome, but accurate
staging may help influence current advice regarding
adjuvant therapy. UPSC may exist in both "pure" and
"mixed" fonns with other endometrial cancer sub¬
types, in particular EEC and clear cell endometrial car¬
cinoma (CCEC). Sherman et alP2) state that the
diagnosis of UPSC should be reserved for cancers with
more than 25% UPSC pattern in the final resection
specimen, although this figure appears arbitrary.
Data as to the optimum management of UPSC are
limited due to its relative rarity. This audit was
performed to look at the patient characteristics, histo¬
pathologic characteristics, and outcomes of various
treatment regimens of UPSC. In particular, we wished
to determine the accuracy of diagnosing UPSC on
endometrial pipelle biopsies or curettings, whether the
histologic subtypes seen in the diagnostic biopsy corre¬
lated with those seen in the final resection specimen,
and also what percentage of UPSC pattern is required
to confer the poor prognostic phenotype. To date, there
have been several studies looking at cither the onco
logic or the surgical management of UPSC, ranging
from 9 to 129 cases'3,6,9,13"18'. Our review of the man¬
agement of this challenging disease is the fourth largest
of its kind (67 patients), and to our knowledge, the first
to address these specific pathologic questions.
Materials and methods
Between 1994 and 2003, 67 patients had a tissue diag¬
nosis of pure UPSC or a mixed carcinoma containing
a UPSC component made on initial biopsy or in the
resection specimen. All these cases were reviewed, and
the management was discussed at the regional gyneco¬
logical oncology clinicopathologic meeting. Of these, 59
patients had surgical intervention, and 57 received ad¬
juvant therapy of radiotherapy + / — chemotherapy.
The patient demographics, histopathology, and
treatment were recorded.
Patient characteristics
Surgical and oncologic medical records were reviewed
to obtain information about patients' age at presenta¬
tion, any previous history of breast cancer, the treat¬
ment, and follow up data, in particular the site of any
relapse. The primary end points were progression-free
survival (PFS) and overall survival (OS), defined as
the period from the date of diagnosis to the date of
recurrence or the last clinic visit (if alive) or the date of
death. Data were censored if information on survival
was not available or the patient had ceased to be fol¬
lowed up for any reason but had not died of cancer.
Histopathologic characteristics
All diagnostic biopsies and hysterectomy sections
from the 67 patients were reviewed by two patholo
gists (D.F. and H.M.). The diagnosis of UPSC, CCEC,
and EEC were made using the classical microscopic
features, which are well known. The pipelle or endo¬
metrial curettings were reviewed to determine if defin¬
itive diagnosis of UPSC was possible on the original
biopsy. Then, the hysterectomy specimens were re¬
viewed to determine if it was a pure UPSC or mixed
tumor. If it was a mixed tumor, the percentage of
UPSC, EEC, and CCEC of the total tumor present was
estimated in the tissue piocessed foi histologic analy¬
sis. Estimates were made by counting low-power
(X20-X40) fields of each pattern and dividing this by
the total number of fields. Data were compared, and
the three discrepancies resolved by case conference.
The number and nature of specimens additional to the
hysterectomy specimen received (ie, omentum, pelvic
lymph nodes, or peritoneal washings) were noted,
along with the pathologic stage according to the 1988
FIGO surgical staging criteria at the time of resection.
Oncologic characteristics
The adjuvant therapy was recorded, and the chemo¬
therapy and radiotherapy regimens (external beam
+ /— vaginal cesium) were documented. Where the
data were available, details of the treatment of recur¬
rence were also noted.
Statistical analysis
All statistical analyses were performed using SPSS soft¬
ware (SPSS Inc, Chicago, IL). The Spearman's rank test
was used to assess the correlation of the initial diagnos¬
tic biopsy with the definitive hysterectomy histology
percentage histologic subtype. OS and PFS were esti¬
mated on the basis of Kaplan-Meier curves and the log-
rank test used as a univariate analysis of prognostic fac¬
tors. A P value of less than 0.05 was considered statisti¬
cally significant, and variables that had a P value of less
than 0.05 were entered into a Cox regression model.
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Results
Patient characteristics
The median age of the patients was 68 years (range
49-89 years). Nine patients (13%) had a medical his¬
tory of breast cancer. No patients developed breast
cancer after the time of diagnosis of UPSC. The
median follow-up for all patients was 14.5 months
(range 1-114 months). The numbers and percentages
of each patient with each stage of disease are shown in
Table 1, along with 1-year and 3-year OS and PFS by
stage. OS and PFS correlated significantly with the
stage of disease (P < 0.01; Fig. 1), the median OS was
67, 43, 14, and 9 months for stage I, II, III, and IV dis¬
ease, respectively. The median PFS for stage I disease
was not reached in this study, due to censoring, but
the median PFS for stage II, III, and IV disease was 43,
9, and 8 months, respectively.
Surgical analysis
Fifty-nine patients underwent surgery. All these
patients underwent a total abdominal hysterectomy,
bilateral salpingo-oophorectomy. Twenty-four patients
(40.1%) had, in addition, omental sampling, 21 patients
(87.5%) an omental biopsy, and 3 patients (12.5%) full
omentectomy. Seven patients (11.9%) had a pelvic node
clearance; in 30 patients (50.9%), peritoneal washings
were taken. In 7 patients total abdominal hysterectomy,
bilateral salpingo-oophorectomy, omentectomy, and
pelvic node sampling were carried out and peritoneal
washings were taken. No patients had para-aortic node
sampling.





1 year 3 years 1 year 3 years




Stage II 14 (20) 81.8 60.1* 81.8 50.9**
1IA 7(10)
IIB 7(10)




Stage IV 9(13) 0 ND 41.6 ND
All patients 67 61.5 46.2 67.0 39.4
ND, no data.
*P < 0.01; **P < 0.01.
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Seven (29%) omental samples were positive for met¬
astatic disease, two (28.5%) pelvic lymph node clear¬
ances were positive, while six of 30 (20%) of peritoneal
washings contained malignant cells. Patients who had
a negative omental biopsy at the time of operation
showed a significantly better PFS and OS (P < 0.01)
than those who had a positive biopsy (Fig. 2A). Of the
three omentectomies performed, one was positive and
two were negative. Positive peritoneal cytology was
weakly associated with poor prognosis (log-rank test,
P = 0.15), while the effect of pelvic lymphadenectomy
on prognosis could not be analyzed due to small num¬
bers of patients.
Histopathologic analysis
On reviewing the pathology reports, 63 of the cases
were diagnosed by pipelle biopsy, curettage, or hys-
teroscopic biopsy; one case was diagnosed on cervical
cytology, and three cases were from hysterectomy his¬
tology. Of the 63 patients who had a preoperative
diagnostic biopsy, 23 biopsies (36.5%) showed pure
UPSC histology and 39 (62%) showed mixed histo¬
logic subtypes including a UPSC component. Thirty
nine of the diagnostic biopsies (63%) were described
as serous, papillary, mixed serous/other histologic
subtype in the original pathologic reports, and on
review, 62 of the biopsies (98.5%) contained a UPSC
component. The one biopsy (1.5%) that did not contain
a UPSC component was reviewed as 100% CCEC, and
on hysterectomy, the tumor was reviewed as 100%
UPSC. The correlation between the initial biopsy and
the hysterectomy histology subtypes is illustrated in
Figure 3. While there was a weak positive correlation
between the diagnostic biopsies and the hysterectomy
diagnoses for UPSC and CCEC (Spearman's rank cor¬
relation coefficient 0.47 and 0.30, respectively, P <
0.01), the correlation is much stronger for EEC (Spear¬
man's rank correlation coefficient 0.70, P < 0.01). In
addition, those biopsies, which overestimated the
amount of UPSC in the resection, were usually the
same cases in which the percentage of CCEC was un¬
derestimated. In Kaplan-Meier analyses of survival,
the OS and PFS were not significantly different in
patients with pure and mixed histologic patterns or
percentage of UPSC (including less than 25% UPSC
compared to more than 25% UPSC) in the diagnostic
biopsies or the resections (Fig. 4). In addition, whether
UPSC was mixed with EEC or CCEC made no differ¬
ence to survival. Serous endometrial intraepithelial
carcinoma was identified in two of the hysterectomy
specimens.
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Figure 1. A) OS by stage (P < 0.01), and B) PFS by stage (P < 0.01).
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Adjuvant therapy
Fifty-seven patients received adjuvant therapy. Thirty
patients (52.6%) received radical radiotherapy, and
three patients (5.2%) palliative therapy. Of the two
patients who did not receive radiotherapy, one was
deemed to have had curative surgery (stage I disease)
and the other war, deemed unfit for therapy. In addition
to radiotherapy, 28 patients (49.1%) received adju¬
vant chemotherapy with different regimens includ¬
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Figure 2. Kaplan-Meier curves of treatment variables by OS. A) Omental sampling P < 0.01 (log-rank test), B) radiotherapy P < 0.01
(log-rank test), C) intracavitary radiotherapy P < 0.01 (log-rank test), and D) chemotherapy P = 0.64 (log-rank test).RT, radiotherapy; Cis,
cisplatinum; C&T, carboplatin and paclitaxel (Taxol); C, carboplatin.
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Figure 3. Scatter plots to represent
percentages of histologic subtypes in
diagnostic biopsies vs resection speci¬
mens. Each spoke on a data point
represents one case. Best-fit lines (red)
show a positive correlation between




cisplatin (Table 2). Patients treated with radical radio¬
therapy postoperatively had a significantly better prog¬
nosis by univariate analysis (P < 0.01; Fig. 2B, C). The
median OS was 29 months in patients receiving radical
radiotherapy compared with 12 months in patients not
receiving radical radiotherapy, and the median OS was
67 months in patients receiving palliative radiotherapy
compared with 12 months in patients not receiving pal¬
liative radiotherapy. There were no significant differ¬
ences in survival in patients treated with or without
chemotherapy (Fig. 2D) or between the different che¬
motherapy regimens.
Recurrence analysis
Fifteen (22.4%) patients had recorded recurrences. Of
these, five (33%) were distant metastases (lung, liver,
omentum, and neck lymph nodes) and ten (67%) were
locoregional recurrences. Median time to recurrence
was 9 months (range 4-17 months). Two omental re¬
currences were in patients who had positive omental
biopsies. Neither had underwent complete omentec-
tomy. The recurrence rate in stage I-IV patients was
12%, 14%, 36%, and 33%, respectively. Further sur¬
vival analysis was not possible due to the small num¬
bers in each stage and nonstandardized treatment
regimens.
Discussion
This study of UPSC is the third largest retrospective
series of its kind with focus on the effect of histopa-
thology on outcome. The high median age of the pa¬
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Figure 4. OS. Less than 25% UPSC
(purple line) compared with greater
than 25% UPSC (green line) in pre¬
operative (A, P = 0.76, log-rank test)
and resection specimens (B, P = 0.56,
log-rank test).
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Table 2. Chemotherapy regimens by stage
Stage C C&T Cis Nil
I 7 2 1 13
11 4 0 1 6
111 5 3 0 5
IV 5 u 0 4
C, carboplatin; Cis, cisplatinum; C&T, carboplatin and
paclitaxel.
previously documented for UPSC117,19'. Thirteen per¬
cent of patients had a personal history of breast can¬
cer, identical to that observed by Slomovitz et al.
and similar to Barakat et aid who observed a similar
rate of high-risk endometrial subtypes in breast cancer
patients regardless of tamoxifen use. The observed
high proportion of UPSC in breast cancer patients ap¬
pears not to be related to BRCA gene status, which
confers an increased risk of ovarian papillary serous
carcinoma and EEC only<6,7>. This suggests that the
observed association between UPSC and breast cancer
may be due to the presence of mutations in a variety
of other cancer predisposing genes such as P53 and
cerbB2.
Only 63% of the biopsies were diagnosed as pure or
mixed UPSC histologic patterns, in line with previous
reports<9,12'14'17'20-22), which have reported the accuracy
of preoperative biopsy from 65% to 93%. Most biopsies
not explicitly stated as UPSC were given grade 3 endo¬
metrial carcinoma diagnoses or classified according to
the other major histologic subtype, usually CCEC.
However, on retrospective review of the biopsies, only
one (1.5%) of the preoperative biopsies did not contain
any UPSC, according to traditional diagnostic criteria,
and the major pattern in this case was CCEC. This may
be explained by the heterogeneity of the disease.
We sought to evaluate whether 25% UPSC pattern,
the value above which the tumor is classified as UPSC,
is prognostically valid111'. We found that the survival
of patients with less than 25% or more than 25% UPSC
in the biopsy or the resection was the same, suggesting
that tumors should be classified, and managed, as
UPSC regardless of the percentage of UPSC in the
pathologic specimen. Our lowest percentage of UPSC
used was 5%. In addition, in keeping with previous re¬
ports, pure or mixed histologic patterns did not show
any survival difference, and survival was the same
regardless of whether UPSC was mixed with a high-
risk subtype, such as CCEC, or a low-risk subtype,
such as EEC19'171, suggesting that UPSC is biologically
dominant in heterogeneous tumors.
We found that a low number of patients underwent
complete surgical staging (40% omental staging, 11.9%
pelvic node clearance, 50% cytology), which may in
part be explained by the changing surgical practice
over the period analyzed and difficulties with the
interpretation of the diagnostic biopsies. While this
raises the possibility that the patients might not be
accurately surgically staged, our survival rates are
consistent with the generally accepted long term sur¬
vival rates of 35-50% for patients with stage I and
II UPSC and 0-15% for patients with stage III and IV
diseases123'.
Gehrig et aid2® showed that the sensitivity of a visu¬
ally negative omentum was 89%, concluding that,
with a microscopic metastasis rate of 4%, surgical
sampling does not need to be included in the routine
surgical staging of UPSC. The clinical consequences of
understaging is underscored by the fact that in our
data two recurrences (13%) occurred in biopsy posi¬
tive omenta that were not removed by omentectomy,
and these two patients had stage III disease that, while
still a poor prognosis group, may have benefited from
additional abdominal surgical clearance. Omentec¬
tomy may result in better local control of disease and
more directed and appropriate adjuvant therapy.
Unfortunately, our data were too small to establish
a link between omentectomy and survival. Although
we had a low rate of pelvic lymphadenectomy, the
diagnostic value of systematic lymphadenectomy has
recently been validated by Slomovitz et a/.117', who
reported 19% lymph node involvement in patients
without myometrial invasion. Furthermore, the
importance of performing a formal lymph node
dissection is emphasized by the absence of pelvic side-
wall failures following observation in a population at
risk for recurrence125' and may explain why two of
the patients, who had not underwent formal pelvic
lymphadenectomy, had pelvic recurrences.
We did not show any significant impact of adjuvant
radiotherapy or chemotherapy on PFS or OS. Ramon-
detta et aid2® showed that single-agent paclitaxel
showed a tumor response in 77% of patients and used
in a neoadjuvant fashion with cisplatin, and Zanotti
et al.(27) observed responses in eight out of nine
patients. In addition, Kelly et al.a2) recently showed
that platinum-based chemotherapy improved disease-
free survival and OS of patients with stage 1 UPSC
and vaginal cuff radiation provided local control of
disease. However, our study failed to show that treat¬
ment with these agents converted into an objective
improvement in PFS or OS. This is probably due to
the short average follow-up time (14 months) and
possibly the inadequate surgical staging, resulting in
patients being understaged.
Twenty-two percent of patients in this study had fur¬
ther disease. This is far fewer than the percentage
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observed by other groups, who have documented
recurrence rates of between 50% and 75%, using vari¬
ous adjuvant therapies, radiotherapy alone, or with the
addition of chemotherapy using platinum and/or pacli-
taxel alone, as used in our study'27 . Our results,
therefore, compare favorably with similarly staged tu¬
mors at equivalent median follow-up, although similar
to these studies stage III and IV tumors remain a partic¬
ular management problem due to higher rates of recur¬
rence (36% and 33% for stage III and IV carcinomas
compared with 12% and 14% for stage I and II carcino¬
mas, respectively). Establishing the exact reasons for
favorable recurrence rates is hampered by limited
patient numbers and inconsistent and nonrandomized
adjuvant therapies, but it appears that surgery pro¬
duces good regional control in this group, with 67%
locoregional control compared with the 87% observed
by Sood et al}2S\
Despite having been described as a distinct clinical
entity for over 20 years, UPSC remains a management
challenge for the multidisciplinary team due to the
paucity of understanding on the epidemiology, patho¬
genesis, natural history, and optimal treatment strate¬
gies for this important and aggressive variant of
endometrial adenocarcinoma. These data contribute to
the growing body of literature on UPSC and address
diagnostic and treatment uncertainties for the pathol¬
ogy, surgical, and oncologic teams. This study raised
awareness for the need of accurate and complete surgi¬
cal staging at a local level. However, we have not
altered our approach to the use of adjuvant chemora-
diotherapy for patients with UPSC as our patient num¬
bers were small with a limited follow-up time. This
study contributes to the increasing local, national, and
international awareness of the need to invest in ran¬
domized clinical research trials on UPSC, at a time
where alternative treatment modalities may become
increasingly effective.
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The pattern of CD98 expression is different between uterine
serous papillary carcinoma and endometrioid endometrial
carcinoma
To the Editor:
CD98 is a disulphide-linked 125-kDa heterodimeric mem¬
brane glycoprotein, which is found on the cell surface of most
nonnal cells, and accumulating evidence suggests that it may
have a role in tumour progression and metastasis. We have
investigated the expression of CD98 in uterine serous papillary
carcinoma (UPSC) and endometrioid endometrial carcinoma
(EEC), tumour types we selected for study because of differing
pathogeneses and patterns of local invasion and metastasis.
CD98 has been shown to be involved in cellular prolifera¬
tion, cell transformation, cell fusion, cell adhesion and the L-
type amino acid transporter (LAT) system, in addition to
regulating integrin activation, and therefore integrin signalling
and anchorage independent growth [1]. Its expression is
upregulated in a variety of tumours including those of larynx,
where a diffuse pattern of expression is associated with more
extensive disease and poorer differentiation [2J. A recent study
showed down-regulation of gene expression of CD98 in cell
lines derived front metastatic adenoid cystic carcinoma
compared to cell lines created from primary adenoid cystic
carcinomas [3]. To date, no studies have been published on the
pattern of expression of CD98 in endometrial carcinomas.
Endometrial carcinoma is the most common pelvic genital
malignancy in the western world. The most common subtype is
EEC, which accounts for about 80% and UPSC accounts for
approximately 10% of endometrial carcinomas. UPSC is
associated with lymphovascular invasion and widespread dis¬
semination and has a significantly poorer prognosis at Stages 1, 2
and 3 compared to EEC.
This study was undertaken to determine whether there is
differential expression of CD98 between EEC and UPSC, which
might explain the increased aggressiveness ofUPSC compared to
EEC. We examined levels of expression not only in the central
viable part, but also at the invasive edge of these tumours.
We created tissue microarrays (TMAs) from 73 cases ofUPSC
and 20 cases of grade 3 EEC using the established technique [4].
At least three cores were taken from the viable central part and
from the invasive edge of the tumours. Immunohistochemistry
(IHC) was performed forCD98 (Primaiy polyclonal IgG antibody,
Santa Cruz, dilution 1:200) with tonsil as the positive control.
Negative controls were obtained by omitting the primary antibody.
All slides were stained using the standard streptavidin biotin
procedure for IHC. AH CD98 expression was membranous and
was assessed using a histoscore. This was calculated by
multiplying the intensity of staining (l=weak, 2=moderate and
3 = strong) by the percentage ofpositively stained cells (1 =<20%,
2 = 20-80% and 3=>80%), thus giving a score between 1 and 9.
To minimise erroneous results, the average score of the cores
sampled from each case was used in calculations.
Table 1 shows a summary of the results. Both tumour types
showed specific staining of neoplastic cells, but there was
significantly greater CD98 expression in EEC compared to
UPSC. The invasive edge of UPSC showed significantly greater
expression of CD98 compared to the viable central part of f >V
tumour, whereas in EEC there was a tendency (which did not
achieve significance) for expression to be decreased at the invasive
edge.
These findings may reflect the different biological properties of
these tumours. EEC usually arises on a background of oestrogen
excess, commonly expresses oestrogen receptors (ER), and can
produce intratumoural oestrogen using aromatase. In contrast,
UPSC usually arises from atrophic endometrium, is generally ER
negative and does not produce intratumoural oestrogen. Lessey et
al. [5] found that integrin expression correlated with steroid
receptor status, as well as with grade, stage and depth of invasion.
We found significantly higher ER and progesterone receptors (PR)
positivity in our EEC cases compared to UPSC (results not shown).
Our finding of increased expression in the viable central part ff
EEC and a non-significant decrease at the invasive edge is similar
to that described by Huang et al. in adenoid cystic carcinoma [3], In
Table 1
Expression of CD98 in the central part of the tumour and at the invasive edge
CD98 (Primary polyclonal IgG UPSC EEC
antibody, Santa Cruz, dilution 1:200) Tumour Invasive edge Tumour Invasive edge
*4.32' 5.10' *5.94 3.92
* P^O.009 (Mann-Whitney U test).
1
P-0.005 (Wilcoxon Signed Ranks).
0090-8258/S - see front matter © 2006 Elsevier Inc. All rights reserved,
doi: 10.1016/j.ygyno,2006.09.026
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contrast, lower levels ofCD98 were seen in the viable central part
of UPSC when compared to the invasive edge. This raises the
possibility that CD98 has different roles in EEC compared to
UPSC. The high CD98 in the viable central part of EEC may be
due in part to the relative increase in PR and ER, but it is also
possible that CD98 plays a role in increasing nutrient uptake in
proliferating cells via the LAT system. In contrast, the increased
expression ofCD98 at the invasive edge ofUPSC compared to the
viable central part may reflect activation of the fil integrin
signalling pathway, increased anchorage independent growth and
thus invasion.
We have shown differences in expression of CD98 between
EEC and UPSC, which may reflect the different biological
properties of these tumours. Further investigation of CD98
interactions with cell adhesion molecules may cast light on
mechanisms of tumour invasiveness and metastasis.
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The role of matrix metalloproteinases-2, -7 and -9 and p-catenin in high grade endometrial
carcinoma
Aims: To determine the expression of matrix metallo-
proteinases (MMPs)-2, -7 and -9 and P-catenin in
uterine serous carcinoma (USC) and endometrioid
endometrial carcinoma (EEC) and to investigate any
difference in expression between EEC and USC which
might explain the mechanism of invasion and aggres¬
sive behaviour of USC.
Methods and results: Tissue microarrays were created
from the viable central part and from the invasive edge
of 20 cases of grade 3 EEC and 73 cases of USC.
Immunohistochemistry was performed using antibod¬
ies to MMPs-2, -7 and -9 and P-catenin. MMPs-2, -7
and -9 and p-catenin were present in both tumour
types; there was significantly higher expression of
MMPs-2 and -9 in EEC compared with USC and
significantly increased expression of MMPs 2 and 9
by carcinoma cells at the invasive edge of USC.
Conclusions: MMPs-2. -7 and -9 and P-catenin are
present in EEC and USC. The increased expression of
MMPs-2 and -9 by carcinoma cells at the invasive edge
of USC is possibly due to increased binding of MMPs
secreted by the stromal cells to carcinoma cells, thus
equipping the USC carcinoma cells with proteases for
invasion.
Keywords: P-catenin, endometrial carcinoma, matrix metalloproteinases, uterine serous carcinoma
Abbreviations: BM, basement membrane; ECM, extracellular matrix; EEC, endometrioid endometrial carcinoma;
MMP, matrix metalloproteinase; TMA, tissue microarray; USC, uterine serous carcinoma
Introduction
Endometrial carcinoma is the most common female
genital malignancy in the western world.1 There are
two main types of endometrial carcinoma: endometri¬
oid endometrial carcinoma (EEC) (Type I) and non-
endometrioid endometrial carcinoma (Type II), which
mainly consists of uterine serous carcinoma (USC),
clear cell carcinoma and malignant mixed mesodermal
tumour (carcinosarcoma). EEC accounts for approxi¬
mately 80% of all endometrial carcinomas and usually
arises from atypical hyperplasia of the endometrium.2'4
It is associated with oestrogen excess. USC accounts for
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approximately 10% of cases of endometrial carcinoma2
and makes up the majority of the Type II carcinomas. It
is an aggressive tumour, usually occurring in elderly
women and is thought to arise from endometrial
intraepithelial carcinoma.5"7 It is not associated with
either atypical hyperplasia or a hyperoestrogenic state.
Although USC comprises 10% of cases of endometrial
carcinoma,2 it accounts for a much smaller proportion
of Stage I endometrial carcinomas.8"10 It is upstaged at
the time of surgery in 60% of cases.11"15 Hui et al.16
examined a series of 40 cases ofminimal uterine serous
carcinoma. Nine of these were endometrial intra¬
epithelial carcinoma and 31 were cases of Stage la
USC. They demonstrated that only when the carcinoma
was confined to an endometrial polyp did the patients
have good prognosis. This aggressive behaviour raises
the possibility that USC interacts with the extracellular
matrix (ECM) in a different way from EEC.
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Invasion and metastasis of tumour cells requires a
variety of complex inteiactiuiis including ccll-ecll
interactions, cell-matrix interactions and degradation
of the ECM. Basement membranes (BMs) constitute
the major natural barrier that cancer cells must
cross several times during the metastatic cascade.
Liotta et al.17 have suggested a hypothetical model in
which tumour invasion and metastasis results from
repetition of three steps: adhesion of cancer cells
to BM glycoproteins; degradation of BMs by
specific proteolytic enzymes; and migration uf cancer
cells.
The theory of tumour progression and heterogeneity
is well established. Tumours are known to lose clonal-
ity early in development and generate subclones with
varying characteristics resulting from mutations. In
theory, only the selected subclone will possess the
appropriate genetic characteristics in order to invade
and metastasize.
Matrix metalloproteinases (MMPs), a family of zinc-
dependent endoproteinases, are widely accepted to
play a role in the invasion and metastasis of
tumours.181,9 Under normal physiological conditions,
MMPs are expressed at a very low level in adult
tissues, except in tissues that undergo remodelling
such as cycling endometrium, normal breast tissue at
the time of involution and the skin during wound
healing.18'20-22 Increased MMP expression and pro¬
teolytic degradation of ECM have been detected in a
wide range of cancers, including those arising from
the breast, colon, ovary and lung and MMP expres¬
sion has been correlated with primary tumour
growth and angiogenesis and also tumour invasion
and metastasis.18,19,23-27
Although some MMPs are synthesized and secreted
by cancer cells, others are synthesized and secreted by
stromal cells and then bind to the cell membrane of
tumour cells.28-34 MMP expression appears to vary
among host organ microenvironments and stromal
MMPs may promote metastasis to one organ in
preference to another. Therefore, antimetastatic effects
based on MMP inhibition may be dependent on MMPs
derived from specific organ microenvironments as well
as tumour cells.35
ProMMP-2, the precursor to active MMP-2, is widely
expressed in normal tissue and the MMP-2 gene has
been described as a 'house-keeping' gene for its role in
normal cellular processes.36 In contrast, active MMP-2
is increased significantly in some neoplastic tissues and
absent in most normal tissues. MMP-2 contributes to
cell migration by a mechanism involving interaction
with collagen.37 MMP-2 has been demonstrated in
endometrial carcinoma cells.38
Altered expression of MMP-7 has been demonstrated
in EEC and increased expression ofMMP 7 is associated
with lymph node metastasis.38-41 Matrisian et al,36
have shown that induction of MMP-7 expression in
tumour cells increases tumorigenicity and metastases,
while inhibition of MMP-7 leads to decreased metasta¬
sis.42,43 In addition, they found that MMP-7 expression
appeared to be associated with a less aggressive
phenotype, despite being involved in invasion. In
contrast, Misugi et a/.38 have demonstrated that
increased expression of MMP 7 is found in high-grade
endometrial carcinomas.
(3-Catenin has roles in both cell-cell adhesion and
intracellular signalling. It links to intracellular
E-cadherin and thus connects E-cadherin to the actin
cytoskeleton.44-46 Cadherin-catenin complexes also
have roles in intercellular communication and modu¬
lation of cell function in both normal and malignant
tissues. Failure to assemble the E-cadherin-catenin
complex or to connect properly to the actin cyto¬
skeleton results in loss of cell adhesion, which may
be involved in tumour spread. Signalling through the
cadherin-catenin complexes is involved in the regu¬
lation of epidermal growth factor receptor distribu¬
tion.47
MMP-9 expression has been shown to be altered in
EEC and increased expression is associated with
myometrial invasion.38-41 In addition, Park et al.48
have shown that synthesis and secretion of MMP-9 is
down-regulated by P-oestradioI. Cioppi et al.49 found
that MMP-9 expression is higher in oestrogen receptor-
positive endometrial carcinomas.
Although USC comprises only 10% of endometrial
carcinomas, it accounts for a greater proportion of
deaths. This study was undertaken to investigate the
expression of MMPs-2, -7 and -9 in USC and EEC,
and in particular to see if there was any difference in
expression between the two tumour types which
might explain the observed difference in aggressive
behaviour. As P-catenin has a role in cell-cell
adhesion and studies on colon and breast carcinoma
have shown both positive and negative correlations
between the expression of p-catenin and MMP-7, we
also examined the expression of P-catenin in these
tumours. It is well recognized that tumours are
heterogeneous and examining the central part of the
tumour alone may give misleading results as regards
the invasiveness of the tumour as a whole. We used
tissue microarrays (TMAs) to examine a relatively
large number of cases, in order to be able to
demonstrate differences in expression of these pro¬
teins between the viable central part of the tumour
and the invasive edge in USC and EEC.
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The Medicine/Clinical Oncology II Research Ethics
Committee of the Lothian Research Ethics Committee
gave ethical approval for this study.
Materials and methods
TISSUES
Archival tissue samples were selected from the Royal
Infirmary of Edinburgh Department of Pathology, the
slides were reviewed by H.M. and A.R.W.W. the
diagnosis of USC or EEC was confirmed and appropriate
blocks selected. Haematoxylin and eosin (H&E) sections
then had at least one area from the centre of the
tumour and invasive edge marked on the slide by the
pathologist. The samples included 20 International
Federation of Gynaecology and Obstetrics (FIGO) Grade
3 cases of EEC and 73 cases of USC. As we did not
identify any cases of endometrial intraepithelial carcin¬
oma and only three cases of USC were at Stage la,
these cases were not treated as a separate group. All
tissue had been routinely fixed in 4% buffered formal¬
dehyde and processed to paraffin blocks by routine
methods.
TISSUE MICROARRAY
A microarray instrument (Beecher Instruments, Sun
Prairie, WI, USA) was used. In order to construct the
microarray, empty paraffin blocks of a depth of 5-
10 mm were produced. Cores of wax, 0.8 mm dia¬
meter, were extracted from the empty blocks and
replaced with cores of 0.6 mm diameter taken from the
tissue blocks at sites corresponding to the previously
selected areas on the H&E slides. Three cores were
taken from each area marked on the slide, so that at
least three cores were taken from each case. The cores
were punched at 1-mm intervals, at least three cores
per case, to decrease the risk of aberrant results due to
tumour heterogeneity. A grid system with each core
having a coordinate reference (X axis, Y axis) was used
to allow cross reference between core location and
parent case. The microarray blocks were identified as
EEC tumour, EEC invasive edge or USC tumour or USC
invasive edge.
Once the microarrays were complete, the blocks were
sealed in a 60°C oven for 10 min.
IMMUNOHISTOCHEMISTRY
From the array blocks, sections were cut at 3 pm
thickness and mounted on positively charged capillary
action slides (Dako, Copenhagen, Denmark) and incu¬
bated at 60°C overnight. The slides were dewaxed and
rehydrated prior to antigen retrieval.
mmp-2
Antigen retrieval was performed by immersing the test
slides along with a section of normal appendix (as the
positive control) in 0.01 m ethylenediamine tetra-
aceticacid (EDTA), pH 8.0 and microwaving at high
power for 15 min. The primary monoclonal antibody
was the 17B11 clone (NovoCastra Laboratories, New¬
castle, UK) and was used at a dilution of 1 : 40.
Negative controls were obtained by omitting the
primary antibody.
mmp-7
No antigen retrieval was performed. A slide of breast
carcinoma was used as the positive control. The
primary monoclonal antibody was clone 1D2 (Chem-
icon International, Chandlers Ford, UK) and was used
at a dilution of 1 : 25. Negative controls were obtained
by omitting the primary antibody.
mmp-9
Antigen retrieval was performed by immersing the test
slides along with a slide of kidney (as the positive
control) in 0.01 m EDTA, pH 8.0 and pressure cooking
for 7 min. The primary monoclonal antibody was clone
15W2 (NovoCastra Laboratories) and was used at a
dilution of 1 : 80. Negative controls were obtained by
omitting the primary antibody.
P-CATENIN
Antigen retrieval was performed by immersing the test
slides along with a slide of tonsil (as the positive
control) in 0.01 m EDTA, pH 8.0 and microwaving
at high power for 15 min. The primary monoclonal
antibody was the p-catenin-1 clone (Dako) and was
used at a dilution of 1 : 50. Negative controls were
obtained by omitting the primary antibody.
All slides were stained on the Dako TechMatelM 500
plus, using the Dako ChemMate'1 M EnVision™ Detec¬
tion kit and the standard operating procedure for
routine immunohistochemistry.
SCORING
The scores for MMP-2, MMP-7, MMP-9 and p-catenin
were calculated by multiplying the intensity of staining
(1, weak; 2, moderate; and 3, strong) by the percentage
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of cells showing positive nuclear staining (1, <20%;
2, 20-80%; and 3, > 80%), thus giving a score between
1 and 9.
STATISTICAL ANALYSIS
The mean scores of the three areas of tumour assessed
for each case of USC and EEC were calculated. The
results from the main part of the tumour were used in
calculations to determine if there were any differences
between tumour types. A paired t-test was performed
for the parametric results and a Mann-Whitney U-test
was performed for the non-parametric results. A
P-value of < 0.05 was considered to be significant.
The Wilcoxon matched-pairs signed-ranks test was
used to estimate the relationship between staining
patterns of the different antibodies used between the
main part of the tumour and at the invasive edge. A
P-value of <0.05 was considered to be significant.
The Pearson pairwise correlation coefficient was used
to determine any correlation between expression of
different MMPs and p-catenin.
Results
INTERTUMOUR VARIABILITY
Significantly greater MMP-2 expression was present in
EEC carcinoma cells compared with USC carcinoma
cells (P < 0.05, Mann-Whitney U-test; Table 1). There
was no significant difference in MMP-2 expression
between USC and EEC stromal cells. In addition, there
was no significant difference in either carcinoma cell or
Table 1. Expression of matrix metalloproteinases (MMPs)-2,
-7 and -9 and fi-catenin in the central part of the tumour in
uterine serous carcinoma (USC) and endometrioid endo¬
metrial carcinoma (EEC)
Antibody USC EEC
MMP-2 0.53* | 1.43*
MMP-2 stroma 1.68 1.36
MMP-7 1.81 1.77
MMP-7 stroma 1.28 1.51
MMP-9 0.90 1.17
MMP-9 stroma 1.24** 2.44**
(3-Catenin 7.05 7.78
*P < 0.05 (Mann-Whitney U-test); **P = 0.001 (Mann-
Whitney U-test).
stromal cell expression of MMP-7 between USC and
EEC. Although there was no significant difference in
MMP-9 expression between USC and EEC carcinoma
cells, there was significantly greater MMP-9 expression
seen in EEC stromal cells (P = 0.001, Mann-Whitney
U-test; Table 1). There was no significant difference in
P-catenin expression between USC and EEC. Scatter-
plots and Pearson pairwise correlation coefficient
showed no direct or inverse correlation between
p-catenin expression and MMPs-2, -7 or -9.
INTRATUMOUR VARIABILITY
Uterine serous carcinoma
There was significantly greater MMP-2 expression in
carcinoma cells at the invasive edge compared with
those in the viable central part of the tumour (P =
0.045, Wilcoxon signed-ranks test). However, there
was no significant difference in expression of MMP-2 in
stromal cells between the invasive edge and the viable
central part of the tumour (Table 2). MMP-2 immuno-
reactivity was present in both the cytoplasm and at the
cell membrane (Figure IB).
There was no significant difference in either MMP-7
or MMP-9 expression between the viable central part of
the tumour or the invasive edge in either carcinoma
or stromal cells (Table 2). Immunoreactivity of both
MMP-7 and MMP-9 in both carcinoma and stromal
cells was cytoplasmic and membranous (Figures ID
and 2B, respectively).
Table 2. Expression of matrix metalloproteinases (MMPs)-2,
-7 and -9 and (3-catenin in the central part of the tumour and







MMP-2 0.53 0.79* 1.43 1.69
MMP-2 stroma 1.68 1.54 1.42 1.46
MMP-7 1.81 1.69 1.77 1.61
MMP-7 stroma 1.27 1.21 1.52 1.51
MMP-9 0.90 1.08 1.14 1.09
MMP-9 stroma 1.24 1.22 2.51 1.76
(3-Catenin 7.05 7.94** 7.19 7.63
*P = 0.045 (Wilcoxon signed-ranks test); **P - 0.03 (Wil¬
coxon signed-ranks test).
USC, Uterine serous carcinoma; EEC, endometrioid endo¬
metrial carcinoma.
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Figure 1. Expression ofmatrix metalloproteinases (MMPs). A, MMP-2 in endometrioid endometrial carcinoma (EEC). B, MMP-2 in uterine serous
carcinoma (USC). C, MMP-7 In EEC. D. MMP-7 in USC.
There was significantly greater expression of
p-catenin in carcinoma cells at the invasive edge
compared with those in the viable central part of the
tumour (P = 0.03, Wilcoxon signed-ranks test,
Table 2), However, all p-catenin expression was mem¬
branous (Figure 2D).
There was significantly greater expression of MMP-2
in stromal cells compared with carcinoma cells in both
the viable central part of the tumour and at the
invasive edge (P < 0.05 and P = 0.001, respectively,
Wilcoxon signed-ranks test. Table 3). In contrast,
there was significantly less expression of MMP-7 in
the stromal cells compared with the carcinoma cells in
both the viable central part of the tumour and at the
invasive edge (P < 0.05 and P = 0,001, respectively,
Wilcoxon signed-ranks test, Table 3). There was signi¬
ficantly less MMP-9 expression in carcinoma cells
compared with stromal cells in the viable central part
of the tumour (P = 0.02, Wilcoxon signed-ranks test,
Table 3), but there was no significant difference in
MMP-9 expression between these cells at the invasive
edge.
Endometrioid endometrial carcinoma
No significant differences in expression of any of the
proteins (MMPs-2, -7, -9 or p-catenin) were noted in
either carcinoma cells or stromal cells at the invasive
edge compared with those in the viable central part of
the tumour (Table 2). Expression of all the MMPs was
both cytoplasmic and membranous (Figures 1A,C and
2A, respectively). Two of the 20 EEC cases showed
nuclear P-catenin expression (Figure 2C). The remain¬
der showed membranous staining.
There was no significant difference in expression of
MMP-2 between carcinoma and stromal cells in either
the viable central part of the tumour or at the invasive
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Figure 2. Expression ofmatrix metalloproteinases (MMPs). A, MMP-9 in endometrioid endometrial carcinoma (EEC). B, MMP-9 in uterine serous
carcinoma (USC). C, Nuclear P-catenin in EEC. D, Membranous P-catenin in USC.
Table 3. Variation in matrix metalloproteinase (MMP)
expression between tumour and stromal cells in uterine
serous carcinoma










MMP-2 0.53* 1.68* 0.79+ 1.54+
MMP-7 1.81** 1.27** 1.69++ 1.21++
MMP-9 0.90*** 1.24*** 1.08 1.22
*P < 0.05 (Wilcoxon signed-ranks test); **P < 0.05 (Wilc-
oxon signed-ranks test); ***P = 0.02 (Wilcoxon signed-
ranks test).
tP = 0.001 (Wilcoxon signed-ranks test); ++P = 0.001
(Wilcoxon signed-ranks test).
Table 4. Variation in matrix metalloproteinase (MMP)
expression between tumour and stromal cells in endometrioid
endometrial carcinoma










MMP-2 1.43 1.42 1.69 1.46
MMP-7 1.77* 1.52* 1.61 1.51
MMP-9 1.14** 2.51** 1.09+ 1.76+
*P = 0.018 (Wilcoxon signed-ranks test); **P = 0.011
(Wilcoxon signed-ranks test).
tP = 0.012 (Wilcoxon signed-ranks test).
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edge (Table 4). There was significantly greater expres¬
sion of MMP-7 in carcinoma cells compared with
stromal cells in the viable central part of the tumour
(P = 0.018, Wilcoxon signed-ranks test, Table 4), but
there was no significant difference in expression
between the cell types at the invasive edge. Signifi¬
cantly greater expression of MMP-9 was noted in
stromal cells compared with carcinoma cells in both
the viable central part of the tumour and at the
invasive edge (P = 0.011 and P = 0.012, respectively,
Wilcoxon signed-ranks test, Table 4).
Discussion
USC is an aggressive endometrial tumour with a
notable propensity for lymphovascular space invasion
and a poor prognosis. We performed this study to
determine whether MMPs have a role in their increased
invasiveness in comparison with EEC. We confirmed
the findings of Misugi et al.iH and Moreno-Bueno
et at.50 and demonstrated MMPs-2, -7 and -9 and
p-catenin to be present in both USC and EEC.
In addition, the present study looked for differences
in expression of these proteins between the different
histological tumour types and within the tumours (the
viable central part of the tumour and at the invasive
edge). We demonstrated MMP-2 expression in both EEC
and USC carcinoma cells, confirming the findings of
Park et of.48 Park et al.48 demonstrated that synthesis
and secretion of stromal MMP-2 is up-regulated by
P-oestradiol. In addition, they showed that the inva¬
siveness of cells from an endometrial adenocarcinoma
cell line was enhanced by recruitment of MMP-2
secreted by endometrial stromal cells to their cell
membrane, which was further enhanced by the pres¬
ence of P-oestradiol.
The finding of significantly higher MMP-2 expression
in EEC carcinoma cells compared with those in USC
may partly reflect the different biological properties of
these tumours. EEC is a tumour which usually arises on
a background of oestrogen excess, which commonly
expresses oestrogen receptor and can produce endo¬
genous oestrogen using aromatase.'1 On the other!
hand, USC usually arises from atrophic endometrium,
is generally oestrogen receptor-negative and does not!
produce endogenous oestrogen. Park et al48 have
demonstrated that p-oestradiol stimulates MMP-2
secretion in adenocarcinoma cell lines; it is therefore
possible that the differential secretion may be due to
increased endogenous oestrogen in EEC compared with
USC. We found significantly higher oestrogen receptor
positivity in our EEC cases compared with USC (results
not shown).
We found similar levels of MMP-2 in EEC carci¬
noma and stromal cells and although there was
increased expression of MMP-2 in carcinoma cells at
the invasive edge of the tumour, this was not
statistically significant. However, we did find a signi¬
ficantly higher level of MMP-2 in USC stromal cells
compared with carcinoma cells both in the viable
central part of the tumour and at the invasive edge.
In addition, the USC carcinoma cells showed a
significant increase in MMP-2 expression at the
invasive edge compared with the viable central part
of the tumour. MMP-2 is synthesized and secreted by
stromal cells and then binds to the TIMP-2:MT-MMP
complex on the carcinoma cell surface;32 this differ¬
ence in expression raises the possibility that an
invasive subclone of USC uses increased carcinoma
cell binding of MMP-2 to equip the cells with the
proteases required for invasion.
We did not demonstrate any intertumoral or intra-
tumoral differences in expression of MMP-7. There was
significantly more expression of MMP-7 in carcin¬
oma cells compared with stromal cells in both USC and
EEC. Our findings are in keeping with the published
literature that MMP-7 is generally expressed in
tumours.38-41 As this study examined high-grade
endometrial cancers only, we could not confirm or
refute the findings of Misugi et al.™ who showed
differential expression of MMP-7 between the different
grades of EEC.
There was no significant difference in P-catenin
expression between EEC and USC. However, we did
find that P-catenin expression was increased signifi¬
cantly at the invasive edge of USC. All USC cases
demonstrated membranous expression of P-catenin
and only two EEC cases (10%) demonstrated nuclear
expression. All other cases showed membranous
expression. Our finding that 10% of EEC cases showed
nuclear expression is less than that reported by
Moreno-Bueno et al.,52 who found that nuclear
P-catenin expression was present in 31% of EECs
and 3% of non-endometrioid endometrial carcino¬
mas.53 It is possible that this discrepancy is due to our
lease selection of only high-grade EEC, and p-catenin
mutations may be more important in the development
|of Grade 1 and Grade 2 EEC.
As well as roles associated with cadherin function,
P-catenin is also involved in intracellular signalling, as
it is a member of the Wnt pathway. The activation of
the Wnt signalling pathway due to P-catenin mutations
has been implicated in the development of some
endometrial carcinomas. However, up to 25% of
endometrial carcinomas have P-catenin nuclear accu¬
mulation without evidence of P-catenin mutations,
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suggesting alterations in other molecules that can
modulate the Wnt pathway such as APC, y-catenin,
AXIN1 and AXIN2. In ovarian cancer the presence of
nuclear P-catenin is an indicator of good prognosis, but
whether this has the same effect in endometrial cancers
is as yet unknown.
Crawford et al.5* have reported a positive correla¬
tion between nuclear p-catenin protein levels and
MMP-7 transcripts in colonic carcinoma. They did not
find any MMP-7 expression in cells that lacked
P-catenin protein accumulation. Mylona et al.55 have
demonstrated an inverse correlation with nuclear
P-catenin expression in breast carcinoma. We did not
demonstrate any inverse or direct correlation between
p-catenin expression and any of the MMPs. This may
be due to the relatively small numbers of cases
involved. Alternatively, this may be because the studies
that have demonstrated either inverse or direct corre¬
lations have focused on colonic carcinoma where
P-catenin expression is nuclear, reflecting mutation in
the P-catenin gene, and the studies by Mylona et al.53 in
breast carcinoma also focused on p-catenin mutation.
We found significantly higher expression of MMP-9
in EEC compared with USC and also significantly higher
expression of MMP-9 in stromal cells compared with
carcinoma cells in the viable central part of the tumour
in both EEC and USC. In addition, there was signifi¬
cantly higher expression of MMP-9 in stromal cells
compared with carcinoma cells at the invasive edge
of the EEC cases. However, there was no significant
difference in MMP-9 expression between the invasive
edge stromal cells and carcinoma cells in USC. MMP-9
is normally synthesized and secreted by stromal cells
and binds to CD44 on carcinoma cells.32 The loss of
this differential expression between carcinoma cells and
stromal cells at the invasive edge of USC cases may
indicate that MMP-9 synthesis and secretion by stro¬
mal cells is unchanged at the invasive edge of the
tumour, but binding of MMP-9 by the invading
carcinoma cells is increased, perhaps enhancing their
invasive potential.
Hui et al.16 have recently demonstrated differences in
outcome between patients with Stage la USC arising
in a polyp and in the 'normal' endometrium. In view
of our results showing differences in expression of
MMPs-2 and -9 between the main part of the tumour
and the invasive edge, it would be interesting to
examine more closely cases of endometrial intraepit¬
helial carcinoma and Stage la USC.
In summary, this immunohistochemical study has
confirmed that MMPs-2, -7 and -9 and P-catenin are
present in endometrial carcinomas and specifically in
both EEC and USC. We found significantly higher
expression of MMPs-2 and -9 in EEC compared with
USC. This may be due to the known relationship
between these MMPs and oestrogen status. Despite
the lower expression of MMP-2 and MMP-9 in USC
compared with EEC, we did show increased expression
of MMP-2 and MMP-9 by carcinoma cells at the *
invasive edge of USC. This is probably due to increased
binding to carcinoma cells of MMPs secreted by the
stromal cells. This difference in staining pattern
between the viable central part of the tumour and
the invasive edge supports the theory of an invasive
subclone of USC acquiring activated proteases in order
to invade.
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Appendix 2
Individual results of P53 from whole sections (WS), tissue microarray (TMA) and
compressed scores (POS NEG) for Chapter 3 TMA Validation.
WS TMA
POS POS SCORE SCORE SCORE SCORE
Number WS NEG NEG 1 2 3 4 MISSING
1 2 0 0 3 4 1
2 2 2 2 0 1 0 1 2
3 2 0 0 0 4 0
4 1 2 2 0 6 0 0 0
5 3 2 2 0 0 0 2 0
6 2 2 1 4 0 0 0 0
7 0 0 0 0 4
8 2 0 2 1 0 1
9 2 4 0 2 0 0
10 2 0 0 0 6 0
11 3 2 2 0 0 2 0 0
12 2 2 2 3 2 0 0 1
13 2 2 2 0 1 1 0 0
14 3 2 2 0 0 0 3 1
15 3 2 2 0 0 0 5 1
16 3 2 2 0 0 0 2 0
17 3 2 2 0 0 0 3 1
18 3 2 2 0 0 0 8 1
19 2 2 2 0 4 0 0 0
20 2 0 o 0 4 0
21 2 0 0 0 4 0
22
23 2 0 0 0 6 0
24 2 0 0 0 4 0
25 2 1 1 0 0 2
26 1 4 0 0 0 0
27 3 2 2 0 0 8 0 0
28 0 1 1 2 0 0 0 2
29 2 2 1 4 0 0 0 0
30 2 0 0 2 0 0
31 3 2 2 0 0 0 4 2
32 2 2 2 0 0 2 0 0
33 3 2 2 0 0 3 2 1
34 3 2 2 0 0 0 3 1
35 2 0 1 2 0 1
36 0 0 0 0 2
37 2 2 2 0 1 3 0 2
38 2 0 2 0 0 2
39 2 0 0 0 10 0
40 2 0 0 0 3 1
41 3 2 2 0 0 0 4 0
49 3 2 2 0 0 0 4 0
43 0 1 1 3 0 0 0 1
44 3 2 2 0 0 0 4 0
197
ws TMA
POS POS SCORE SCORE SCORE SCORE
Number ws NEG NEG 1 2 3 4 MISSING
45 2 2 2 0 2 0 0 2
46 3 2 2 0 0 0 4 0
47 3 2 2 0 0 0 2 2
48 3 2 2 0 0 0 7 1
49 1 2 0 0 0 0
50 2 2 2 0 0 2 0 0
51 2 2 1 2 0 0 0 0
52 3 2 2 0 0 0 6 0
53 3 2 2 0 0 0 1 1
54 2 2
55
56 2 2 0 0 0 0 2
57 3 2 1 2 0 0 0 0
58 2 0 1 1 0 0
59 3 2 2 0 0 0 2 0
60 3 2 2 0 0 0 4 0
61 3 2 2 0 0 1 0 1
62 2 2 1 2 0 0 0 2
63 2 2 2 1 1 0 0 2
64 2 0 6 0 0 0
65 2 1 4 1 0 0
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